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ABSTRACT

AGE-RELATED EFFECTS ON THE MITOGEN-ACTIVATED PROTEIN KINASE
AND PHOSPHATIDYLINOSITOL 3-KINASE PATHWAYS IN BREAST CANCER
AND THE CHARACTERIZATION OF NOVEL MEK5 INHIBITORS

By
Darlene A. Monlish
December 2013

Dissertation supervised by Jane E. Cavanaugh, Ph.D.
Age remains the most common demographic risk factor in breast cancer. The
underlying cellular signaling mechanisms responsible for the age-associated rise in
disease incidence have not yet been determined. Studies presented herein aim to elucidate
age-related changes in the extracellular signal-regulated kinases, ERK1/2 and ERK5, of
the mitogen-activated protein kinase (MAPK) pathway, and in the phosphatidylinositol 3kinase/Akt (PI3K/Akt) pathway. Further, the role of the MEK5-ERK5 cascade in breast
cancer cell proliferation, migration, and invasion was analyzed. In addition, several series
of novel MEK5 inhibitors were characterized with regard to both efficacy and selectivity.
In vitro assessment revealed distinct patterns of kinase expression and activation among
iv

the three breast cancer cell lines evaluated. In a spontaneous model of breast cancer, the
expression and activation of ERK5 increased with age in tumor tissue, while no changes
were observed in adjacent normal mammary tissue. Pharmacological inhibition of ERK5
decreased cell migration and invasion in a cellular model of triple-negative breast cancer.
In addition, studies involving single and dual delivery of kinase inhibitors further
promote targeting ERK5 in breast cancer due to its role in the upregulation of the related
ERK1/2 and Akt pathways and suggest ERK5 exhibits specialized patterns of activation
with regard to distinct tumor subtypes. The patterns of expression strongly indicate the
need for individual tailoring of pharmaceutical interventions based on patient hormonal
status and age and suggest the important role of the novel protein kinase, ERK5, in cell
invasion and migration. The characterization of a series of diphenyl aniline compounds
revealed a putative MEK5 inhibitor capable of reducing cell growth and reverting the
epithelial-to-mesenchymal transition in triple-negative breast cancer cells. Full
characterization of the MEK5-ERK5 cascade in breast cancer will assist in the
development of more targeted inhibitors, thereby reducing toxicity and increasing
efficacy in select patient cohorts.
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CHAPTER 1
LITERATURE REVIEW

1.1

INTRODUCTION

1.1.1 Cancer
Cancer accounts for nearly 8 million deaths worldwide each year. In the United
States (U.S.), cancer remains a leading cause of death, second only to heart disease
(World Health Organization (WHO), 2013; National Cancer Institute (NCI), 2013). Over
1.6 million men and women will be diagnosed with cancer in the U.S. this year (NCI,
2013), corresponding with a lifetime risk of nearly half of males and one-third of females
developing the disease (Centers for Disease Control and Prevention (CDC), 2013). While
the term “cancer” refers to a group of over 100 diseases, at its core, cancer is defined as a
deviation from normal cellular homeostasis to a neoplastic state in which cells divide
uncontrollably outside of their normal borders, and devoid of homeostatic regulation.
Lung, stomach, liver, colorectal, and breast cancers are the most commonly diagnosed
tumors worldwide (WHO, 2013).
Recently, eight hallmarks of cancer that promote tumor growth, survival, and
metastatic dissemination were established and include the following: sustaining
proliferative signaling, evading growth suppressors, activating metastasis and invasion,
enabling

replicative

immortality,

inducing

angiogenesis,

resisting

cell

death,

reprogramming of energy metabolism, and evading immune destruction. In addition, two
notable characteristics of cancer cells that allow them to perform the aforementioned
functions include the development of genomic instability and the ability to exploit
immune-initiated inflammation to promote tumor progression (Hanahan and Weinberg,
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2011). The majority (~80%) of tumors are carcinomas, originating from epithelial tissues.
Other, non-epithelial cancers include the following: sarcomas, derived from connective
and mesenchymal tissues; cancers arising from blood-forming, or hematopoietic tissue;
and neuroectodermal tumors, which arise from cells of the central and peripheral nervous
systems (Weinberg, 2007).
Solid primary tumors are further delineated as either benign, when the tumor
grows locally and does not invade adjacent tissue, or malignant, when the tumor has
invaded neighboring tissue and is capable of producing metastases. Metastatic
progression occurs when cells of the primary tumor undergo oncogenic transformation
and acquire the necessary advantages to overcome the natural barriers designed to
prevent metastasis. Once achieved, the cells disseminate from the tumor and spread to
distant sites throughout the body where they develop new colonies. The most common
sites of metastases for all cancer types are the bone, liver, and lung (NCI, 2013).
Metastasis involves a series of steps that include the following: local invasion,
intravasation, survival and transport through the circulation, arrest and extravasation in
the capillaries and microvessels in distant tissue sites, cell proliferation/formation of
micrometastasis, angiogenesis, and colonization/formation of a macrometastasis (NCI,
2013; Nguyen et al., 2009; Weinberg, 2007). While primary tumors account for
approximately 10% of all cancer deaths, metastatic tumors are the cause of approximately
90% of cancer mortality (Weinberg, 2007).
Across all cancer types a number of risk factors leading to disease development
have been identified in recent years, including heredity, tobacco and alcohol use, obesity,
exposure to radiation and ultraviolet rays, and environmental chemical carcinogens
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(American Cancer Society (ACS), 2013). According to the WHO, approximately 30% of
cancer-related deaths are due to behavior and dietary choices (WHO, 2013). In contrast,
there are numerous lifestyle measures that have been identified to reduce cancer
incidence, including maintaining a healthy diet, abstaining from or eliminating tobacco
use, limiting exposure to environmental toxins, sustaining a healthy weight, and
scheduling routine health screenings (CDC, 2013). In addition to lifestyle changes, more
aggressive methods of cancer prevention continue to emerge as research fields, such as
tumor immunology, continue to expand and provide innovative, preemptive approaches.
The advent of tumor vaccines exemplifies a novel preventative mode of treatment
that relies heavily on immune surveillance. Designed for non-diseased populations
genetically predisposed to certain cancer types, or whose lifestyles indicate the potential
for cancer initiation or for selective patient cohorts, vaccines must be designed as targetspecific to overcome the natural defense system of cancer cells. To date, three vaccines
have received approval for use against the hepatitis B virus, two strains of the human
papillomavirus, and metastatic prostate cancer (NCI, 2013). Cancer prevention combined
with the introduction of new, often target-specific, therapeutic measures has led to an
overall decrease in cancer death rates in the U.S. over the past decade, particularly in
patients afflicted with the four most common cancer types (colorectal, lung, female
breast, and prostate) (Jemal et al., 2013). Despite these promising findings, however,
cancer incidence has remained steady or increased for a number of tumor types in several
patient populations, including the elderly.

3

1.1.1.1 Cancer and Aging
Aging remains the most common demographic risk factor for the majority of
malignancies. The number of cancer patients is expected to double from 1.3 million in
2000 to 2.6 million by the year 2050, while the proportion of patients aged 75 and older
is expected to increase 12% between 2000 and 2050, raising from 30% to 42% of total
cases (Balducci and Ershler, 2013; Figure 1). In industrialized countries, the median age
for cancer diagnosis is approaching 70 and this age is expected to continue to rise. In the
U.S., the median age at diagnosis was 66 for all cancer types in men and women between
the years of 2002-2006 (NCI, 2013).
Several cellular and molecular hallmarks of aging have been identified to provide
a phenotype of the aging process, including: telomere attrition, epigenetic alterations, loss
of proteostasis, genomic instability, deregulated nutrient sensing, mitochondrial
dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular
communication (López-Otín et al., 2013). At the basis of aging is accumulated cellular
damage; similarly, in cancer, genetic mutations and aberrant signaling often leads to
advantages exploited by cells for uncontrolled growth eventually resulting in tumor
formation.
Three possible mechanisms that may account for the age-associated increase in
cancer prevalence include prolonged carcinogenesis, molecular and physiological
changes that provide a favorable environment for tumor growth and survival, and
decreased defense mechanisms against environmental toxins and carcinogens (Balducci
and Ershler, 2005). It has been hypothesized that the extended exposure to carcinogens
may link between cancer and aging as carcinogens act during both the initiation and
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promotion phases of tumor formation (Anisimov et al., 2009). Genomic alterations and
oxidative stress resulting from carcinogen exposure, combined with age-related
immunosuppression, have also been suggested to contribute to the increased prevalence
of cancer over time, however such changes may be cell- and/or species-specific
(Anisimov et al., 2009; Romanov et al., 2001). Numerous age-related changes to the
immune system, including decreased T-cell receptor diversity, reduced immune cell
production, and declined thymic function, have been proposed to promote cancer growth
in the elderly (Derhovanessian et al., 2008). In addition, age-associated alterations in the
tumor microenvironment may positively influence tumor initiation and growth.
In an aged mouse model of breast cancer, for example, caveolin (Cav)-1-knockout
mice demonstrated that tumors grown in a Cav-1 deficient microenvironment displayed
more than five times the growth as compared to tumors in age-matched control animals
with wild-type environments (Mercier et al., 2012). As compared to the wild-type control
animals, the tumor microenvironments in the Cav-1 knockout mice were observed to
contain increased stromal content rich with vimentin-positive myofibroblasts, a marker of
oxidative stress (Mercier et al., 2012), providing evidence of molecular and physiological
changes associated with aging that contribute to tumor growth.
For many years, it has been known that there is an age-associated increase in
chromosomal instability (Curtis, 1963). Several tumor types and cancer syndromes,
including breast malignancies and the neurodegenerative disorder, ataxia-telangiectasia
(AT), are, in part, caused by germline genetic mutations. Mutations, such as those to the
breast cancer susceptibility gene-1 (BRCA1) in breast cancer and the ataxia-telangiectasia
mutated (ATM) kinase in AT, suggest a link between genomic integrity and cancer
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susceptibility (Finkel et al., 2007). In addition to the accumulation of cellular damage
with age, endogenous cellular defenses also wane. Telomeres, the specialized structures
at the ends of chromosomes that are essential for chromosomal stability, shorten with age
(Harley et al., 1990). This observation has led to the “telomere hypothesis” that links
telomeres to cellular senescence and aging, again relating accumulated chromosomal
damage to cancer (Finkel et al., 2007).

Figure 1. Estimated cancer burden in the United States. The number of cancer patients in
the United States is projected to continue to steadily increase, resulting in twice as many
cases in 2050 as compared to 2000. The elderly population (≥ 65 years) constitutes the largest
proportion of cancer cases. Adapted from Balducci and Ershler, 2005.

Although over half of all patients diagnosed with cancer are over the age of 65,
very limited data and resources are available regarding proper disease management. The
lack of information may be due to underrepresentation of elderly persons in clinical trials,
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where patients over the age of 70 only constitute 10% of the population in studies on
cancer prevention and treatment (Benson et al., 1991; Extermann, 2004; Hutchins et al.,
1999). With the number of elderly persons (>65 years) expected to consistently grow and
more than double to over 90 million by the year 2060 in the U.S., the need for targeted
preventative and therapeutic interventions for this patient cohort becomes imperative
(Administration on Aging, 2013).
Genetic predisposition and physical, behavioral, and chemical carcinogens are
just some of the numerous factors that account for cancer incidence rates. Ethnicity and
age also affect incidence rates as a result of genetics and the accumulation of risk factors
over time. Despite advances in cancer awareness efforts and prevention, overall incidence
rates in female cancers have only stabilized from 1973-2010 in the U.S., in contrast with
the decline observed in males. Breast cancer had the highest incidence rate in women
from 2005-2009, followed by colorectal and lung cancer. In particular, an increase in
breast cancer incidence was observed in women aged 50-64 and in black and Asian and
Pacific Islander women during this time period (Jemal et al., 2013).
1.1.2 Breast Cancer
Human female mammary glands are situated within the breast, forming a complex
organ that contains 15-20 lobes. Each lobe is further divided into lobules that branch
from the nipple and hold alveoli, which are hollow sacs lined with milk-secreting
cuboidal cells surrounded by myoepithelial cells. Supported by fat and connective tissue,
a network of ducts functions to connect the lobes, lobules, and alveoli, and carry milk to
the nipple. In addition, breast tissue contains blood vessels, lymph nodes, lymph
channels, and nerves. Breast tumors most often arise in the lining of the milk ducts,
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resulting in ductal carcinomas; tumors may also occur in the lobes where milk is
produced, and are thus termed lobular carcinomas. Rarely, sarcomas, such as phyllodes
tumors and angiosarcomas, may occur in the connective tissue of the breast.
Breast tumors are further classified based on several characteristics including
invasiveness, morphology, and the presence or absence of hormone receptors. To date,
clinicians have identified 18 distinct histopathological subtypes of the disease (Lakhani et
al., 2012). Ductal carcinoma in situ (DCIS) are non-invasive tumors that have not spread
beyond the boundary of the duct where it originated. Once the tumor has infiltrated
beyond the membrane of the duct or lobe where it originated, it is termed invasive. The
two most common invasive tumor types are invasive ductal carcinomas (IDCs),
accounting for approximately 80% of breast tumors, and infiltrating, or invasive, lobular
carcinomas (ILCs), which comprise approximately 10-15% of breast cancers. IDCs may
be further delineated into medullary (<5% of all breast tumors), mucinous or colloid
(~2%), tubular (<2%), or papillary (<1%) based on cellular morphology. Although rare,
inflammatory breast cancer accounts for approximately 1-3% of all breast cancer cases
and is often associated with a higher chance of metastasis and worsened prognosis (ACS,
2013).
Tumors are also graded based on a combination of tubule formation, mitotic rate,
and nuclear grade. Furthermore, tumors are assigned stages based on tumor diameter,
nodal involvement, and metastasis (The Sidney Kimmel Comprehensive Cancer Center,
2013). The most clinically relevant characteristics of breast tumors include tumor grade,
receptor status, and the amplification of the human epidermal growth factor receptor-2
(HER2), also known as the erythroblastosis oncogene-B2, neu, or ErbB2.
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The steroid hormonal receptor status of breast tumors has long been recognized as
both a predictive and prognostic factor. Over 100 years ago, ovariectomy, and subsequent
removal of the ovarian reproductive hormones, estrogen and progesterone, was
recognized as a therapeutic option to prevent breast cancer recurrence (Beatson, 1896).
Both hormones are known to contribute to the development and physiological function of
the breast tissue (Lyons, 1958) and have since been recognized as driving forces in breast
carcinogenesis (Key and Pike, 1988; Henderson and Feigelson, 2000). As compared to
non-diseased breast tissue, in both premalignant and malignant breast tissue, estrogen
receptor-alpha (ERα) and progesterone receptor (PR) protein levels are elevated (Allred
and Mohsin, 2000). Therefore, these receptors have been therapeutically exploited with
the development of endocrine treatments targeted against the receptors in the breast
lesions in which they are expressed.
Endocrine treatments have revolutionized the treatment of hormone-dependent
breast cancer. Acting at the receptor level, selective estrogen receptor modulators
(SERMs), such as tamoxifen and raloxifene, antagonize the binding of ligands at the ER,
while fulvestrant acts to downregulate the ER. In addition, aromatase inhibitors (AIs),
including anastrozole, exemestane, and letrozole, act to disrupt estrogen biosynthesis.
Despite the therapeutic benefits observed with these medications, studies have found that
relapse occurred within 15 years in over 30% of patients with early ER + breast cancer
who received adjuvant tamoxifen treatment. Furthermore, relapse was noted in
approximately 20% of patients within 9 years of treatment with AIs (Miller et al., 2011).
These studies indicate the need for alternative and novel adjuvant treatment options for
this patient cohort.
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In addition to ERα and PR, the amplification of HER2, observed in 20-30% of
breast cancer cases, has been utilized as a clinical prognostic indicator since 2007
(Thibault et al., 2013; Goldhirsch et al., 2007). HER2 is one of a family of four plasmamembrane bound proto-oncogenic growth factor receptors within the epidermal growth
factor receptor (EGFR) family of receptor tyrosine kinases (RTKs). Classified as an
orphan receptor, HER2 does not become activated upon ligand binding. Rather,
activation of HER2 requires either ligand-dependent heterodimerization with a familial
EGFR or other membrane receptor, or ligand-independent homodimerization. Activation
of HER2 is an early event in breast tumorigenesis; its differential expression in human
breast tumors has indicated it as a clinically validated target (Gutierrez and Schiff et al,
2011).
Notably, approximately 30-60% of breast tumors do not express ERα and/or PR,
and the majority of non-malignant proliferating breast epithelial cells are receptor
negative (Table 1; Wiebe et al., 2013). Breast tumors that are deemed “triple-negative”
are characterized by the lack of ER, PR, or HER2 expression, and constitute 10-25% of
the breast cancer patient population. In addition n to the lack of sensitivity to hormone
receptor-targeted therapeutics, triple-negative breast cancer (TNBC) is characterized as
an aggressive histological subtype that may be further delineated into as many as five
distinct subtypes, adding to the growing complexity of this disease. These subtypes
include basal-like (75-85%) and claudin-low, referring to low expression of the claudin
genes that are involved in epithelial cell tight-tight junctions (Bayraktar and Gluck, 2013;
O’Toole et al., 2013; Perou et al., 2000). TNBC patients have a shorter time to
recurrence, higher mortality, and a larger percentage of visceral metastases, as opposed to
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nodal or bony, when compared to non-TNBC patient cohorts (Kennecke et al., 2010;
Dent et al., 2007). While African American women have the lowest incidence of breast
cancer overall, they have the highest mortality rate, likely due to possessing the highest
incidence of TNBC (Pacheco et al., 2013).

Breast Cancer Subtype

Receptor Expression

Luminal A

ER+ and PR+/–, HER2–

Luminal B

ER+ and PR+/–, HER2+

Triple-Negative

ER–, PR–, HER2–

HER-2 Type

ER–, PR–, HER2+

Table 1. Hormonal Receptor Profiles in Distinct Breast Cancer Subtypes. The
differential expression of the estrogen, progesterone, and human epidermal growth factor
receptors are utilized to distinguish between several breast tumor types.

Breast cancer is the leading cause of death in women worldwide, with an
estimated 1.4 million cases expected this year (ACS, 2013). Over 230,000 women and
nearly 2,500 men will be diagnosed with breast cancer in the United States in 2013 (NCI,
2013). Of these, nearly 40,000 women and over 400 men will succumb to the disease.
Several risk factors increase the likelihood of developing breast cancer, including age at
first menarche, a family history of the disease, dense breast tissue, and the presence of
germline mutations in the tumor suppressors, BRCA1 and the breast cancer susceptibility
gene-2 (BRCA2). Inheriting a mutation in either BRCA1 or BRCA2 raises the likelihood a
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woman will develop breast cancer during her lifetime from 12% to 60% (NCI, 2013). As
with most human malignancies, age is the strongest demographic risk factor associated
with breast cancer incidence (Edwards et al., 2002).
1.1.2.1 Breast Cancer and Aging
The female risk of developing breast cancer steadily increases beginning around
age 30, with approximately 75% of newly diagnosed cases occurring in women over the
age of 50 and one-third in women over the age of 70 (Pirone et al., 2012; Walker et al.,
2007). Hormonal influences have been indicated, as a larger proportion of diagnoses in
younger women (age <45) are estrogen-receptor negative (ER–), whereas the majority of
breast cancers in older women (age >70) are estrogen-receptor positive (ER+). Medullary
and inflammatory breast carcinomas, typically associated with the ER – phenotype, are
more typical in younger women and incidence rates tend to increase to age 50 (Anderson
et al., 2006). An inverse relationship exists between younger age and more aggressive
biomarkers, including overexpression of HER1 and HER2 receptors, higher Ki67
expression, indicative of increased cell proliferation, and mutated expression of p53, a
tumor suppressor protein (Yau et al., 2007).
Whereas medullary and inflammatory diseases are more typical in younger
cohorts, papillary and mucinous carcinomas are more likely to occur in patients over the
age of 50 (Anderson et al., 2006). Invasive cancers that occur in women >75 years or
older differ from those occurring in their younger counterparts, as they are highly likely
to be ERα-positive, with a low rate of proliferation and low frequency of markers
associated with aggressiveness, including EGFR, HER2, and p53 (Walker et al., 2007).
Together, these studies indicate that the profile of breast cancer changes with age, yet the
12

cellular contributions to these age-related alterations remain undetermined and were a
major focus of the project described within.
In a study of normal mammary epithelial cells, researchers observed an ageassociated decline in myoepithelial cells and an increase in luminal cells that express
keratin 14 and integrin-α6, normally expressed exclusively in myoepithelial cells in
women under the age of 30 (Garbe et al., 2012). In addition, this team noted an agerelated increase in defective multipotent progenitor cells, resulting in incompletely
differentiated luminal and epithelial cells. A reduction in myoepithelial cells, known to
act as tumor suppressors, is associated with increased breast tumor progression and
invasiveness (Damiani et al., 1999; Sternlicht et al., 1997; Gudjonsson et al., 2002);
therefore, the Garbe study is the first to suggest that age-associated changes on the
cellular level may promote malignant transformation in breast tissue.
Studies have demonstrated age-related variations in both tumor growth and
immunological response. In one study, fewer tumor-infiltrating lymphocytes were
detected in samples from older women, indicative of a dampened immune response with
age (Kurtz, 1996). Another study found that following partial mastectomy, the local
recurrence rate was only 3% in women over the age of 55 as opposed to 18% in women
younger than 55 (Veronesi et al, 2001). These results suggest that age-related anatomical
differences in the mammary gland between young and older women, including the loss of
well-defined ductal branches and gland integrity, affect the risk of tumor recurrence.
Though dependent on the histological subtype, tumor grade, and stage, breast tumor
biology also changes with age, as those malignancies found in elderly women are
typically more indolent when compared to those in younger patients. Balducci and
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Ershler hypothesize this may be due to senescence of the immune system and endocrine
function, or a decreased number of tumor cells in the growth fraction (2005). Despite
these findings, the underlying age-related cellular and genetic alterations in breast cancer
remain largely undefined.
1.1.2.2 Experimental Models of Breast Cancer
In order to gain a better mechanistic understanding of breast cancer tumorigenesis
and progression, a number of cellular models derived from primary human tumors have
been employed experimentally for over 50 years. The first human cell line was
established in 1952 from a cervical carcinoma, while the first breast cancer cell line was
established six years later in 1958, providing researchers with a mostly homogenous
population of cells capable of self-replication and experimental manipulation. Since then,
numerous human breast cancer cell lines, explanted from a wide array of tumor subtypes
and hormonal profiles, have been established, allowing for long-term propagation in vitro
and resulting in a more comprehensive understanding of the cellular dysfunction that
leads to tumorigenesis.
The immortalized breast cancer cell lines that have been established in culture
may be delineated into one of five classes, based on the molecular classification of the
tumor from which they were derived, including: 1) luminal A (ER+/PR+/–/HER2–); 2)
luminal B (ER+/PR+/–/HER2+); 3) basal (ER–/PR–/HER2–); 4) claudin-low (ER–/PR–
/HER2–); and 5) HER2 (ER–/PR–/HER2+) (Holliday and Speirs, 2011). Notably, the
majority of the most commonly used breast cancer cell lines have been established from
pleural effusions and aspirates that have resulted from metastases, whereas few cell lines
are available that represent early-stage and less aggressive breast carcinomas. Cell lines
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representing rare breast tumors, including phyllodes tumors and inflammatory breast
carcinomas, are also largely underrepresented by experimental models (Holliday and
Speirs, 2011).
The ER-positive MCF-7 cell line represents the most commonly utilized in vitro
models for studies involving anti-estrogen therapies (Holliday and Speirs, 2011). Several
subclones containing various nuclear receptor profiles have been derived from this line,
allowing further translational studies regarding endocrine treatments (Sweeney et al.,
2012). In addition to the MCF-7 cell line, other cell lines of the luminal A subtype,
including T47D cells, are capable of forming tumors in xenograft models in the presence
of estrogen. Cell lines representing other breast cancer subtypes, including BT-474 and
the triple-negative MDA-MB-231 and MDA-MB-468 cells, are also tumorigenic in
animal models; notably, cell lines of the HER2 subtype are typically poor for use in
xenograft models (Holliday and Speirs, 2011). An alternative approach to using
established cell lines is the direct culturing of a primary tumor explant. This method is
not without limitation, however, and the overgrowth of epithelial and stromal cell
populations has impacted its research utility.
There are many advantages to utilizing cell lines for experimental studies,
including the ease of handling and management, cellular homogeneity, and long-term
storage potential. Despite these positive attributes, there are also inherent risks in using
cell lines. The possibility of cross-contamination from other cell lines exists, as does
interlaboratory variability, and the potential for genotypic and phenotypic drifts (Burdall
et al., 2003). Cell lines also lack the presence of stromal cells and three-dimensional
structure, further limiting effectiveness as a model of human tumors (Kim et al., 2004). In
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addition, subpopulations with particular phenotypic alterations may arise, resulting in the
clonal selection of cells that are prone to more rapid cell division following repeated
passaging in culture. Taken together, how closely cell lines represent the heterogeneity of
human breast carcinomas remains controversial, yet they remain an indispensable tool for
laboratory assessment of the disease.
To more closely mimic human breast cancer, many studies rely on the use of
animal models. The most commonly employed models include rodents that have either
been genetically altered, such as transgenic or knockout animals, or animals that are
capable of accommodating the growth of human xenograft tumors. Use of rodent in vivo
models of breast carcinomas provides researchers with the advantage of examining the
cell-cell relationships that exist in a three-dimensional space between the tumor and its
microenvironment, as well as the influence of hormones, cytokines, and immune
modulators on tumorigenesis, growth, and progression.
Under the transcriptional control of the mouse mammary tumor virus (MMTV)
promoter, transgenic MMTV-neu mice carry the inactivated form of the proto-oncogene,
neu. As previously described, genomic amplification of the HER2/neu oncogene occurs
in 20-30% of human breast tumors and its overexpression is inversely correlated with
patient survival. The presence of the neu proto-oncogene in the MMTV/neu mouse model
results in focal tumors in the mammary epithelium that develop after an extended latency
period, making it a more representative model of human breast cancer as compared to
mice that express the neu oncogene. More specifically, intact female mice begin
developing mammary tumors at 4 mo of age, and the median incidence of tumor
formation is 205 days (Guy et al., 1992; Andrecheck et al., 2000).
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As opposed to rodents that receive orthotopic xenografts of human tumors, which
require the mice be immunocompromised, in the MMTV/neu model, the mice have an
intact immune system, thereby providing a more realistic microenvironment. Genetically
engineered mice, such as the MMTV/neu model, also allow for tumors to be followed
from an early point in development, though this may be slow and variable (Richmond
and Su, 2008). Despite the fact that tumors in the MMTV/neu model lack cellular
heterogeneity observed in human tumors, the spontaneous development of tumors in this
model at an age that corresponds to middle-age in women makes it an appropriate choice
for the study described herein.
1.1.3 The Mitogen-Activated Protein Kinase Pathway
The mitogen-activated protein kinase (MAPK) signal transduction pathway acts
to transmit extracellular signals across the cell membrane to intracellular targets through
a series of interacting proteins. The family of MAPK signaling cascades was first
discovered in the late 1980s and is highly conserved among eukaryotes; in some cases,
they act downstream of the oncoprotein, Ras, to carry out numerous cellular functions,
including proliferation, gene expression, differentiation, motility, metabolism, survival,
and apoptosis (Ray and Sturgill, 1987; Krishna and Narang, 2008; Marshall, 1995). In
mammals, six unique groups of MAPKs are known, including the extracellular signalregulated kinases (ERK), ERK1/2, ERK3/4, ERK5, ERK7/8, c-Jun N-terminal kinase
(JNK1/2/3), and p38 (α/𝛽/𝛾/𝛿) (Krishna and Narang, 2008). Of the known MAPK
pathways, the ERK1/2, JNK, and p38 pathways are the most characterized. Each of these
pathways is conserved in Drosophila and Caenorhabditis elegans, while five MAPK
pathways have been identified in Saccharomyces cerevisiae (Yang et al., 2013). Multiple
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encoding genes and splice variants that result in numerous isoforms add complexity to
the mammalian MAPK cascade.

Figure 2. The Mitogen-Activated Protein Kinase family. The mitogen-activated protein
kinase (MAPK) family of proteins consists of a canonical three-tier signaling module that
ultimately results in the phosphorylation of one of the terminal MAPKs that comprise the
family- ERK1/2, ERK5, p38, or JNK1/2/3, followed by the downstream physiological
outcome. Adapted from Nithianandarajah-Jones et al., 2012.

Despite the differences, for many of the MAPKs, each consists of a canonical
three-tier signaling module comprised of a mitogen-activated protein kinase kinase kinase
(MAPKKK), also known as MEKK, which phosphorylates the downstream mitogenactivated protein kinase kinase (MAPKK), also referred to as MEK, which subsequently
phosphorylates a terminal MAPK (Figure 2). The activators of the atypical MAPKs,
including ERK3/4, ERK7, and ERK8 have not been fully elucidated and it has not been
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determined if these kinases conform to the typical three-tier system described (Drew et
al., 2012).
In mammals, the MAPK cascade may be activated by numerous extracellular
stimuli, including growth factors, such as epidermal growth factor (EGF), vascular
endothelial growth factor (VEGF), or platelet-derived growth factor (PDGF), cytokines,
hormones, phorbol esters, and environmental stressors, including oxidative stress and
carcinogens (Krishna and Narang, 2008). Typically, MAPK signaling occurs by one of
three transduction mechanisms: RTK activation, G-protein coupled receptor (GPCR)
activation, or hormone receptor activation (Flaherty et al., 2010). The binding of the
ligand to the RTK induces both dimerization of the receptor and autophosphorylation of
specific tyrosine residues in the C-terminal region (Frémin and Meloche, 2010).
MEKK is a dual specificity kinase capable of phosphorylating serine/threonine
(Ser/Thr) and tyrosine residues; it is activated by either phosphorylation or by interaction
with guanosine-5’-triphosphate (GTP) proteins of the Ras/Rho family in response to an
extracellular stimulus through a guanine nucleotide exchange on Ras. The exchange
occurs via a complex of the guanine nucleotide exchange factor (GEF), Sos (from
Drosophila son of sevenless), and the growth factor receptor-bound adaptor protein,
Grb2, which are recruited to the tyrosine-phosphorylated receptor or through Shc-Grb2Sos complexes (Marshall, 1995). Downstream of MEKK, MEK is also a dual specificity
kinase that phosphorylates MAPK on a conserved threonine-X-tyrosine (T-X-Y) motif
(Marshall, 1994). Once activated, MAPKs then activate downstream targets, including
DNA-binding transcription factors, histones, and cytoskeletal proteins, on Ser/Thrproline residues.
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Several upstream MEK activators of the MAPKs are known, including MEK1 and
MEK2 for ERK1/2, MKK4 and MKK7 for JNKs, MKK3 and MKK6 for p38, and MEK5
for ERK5 (Drew et al., 2012). The physiological effect that results from MAPK signaling
is determined by several factors, including the cell type and the magnitude and duration
of kinase activation (Marshall, 1994). MEKs demonstrate a high degree of substrate
specificity; in turn, specificity of the MAPK for its substrate is determined by the docking
domain on that substrate as the MAPK tethers the target to its docking domain to increase
the reaction efficiency. The phosphorylation reactions that result are regulated by protein
phosphatases, transcription factors, enzymes, subcellular localizations, and binding
partners, which ultimately affect gene expression (Drew et al., 2012; Yang et al., 2013).
Furthermore, phosphatases and scaffold proteins associate with components of the
MAPK pathway to regulate signal transduction and phosphatases also play a role in
feedback loops that affect the duration of signaling (Owens and Keyes, 2007; Yang et al.,
2013). Protein phosphorylation remains the most widespread class of post-translational
modification in signal transduction (Roskoski, 2012).
1.1.3.1 The MEK1/2-ERK1/2 Pathway
The ERK1/2 pathway was the first MAPK identified in mammals in the early
1990s and remains the most characterized member of the MAPK family. The two
isoforms, ERK1 and ERK2 (p42 and p44), possess 83% amino acid identity and are
ubiquitously expressed in all tissue types (Krishna and Narang, 2008; Seger and Krebs,
1995). The direct upstream activators of ERK1/2 are the 45kDa MEK1, and MEK2
(46kDa). Both MEK 1 and MEK2 are regulated by numerous
phosphorylation/dephosphorylation events (Shaul et al., 2007). In general, the ERK1/2
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cascade is activated by growth factors, while JNK and p38 are most often activated by
extracellular stress (Yang et al., 2013). The growth factors bind to and activate the cell
surface receptor, such as a RTKs and GPCRs. Following ligand binding, the conversion
of Ras from the guanosine diphosphate (GDP)-bound form to the GTP-bound form is
mediated by the GEF, Sos. A Ras effector molecule, such as Raf-1, A-Raf, and B-Raf, is
then attracted to the effector loop of Ras and becomes tethered to the membrane where
Ras is bound (Krishna and Narang, 2008; Weinberg, 2007). For the ERK1/2 pathway, the
MAPKKK Raf-1, then phosphorylates the downstream dual specificity MAPKK
MEK1/2, which, in turn, activates the terminal MAPK, ERK1/2, within the T-X-Y motif
(Figure 3).

Figure 3. The MEK1/2-ERK1/2 pathway. The terminal ERK1/2 is activated through a
series of phosphorylation events that occurs upstream following ligand binding to the
receptor tyrosine kinase (RTK) or G-protein coupled receptor (GPCR). The MEK1/2ERK1/2 pathway adheres to the three-tier activation module from the MAPKKK to the
MAPK as described in the text. Adapted with permission from Frémin and Meloche, 2010.
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To date, the ERKs are the only known substrates of MEK, signifying MEK is a
source of specificity for the cascade (Pearson et al., 2001). A substantially higher amount
of MEK than Raf-1 results in signal amplification (Santen et al., 2002). MEK also
functions as a cytoplasmic anchor for ERK (Shaul and Seger, 2007). Raf-1 is the major
mediator associated with the activation of MEK1 and MEK2, however these kinases are
also phosphorylated by the Mos protooncogene product, MEK kinase 1 (MEKK1) (Cobb
and Goldsmith, 1995). Once ERK becomes activated, it phosphorylates cytoplasmic
substrates, such as p90 ribosomal S6 kinase (RSK), calnexin, and PLA-2. A significant
proportion of activated ERK also translocates and accumulates in the nucleus where it
may phosphorylate several transcription factors involved in cell proliferation,
differentiation, and angiogenesis, including Ets, Elk-1, Mnk1, c-fos, c-Jun, and c-myc
(Lenormand et al., 1993; Yoon and Seger, 2006; Weinberg, 2007). The determination of
substrate specificity has been attributed to the duration and strength of signals,
interactions with scaffold proteins, crosstalk with alternative signaling pathways, and
subcellular localization (Shaul and Seger, 2007).
Both ERK1 and ERK2 may form homodimers, and it has been established that
ERK dimers are primarily located in the cytoplasm, and have been proposed to be
required for the activation of cytoplasmic ERK substrates. Conversely, monomeric ERK
is responsible for the phosphorylation of nuclear transcription factors (Casar et al., 2008;
Yang et al., 2013). A large portion of ERK1/2 (50-70%) is found in the nucleus within 10
to 20 min following pathway stimulation (Chen et al., 1992). In addition, the ERKs may
phosphorylate MAPK-activated protein kinases (MAPKAPK) that increase the
specificity, amplification, and diversity of the MEK1/2-ERK1/2 pathway (Krishna and
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Narang, 2008). Activation of the ERK1/2 cascade following extracellular activation may
be either transient (lasting approximately 20 min) or sustained (lasting up to 2 to 3 h)
(Wortzel et al., 2011). In addition to the 200 previously identified substrates of ERK1/2,
a quantitative phosphoproteomics study recently classified 155 novel ERK1/2 substrates,
including 128 new targets (Wortzel et al., 2011; Courcelles et al., 2013).
Auto-regulation of the MEK1/2-ERK1/2 cascade occurs by ERK1/2 inactivation
of MEK1 or ERK1/2 upregulation of specific phosphatases, such as MAPK dualspecificity phosphatases (MKP2 and 3) (Whyte et al., 2009). In addition to scaffold
proteins previously discussed, the self-directed regulation determines both the intensity
and duration of the MEK1/2-ERK1/2 cascade.
1.1.3.2 The MEK5-ERK5 Pathway
The most recently discovered, and thereby least characterized, member of the
MAPK family of protein kinases, ERK5, is structurally and physiologically similar to
ERK1/2 and, likewise, plays a role in cell survival, differentiation, proliferation, motility,
and apoptosis (Kato et al., 1997; Suzaki et al., 2002; Nishimoto et al., 2006; Li et al.,
2008). In 1995, ERK5 was first discovered by two independent groups. Using a yeast
two-hybrid screen, Zhou and colleagues identified ERK5 as a binding partner for MEK5,
while Lee et al. screened a human placenta cDNA library to identify a novel MAPK gene
that they coined big MAPK (BMK)-1, due to its size relative to the known ERK1/2 (Lee
et al., 1995; Nithianandarajah-Jones et al., 2012; Zhou et al., 1995). Similar to the
previously identified MAPKs, ERK5 is activated by growth factors and stressors,
including EGF, UV radiation, and oxidative stress. The ERK5 pathway also adheres to
the three-tier signaling module. As with relative MAPKs, ERK5 also contains a common
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docking (CD) domain that consists of a short sequence of negatively charged amino acid
residues and allows ERK5 to associate with particular docking (D)-domain-containing
substrates (Nithianandarajah-Jones et al., 2012). ERK5 is ubiquitously expressed in
numerous tissue types, such as heart, skeletal muscle, placenta, lungs and kidneys (Lee et
al., 1995; Zhou et al., 1995).

Figure 4. The MEK5-ERK5 pathway. The activation of the terminal MAPK, ERK5, results
from a cascade of phosphorylation events that follow the three-tier module characteristic of
the MAPK signal transduction family. The large C-terminus of ERK5 contributes to unique
cellular functions that separate this pathway from relative kinases in the MAPK family, as
described in the text. Adapted with permission from Drew et al., 2012.

Both MEKK2 and MEKK3 are capable of activating MEK5 in a stimulus- and
cell-type specific manner (Wang and Tournier, 2006). In the MEK5-ERK5 cascade, the
binding of MEKK proteins occurs on the N-terminus extension of MEK5, of which
MEK5α and MEK5β, two splice variant isoforms, have been identified (Drew et al.,
2012). MEK5α is a stronger activator and has a higher affinity for ERK5 than MEK5β,
and contains a unique MAPK docking site on its N-terminus that is different than the
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consensus motifs in other MEKs, including a phox and Bem1p (PB1) domain, which
regulates MEKK2/3 binding with MEK5 (Figure 4) (Wang and Tournier, 2006; Drew et
al., 2012).
Despite the similarities to the relative MAPKs, with a molecular mass of
approximately 100 kDa, a large C-terminus that contains both auto-inhibitory and nuclear
shuttling functions, and a unique 12-loop structure, ERK5 distinguishes itself from other
familial kinases (Cavanaugh, 2004; Drew et al., 2012). The N-terminal conserved MAPK
catalytic domain of ERK5 shares a 50% homology with that of ERK1/2 (Wang and
Tournier, 2006). ERK5 has distinct upstream activators and downstream targets from the
other MAPKs. To date, ERK5 is the only known substrate of MEK5, which, unlike
MEK1/2, is not activated or phosphorylated by Raf-1 (Pearson et al., 2001). Activated
ERK5

subsequently phosphorylates

numerous

transcription

factors,

the

most

characterized being the myocyte enhance factor (MEF) family of proteins: MEF2A,
MEF2C, MEF2D (Kato et al., 1997). The unique C-terminal tail of ERK5 is required for
the phosphorylation of alternative sites on c-Fos that lead to its maximal transactivation;
the C-terminus is also required to achieve maximal activation of the transactivation
activity of fos-related antigen-1 (Fra-1) (Terasawa et al., 2003). ERK5 is also distinct
from ERK1/2 in that it functions in heart development, vasculogenesis, angiogenesis, and
endothelial cell survival (Hayashi et al., 2004).
1.1.3.3 The ERK Pathways in Cancer
As the MAPK signal transduction cascades consist of serine/threonine kinases
that play crucial roles in numerous intracellular signaling events, including proliferation,
survival, angiogenesis, and apoptosis, they present promising targets for the development
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of anticancer agents (Chang et al., 2001; Sebolt-Leopold, 2008). Of particular importance
in carcinogenesis is the pathway in which growth factors and mitogens activate the ERK
pathways. Studies utilizing pharmacological inhibitors of MEK and a negative regulator
of MEK demonstrated a significant alteration in the ability of NIH3T3 fibroblasts to
proliferate in response to growth factors (Sebolt-Leopold and Herrera, 2004).
It is also known that ERK activation is required for cyclin D1 expression and the
duration and intensity of the ERK pathway dictates whether the cell undergoes
differentiation, proliferation, or cell cycle arrest (Marshall, 1995). Furthermore, the ERK
pathway plays a vital role in cellular survival. Apoptosis induced by growth factor
withdrawal, loss of matrix attachment, or cytoskeletal disruption was prevented in cells
following ERK1/2 activation. The pathway also promotes survival by repressing proapoptotic members of the Bcl-2 family of proteins and promoting the expression of the
pro-survival members (Frémin and Meloche, 2010).
As such, the MAPK pathway has been a primary area of cancer research over the
past 20 years (Dhillon et al., 2007), leading to the development of novel target-specific
inhibitors of these pathways that are currently in clinical trials. However, related
toxicities compounded by the development of resistance to these therapies in both
preclinical and clinical models, necessitate further investigation (Saini et al., 2013; Dai et
al., 2011; Hatzivassiliou et al., 2012). The similarities that exist between the ERK1/2 and
ERK5 signaling cascades may contribute to the observed chemoresistance with
anticancer agents that target the MEK1/2-ERK1/2 pathway, as crosstalk between these
pathways and other members of the MAPK family have been noted (Kamakura et al.,
1999; Poddar et al., 2013; Fey et al., 2012; Sabri et al., 2011).
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1.1.3.4 MEK1/2-ERK1/2 Pathway in Cancer
Aberrant signaling within the MEK1/2-ERK1/2 pathway is associated with
several pathologies, including neuro-cardio-facial-cutaneous developmental syndromes,
neurodegenerative diseases, diabetes, and cancer (Courcelles et al., 2013; Wortzel et al.,
2011). Of the known MAPKs, ERK1/2 is the most extensively studied in cancer, as
dysregulation of the cascade has been observed in one-third of all human cancers and has
been noted in numerous solid tumor types, including prostate, bladder, liver, and breast
(Al-Azayzih et al., 2012; Krishna and Narang, 2008; Rodriguez-Berriguete et al., 2012;
Whittaker et al., 2010; Frey et al., 1997; Saini et al., 2013). The pivotal role the MEK1/2ERK1/2 pathway plays in cellular survival, differentiation, and survival denotes how
aberrations in the cascade are observed in a large portion of tumors. Alterations
contributing to cancer transformation occur throughout the entire signaling cascade,
beginning as far upstream as Ras and continuing to the terminal MAPK.
Mutations in the transforming oncogenic RAS genes, particularly in KRAS
(~85%), are observed in approximately 30% of cancers. More specifically, mutant RAS
has been indicated in a variety of tumor types, including pancreatic (90%), colon (50%),
lung (30%), thyroid (50%), bladder (6%), ovarian (15%), breast, skin, liver, kidney, and
some leukemias (Wang and Tournier, 2006). Such correlations are likely due to the
variety of signaling pathways of which Ras lies upstream and the critical cellular
functions these pathways are responsible for controlling. RAS signaling pathways are
often activated in ovarian, stomach, and breast tumors where growth-factor RTKs, such
as EGFR and ERBB2, are overexpressed (Downward, 2003). Downstream of Ras, BRAF
mutations occur in nearly 20% of all cancers (Downward, 2003; Frémin and Meloche,
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2010). Mechanistic studies of the oncogene B-Raf have elucidated unique mechanisms
through which Raf kinases activate MEK-ERK signaling. The BRAF codon 600 mutation
(V600E), in particular, significantly elevates B-Raf kinase activity and, thereby,
activation of the ERK pathway (Garnett and Marais, 2004).
Clinical studies have also found that MEK1/2 and ERK1/2 are hyperactivated in
both solid tumors and hematological malignancies (Horshino et al., 1999; Sebolt-Leopold
and Herrera, 2004). Moreover, activated ERK1/2 is capable of inducing the
overexpression of EGFR ligands, resulting in an autocrine feedback loop (McCubrey et
al., 2007). Deregulation of phosphatases and Sprouty proteins, feedback inhibitors of the
ERK pathway, has been shown to disrupt the antiproliferative effects of transforming
growth factor-beta (TGF-β), thereby leading to uncontrolled cell growth.
Other mechanisms through which ERK1/2 contributes to cancer progression
include the disruption of Rho signaling pathways, the phosphorlyation of the focal
adhesion kinase (FAK) and paxillin proteins involved in cell migration, and the
regulation of protease expression in basement membrane degradation (Krishna and
Narang, 2008). Activated MEK1/2-ERK1/2 signaling has also been shown to promote
phenotypically aggressive tumors. A study involving the orthotopic transplantation of
mammary or intestinal epithelial cells expressing activated MEK1/2 into mice resulted in
the formation of aggressive tumors that progressed to metastases (Frémin and Meloche,
2010).
1.1.3.5 MEK5-ERK5 Pathway in Cancer
The MEK5/ERK5 pathway is constitutively active in numerous cancer types,
including prostate and breast, as compared to normal cells (Drew et al., 2012). In both
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non-transformed and transformed cells, ERK5 has been found to mediate the effects of a
number of oncogenes, including Ras and Src, and its role in tumor development and
progression continues to be elucidated (Kamakura et al., 1999; English et al., 1999;
Barros et al., 2005; Lockhead et al., 2012). For example, in PC12, C2C12, and COS7
cells, Ras was shown to activate ERK5 (Wang and Tournier, 2006). Moreover, in
fibroblasts it has been demonstrated that oncogenic forms of Src activate ERK5 and
ERK1/2, leading to the loss of the actin cytoskeleton and formation of invasive
podosomes (Nithianandarajah-Jones et al., 2012). The Cot oncogene was also shown to
stimulate c-jun promoter activity via ERK5 in NIH3T3 cells, inducing neoplastic
transformation (Chiariello et al., 2000).
As in the MEK1/2-ERK1/2 cascade, alterations responsible for oncogenesis and
tumor progression have been observed throughout the MEK5-ERK5 pathway. Beginning
with the RTK, activated forms of the ErbB2, ErbB3, or ErbB4 receptors have been linked
to the constitutive activation of ERK5 (Esparís-Ogando et al., 2002). Mutations or
overexpression of the ErbB family of RTKs in cancer are associated with poor patient
prognosis, shorter disease-free intervals, therapeutic resistance, and enhanced risk of
metastasis. Further downstream at the terminal MAPK, a study involving mice bearing
xenographic tumors determined that ERK5, acting through the ribosomal protein S6
(RPS6), is critical in the development of tumor vasculature and sustained tumor growth
(Hayashi et al., 2005).
Mutations leading to carcinogenesis may occur anywhere along the ERK5
pathway. This, compounded with the fact that ERK5 is responsible for controlling a large
number of cellular functions, in which aberrations often result in malignancies, signifies
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that a thorough understanding of the ERK5 pathway is crucial for cancer prevention and
treatment. In addition to the aforementioned role in tumor growth and vasculature, it is
known that ERK5 is crucial for proper endothelial cell development and function, as well
as maintaining the integrity of blood cells (Hayashi et al., 2004). Therefore, it is not
surprising that ERK5 also mediates VEGF- and fibroblast growth factor (FGF)-induced
angiogenesis. Several studies have also linked ERK5 with the epithelial-mesenchymal
transition (EMT), a process that occurs during normal embryonic development and
wound healing, but has also been implicated in hyperplasia, the development of
adenomas, and tumor progression (Arnoux et al., 2008; Drew et al., 2012; Edme et al.,
2002).
Activation of the MEK5-ERK5 pathway has been implicated in carcinogenesis
and cancer progression in several tumor types. The ERK5 pathway is known to regulate
cell proliferation and numerous studies have linked dysregulation of the pathway to
aberrant growth in cancer. In malignant mesothelioma, a phosphatidylinositol 3-kinase
(PI3K)/ERK5/Fra-1 pathway was shown to enhance cell proliferation following
hepatocyte growth factor (HGF) stimulation. ERK5 regulation of apoptosis and
proliferation was also demonstrated in multiple myeloma (Carvajal-Vergara et al., 2005).
Not only has ERK5 been linked to increased proliferation, but several studies have also
implicated it plays a role in metastasis. In oral squamous cell carcinoma, ERK5 was
correlated with advanced tumor stage and lymph node metastasis (Sticht et al., 2008). In
NIH3T3 fibroblasts, researchers demonstrated the importance of ERK5, more so than
ERK1/2, in the formation of Src-induced podosomes and the contribution to the invasive
properties associated with constitutively activated Src (Schramp et al., 2008).
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Furthermore, elevated MEK5 expression has been correlated with increased metastasis to
the bone and unfavorable prognosis in patients with prostate cancer and benign prostatic
hypertrophy due to the increased production and secretion of matrix metalloproteinase-9
(MMP-9) (Mehta et al., 2003).
From a therapeutic standpoint, a greater mechanistic understanding of the MEK5ERK5 in cancer metastasis, as opposed to correlative studies, would enhance the
opportunity for targeted intervention. A link between the FAK pathway and ERK5
cascade suggests that integrin-mediated FAK signaling promotes metastasis through the
ERK5 pathway (Sawhney et al., 2009). In prostate cancer studies, researchers found that
overexpression of MEK5 results in the expression of MMP-2 and MMP-9 (Mehta et al.,
2003; Ramsay et al., 2011). Taken together, these findings indicate ERK5 may be critical
for cell attachment to the extracellular matrix (ECM), shedding light on the involvement
of the kinase in cell motility, and thereby offering one such potential avenue for
prevention and treatment. As ERK5 is the only known substrate for MEK5, targeting this
unique pathway may minimize side effects and reduce toxicity by sparing other MAP
kinase activity critical for the homeostasis and survival of healthy cells.
1.1.4 MAPK Pathways in Breast Cancer
Of the three most extensively studied MAPKs, (ERK1/2, p38, and c-Jun), the
MEK1/2-ERK1/2 pathway is the most characterized in breast cancer (Santen et al.,
2002). Though not yet as extensively studied in breast cancer as the MEK1/2-ERK1/2
pathway, emerging studies have revealed the contributions of the MEK5-ERK5 pathway
in carcinogenesis, tumor growth, and chemoresistance. As the mechanistic
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characterization of these pathways progresses, so too does the realization of targetspecific approaches to combating this disease.
In addition to the traditional activators of the MAPK pathway discussed earlier,
estrogen and progesterone may bind to and activate RTKs in breast cancer. Importantly,
in hormone dependent breast cancer, the MAPK pathway is capable of directly catalyzing
the phosphorylation of the ER, resulting in enhanced transcriptional efficiency. The
cytoplasmic substrate, RSK, may also phosphorylate ER, again leading to increased
transcription efficiency (Santen et al., 2002). Furthermore, estradiol (E 2) is capable of
modulating the MAPK pathway directly. After binding to the ERα receptor, E2 activates
c-Src that subsequently activates numerous signaling cascades, including the ERK1/2
pathway, ultimately leading to increased cellular migration, though the extranuclear and
nuclear activities of E2 on cell migration remain to be fully characterized (Li et al., 2010).
Most breast cancer cells possess cell surface receptors for peptide growth factors,
such as EGF. Moreover, HER2/ErbB2 overexpression occurs in 20-30% of breast cancer
patients. As such, EGF binding to ErbB3 or ErbB4 receptors results in homo- or
heterodimerization with ErbB2, increasing kinase activity and leading to receptor
autophosphorylation and downstream signaling to promote cellular proliferation (Renoir
et al., 2013). Upstream of ERK, rare mutations to Ras and Raf also contribute to breast
tumor progression. In 1.5% of patients, K-Ras is mutated, while B-Raf is mutated in 3%
of patients (Saini et al., 2013).
Despite the rare mutation rates of Ras and Raf in breast cancer, increased
expression of gene sets related to the Raf/MEK/ERK pathway have been found to be
higher in TNBC than other subtypes, indicating MEK inhibition may be a viable
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treatment option in patients with this disease subtype (Saini et al., 2013). A study in
TNBC patients found that tumors displaying ERK2 overexpression correlated with an
overall lower patient survival rate as compared to those with low ERK2-expressing
tumors. Interestingly, however, higher overall MAPK activation was associated with a
significantly higher relapse-free survival rate, which the authors speculate may be due to
the cellular localization of the kinases at the time of assessment, warranting further
evaluation (Bartholomeusz et al., 2012).
In as many as 25-50% of breast carcinomas, the MEK1/2-ERK1/2 pathway is
elevated, and in approximately 30% of tumors, ERK1/2 is mutated, though the type of
aberration varies with subtype and individual differences (Pinkas and Leder, 2002; Whyte
et al., 2009). Furthermore, a higher frequency of ERK1/2 activation was observed in ER +
breast tumors as compared to normal breast tissue, and was significantly correlated to
shorter, less efficacious endocrine therapy response (Gee et al., 2001). The
overexpression of the upstream kinase, MEK1, in normal mammary epithelial cells
induced neoplastic transformation in these cells, further linking the pathway to breast
carcinogenesis. Moreover, increased expression of ERK1/2 was observed in the primary
tumors of node-positive patients, indicating ERK1/2 activity may impact metastatic
potential in breast carcinomas (Mueller et al., 2000). In fact, in IDCs, both in vitro and in
vivo results demonstrated activation of ERK1/2 increased the metastatic potential of these
cells by increasing both their migratory and invasive capacities (Ma et al., 2012).
The MEK5-ERK5 pathway, as with the MEK1/2-ERK1/2 cascade, is
dysregulated in breast cancer, contributing to increased proliferation, sustained survival,
decreased apoptosis, and the EMT (Figure 5). One study also revealed ERK5 forms a
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complex with the avβ3 integrin and FAK, leading to aberrant cell adhesion and migration
(Sawhney et al., 2009). The transduction of ERK5 signaling is altered in several different
cell lines representing various hormonal profiles. In the ER+/PR+/- MCF-7 cell line, ERK5
was shown to play a role in chemoresistance, regulation of apoptosis, and mediation of
cellular survival (Weldon et al., 2002). ERK5 is constitutively active in both the BT-474
(ER+/PR+/–) and SKBR3 (ER–/PR–) cell lines; when a dominant negative form of ERK5
was added to these cells, a decrease in proliferation was observed, indicating that the
ERK5 pathway is responsible for directing growth signals in cells with disparate
hormonal profiles (Esparís-Ogando et al., 2002). A study conducted using the triple
negative MDA-MB-231 cell line (ER–/PR–/HER2–) found that ERK5 promotes cell
proliferation through the suppression of the cyclin-dependent kinase (CKI), p21 (PerezMadrigal et al., 2012).
Researchers examining the downstream targets of Breast Tumor Kinase (Brk), a
protein tyrosine kinase overexpressed in 86% of invasive ductal breast carcinomas,
revealed that when Brk is knocked down in the ER+/PR+/- T47D cell line, ERK5, cyclin
D1 expression, and cell migration were reduced. As Brk increases EGF and heregulininduced activation of ERK5, this study suggests Brk-mediated activation of ERK5
enhances tumor progression (Hsieh et al., 2005; Drew et al., 2012). Other studies
demonstrated that ERK5 mediates HGF-induced cell migration through the MET
receptor/BRK pathway, further suggesting a mechanism through which ERK5 contributes
to the progression and metastasis of breast cancer (Castro and Lange, 2010). Notably, in
human breast tumor samples, ERK5 overexpression was observed in tumors regardless of
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HER2 overexpression, indicating that other routes of activation may be involved
(Montero et al., 2009).

Figure 5. The MEK5-ERK5 Cascade in Breast Cancer. The ERK5 pathway contributes to
carcinogenesis and sustained tumor growth and survival in breast cancer. Activation of
numerous downstream cytosolic and nuclear substrates results in a variety of physiological
functions as described in the text. Adapted with permission from Drew et al., 2012.

In addition to the various cellular functions in which ERK5 is involved, the kinase
is also associated with negative patient outcomes. Clinical studies revealed MEK5 was
overexpressed in over 50% of breast tumors analyzed and ERK5 in over 20% of patients;
further, patients with higher levels of ERK5 expression had reduced disease-free survival
time as compared to patients with lower expression of the kinase (Hsieh et al., 2005;
Montero et al, 2009).
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To date, the most commonly targeted MAPK in terms of inhibitor development
has been MEK1 (Sebolt-Leopold and Herrera, 2009). A growing number of inhibitors of
the MEK1/2-ERK1/2 cascade, including MEK162, PD0325901, AZD6244 (selumetinib,
ARRY-142886), CI-1040 (PD184352), and GSK1120212 (trametinib), have recently
completed or entered into clinical trials for the treatment of solid tumors, including breast
carcinomas (Figure 3). The development of numerous successful MEK inhibitors may be
attributed to the relatively few phosphorylation sites present on MEK that are involved in
activation and inactivation (McCubrey et al., 2007). The similarities that exist between
the ERK1/2 and ERK5 signaling cascades have important pharmacological implications
and may contribute to the suboptimal efficacy, off-target toxicity, and chemoresistance
observed with these anticancer agents, as crosstalk between these pathways and other
members of the MAPK family have been established (Kamakura et al., 1999; Poddar and
Paul, 2013; Fey et al., 2012; Sabri et al., 2011). Therefore, given the potential for
compensatory mechanisms to allow the tumor to circumvent the effects of pathway
inhibitors, a more comprehensive, and perhaps patient-specific, therapeutic approach may
be necessary.
1.1.5 The Phosphatidylinositol 3-Kinase Pathway
The phosphatidylinositol 3-kinases are a family of protein kinases that play a
crucial role in regulating a variety of cellular functions, including metabolism, motility,
survival, and proliferation (Cantley, 2002; Bader et al., 2005; Vivanco and Sawyers,
2002). First discovered in the 1980s, there are three classes of PI3Ks: class I, class II, and
class III, each delineated based on structure and function, as well as phosphoinositide
substrate preference and second messenger production (Domin et. al, 1997; Martini et. al,
36

2013). The phosphatidylinositol phosphates contain a membrane-associated phosphatidic
acid group and glycerol moiety that are linked to a cytosolic phosphorylated inositol head
group. The PI3Ks are heterodimers with distinct catalytic and regulatory subunits
(Vivanco and Sawyers, 2002). Extracellular signals to the PI3K pathway are transduced
from growth factors or cytokines intracellularly through the generation of phospholipids,
which activate the serine-threonine protein kinase, Akt, also known as protein kinase B
(PKB), and other downstream cascades. To date, three members of the Akt family have
been characterized: Akt1, Akt2, and Akt3, also known as PKBα, PKBβ, and PKBγ;
despite resulting from three unique genes, these kinases exhibit 80% amino acid
homology (Ghayad and Cohen, 2012).
Activation of downstream effectors within the pathway ultimately mediates
cellular homeostasis through the regulation of protein synthesis, metabolism, and survival
(Liu et al., 2009). For example, PI3K signaling through insulin and insulin-like growth
factor-1 (IGF-1) is critical for metabolism control (Saini et al., 2013). The PI3Ks catalyze
the phosphorylation of inositol-containing lipids, termed phosphatidylinositols (PtdIns) at
the D3-position; the primary substrate is PtdIns(4,5)P 2 (PIP2), which is converted into
PtdIns(3,4,5)P3 (PIP3) (Figure 6). Phosphorylation at the D3 position is required for
binding to the pleckstrin-homology (PH) domain of Akt (Vivanco and Sawyers, 2002).
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Figure 6. The Phosphatidylinositol 3-Kinase Pathway. Growth factors, hormones, or
cytokines signal through RTKs or GPCRs to generate phospholipids that signal to
downstream effector molecules. The PI3K family of proteins regulates numerous cellular
functions, including survival, growth, apoptosis, and DNA repair. Adapted with permission
from Liu et al., 2009.

Class I PI3Ks are the most characterized in the family and are further classified
into two subgroups, IA and IB. Class IA enzymes are activated by RTKs, GPCRs, and
select oncogenes, including RAS, while class IB enzymes are exclusively regulated by
GPCRs (Liu et al, 2009; Vivanco and Sawyers, 2002). Following activation of the RTK,
class IA enzymes are recruited to the membrane by interaction between the Src homology
2 (SH2) domains of the p85 subunit with phosphotyrosines on activated receptors or
associated proteins (Gomperts et al., 2003; Liu et al., 2009). The class IA enzymes
possess the unique ability to activate the serine/threonine specific protein kinase, Akt.
The class IB enzyme that has been characterized is found only in mammals and is a
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heterodimer comprised of the p110γ catalytic subunit and the p101 regulatory subunit.
The p110γ catalytic subunit may be regulated by trimeric G-protein βγ-subunits
(Gomperts et al., 2003; Liu et al., 2009). Class II and III PI3Ks are much less
characterized than class I and the specific activators and cellular functions attributed to
these enzymes remain to be fully elucidated.
Following the conversion of PIP2 to PIP3, signaling proteins with PH domains
accumulate at the site of PI3K activation by directly binding to PIP3. Both Akt and 3phosphoinositide-dependent protein kinase 1 (PDK1), two PH-domain containing
proteins, bind to PIP3 at the plasma membrane, which allows PDK1 to phosphorylate Akt
at the T308 site, leading to partial activation of Akt (Figure 6) (Cantley, 2002; Hemmings
and Restuccia, 2012). The majority of Akt phosphorylation events lead to inhibition of
the target proteins. The partial activation of Akt by PDK1 is sufficient to activate the
mammalian target of rapamycin (mTOR) by phosphorylating, and thereby inactivating,
proline-rich Akt substrate of 40 kDa (PRAS40) and tuberous sclerosis protein 2 (TSC2)
(Hemmings and Restuccia, 2012). mTOR is a serine/threonine kinase composed of two
distinct protein complexes, mTORC1 and mTORC2. Activation of mTOR leads to the
subsequent activation of the downstream effector molecules eukaryotic translation
initiation factor eIF4E-binding protein 1 (4EBP1) and p70S6 kinase (S6K), which then
phosphorylates RPS6, ultimately resulting in increased protein synthesis (Saini et al.,
2013).
To achieve maximal activation of Akt, phosphorylation at Ser473 by one of
several potential kinases, such as PDK2, mTORC2, integrin-linked kinase (ILK), DNAdependent protein kinase (DNA-PK), or Akt itself, is required (Cidado and Park, 2012).
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Once activated, Akt regulates many cellular functions and phosphorylates numerous
cytoplasmic and nuclear substrates. In addition to modulating cellular metabolism,
growth, angiogenesis, and transcription, Akt also exerts control over a number of proteins
directly involved in cell cycle regulation. Among these substrates is p27, a cell cycle
inhibitor, the forkhead box (FOXO) transcription factor proteins, glycogen synthase
kinase-3 beta (GSK-3β), and TSC2 (Figure 6) (Cully et al., 2006; Hemmings and
Restuccia, 2012; Vivanco and Sawyers, 2002).
The family of PI3Ks are regulated in normal cells by a variety of phosphatases
and negative feedback mechanisms. One such mechanism involves p85 and its ability to
both stabilize and inactivate the p110 catalytic subunit (Cuevas et al., 2001). The
dephosphorylation of Akt at T308 by protein phosphatase 2 (PP2A) and at S473 by the
PH-domain leucine-rich-repeat-containing protein phosphatases (PHLPP1/2) also
regulates PI3K/Akt activity (Hemmings and Restuccia, 2012). The tumor suppressor gene
phosphatase and tensin homolog, deleted on chromosome 10 (PTEN, also MMAC1) is
the principal regulator in the PI3K pathway, as it dephosphorylates the 3 position of
PI(3,4,5)P3 to produce PI(4,5)P2 (Cantley, 2002; Saini et al., 2013). The SH-2 containing
inositol 5'-polyphosphatase 1 (SHIP1) or SHIP2 may also dephosphorylate PI(3,4,5)P 3 at
the D5 position, regenerating PI(4,5)P2. Further, inositol polyphosphate 4-phosphatase
type II (INPP4B) is a lipid phosphatase that converts PI(4,5)P2 to phosphatidylinositol
monophosphate (PIP) (Saini et al., 2013).
Loss of the PTEN protein or function through point mutations or other genetic
processes leads to unregulated, constitutive Akt activity as a result of accumulated
PI(3,4,5)P3, and has been observed in a number of human cancers (McCubrey et al.,
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2012; Vivanco and Sawyers, 2002). More specifically, PTEN has been found to be
mutated or deleted in 25-50% of glioblastomas, 40-50% of prostate cancers, and 35% of
endometrial cancers, in addition to being mutated or deleted in Cowden’s disease, which
congenitally predisposes patients to cancer (Scheid and Woodgett, 2001).
1.1.5.1 The PI3K Pathway in Cancer
Hyperactivation of the PI3K/Akt/mTOR pathway has been linked to several
pathologies, including Type II diabetes and cancer. As previously discussed, aberrations
in tyrosine kinase signaling often result in oncogenesis, due to the involvement of growth
factors and the downstream effects on cellular functions, including growth, survival, and
proliferation, which are often uncontrolled in malignancies. This is also the case with the
PI3K pathway, in which dysfunctions leading to cancer are most often attributed to
genetic alterations including the loss of PTEN, amplification of the genomic region
containing Akt, and activating point mutations at PI3K (Ligresti et al., 2009).
Deregulation of PI3K via genetic and epigenetic changes is responsible for approximately
30% of all cancers (Pal and Mandal, 2012).
An example of such alterations is the amplification of the phosphatidylinositol4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, gene, which encodes the
catalytic subunit, p110α. PIK3CA is the most frequently mutated oncogene in human
cancers. Activating mutations induce a gain of function leading to constitutive signaling
and sustained tumor progression (Liedtke et al., 2008). Somatic mutations in PIK3CA
have been noted in several human tumor types, including colon, liver, ovarian, brain,
stomach, lung, and breast (Ligresti et al., 2009). Other mutations and/or amplifications in
the PI3K pathway often observed in cancer include those to the catalytic subunit p110β
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(PIK3CB), the regulatory subunits p85α (PIK3R1) and p85β (PIK3R2), and to Akt
(AKT1).
Further, alterations to the negative regulators, PTEN and INPP4B, may affect
sensitivity to chemotherapeutics and target-specific therapies (Martini et al., 2013). The
TSC1-TSC2-TOR axis has also received attention regarding its role in carcinogenesis.
Mutations to the tumor suppressor genes TSC-1 or TSC-2 lead to tuberous sclerosis, a
syndrome that predisposes patients to malignancies, and inhibition of TOR has
demonstrated effectiveness in preventing tumor development in both murine and human
tumors (Cully et al., 2006).
The activation of Akt that results in increased cell growth, survival, and
proliferation, closely links this kinase to malignancies; furthermore, upregulation of Akt
is often associated with poor patient prognosis. Akt activation mediates other processes
essential for tumor maintenance and progression, including angiogenesis through
hypoxia-inducible factor-1α (HIF-1α) and VEGF and the modulation of EMT through
nuclear factor kappa from B cells (NF-κB) and GSK-3β (McCubrey et al., 2012; Vivanco
and Sawyers, 2002). Additionally, Akt targets numerous apoptotic molecules that play a
role in cell survival. Namely, Akt suppresses the Bcl-2 associated death promoter (Bad)
and promotes Bcl-2 interacting mediator of cell death (Bim) activity (McCubrey et al.,
2012).
Dysregulated activation of the components that comprise the PI3K pathway
results in altered signaling that often leads to oncogenesis. Several cellular functions are
reliant on regulated PI3K signaling to maintain homeostasis and, ultimately, survival.
Deviations in signaling contribute to oncogenesis in numerous tumor types and in a
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variety of functions necessary for cancer cell maintenance and growth. Particularly in
breast cancer, mutations and constitutive activation of the PI3K pathway are associated
with all three major subtypes, contributing to worsened prognosis and treatment
sensitivity and resistance (Saini et al., 2013).
1.1.6 The PI3K Pathway in Breast Cancer
Since the 1990s, the PI3K/Akt/mTOR pathway was recognized to play a crucial
role in the metabolism, growth, and survival of a number of human cancers, including
breast cancer (Liu et al., 2009). As with the MAPK pathway, PI3K pathway alterations
vary based on breast cancer subtype, resulting in different patient outcomes and
necessitating unique treatment regimens. Further, particular mutations to the PI3K
cascade have demonstrated resistance to current chemotherapeutic and endocrine therapy
options, requiring a more thorough understanding of the signal transduction to
circumvent such mechanisms and achieve optimal patient outcomes. PI3K pathway
activation has been associated with poor patient prognosis and advanced tumor stage and
histological grade, warranting further investigation of the molecular mechanisms that
drive this cascade (Ghayad and Cohen, 2010).
Genetic mutations, gains or losses of function, and amplifications within the PI3K
pathway account for the majority of breast carcinomas in which this signaling pathway is
aberrant. A 2004 study by Campbell et al. focused on one such mutation, assessing 284
primary ovarian, breast, and colorectal tumors for mutations in all coding exons of
PIK3CA. Of the 70 breast tumors analyzed, 28 (40%) possessed PIK3CA mutations.
Interestingly, the researchers found no association with prognostic or clinical features,
including histological subtype, estrogen/progesterone/HER2/neu receptor expression
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status, axillary lymph node status, tumor grade or stage (Campbell et al., 2004; Ligresti et
al., 2009).
Conversely, other groups observed that PIK3CA mutations most frequently occur
in hormone receptor-positive and HER2/neu-positive tumors, while rarely occurring in
triple-negative or basal-like breast tumors (Stemke-Hale et al., 2008). Furthermore,
overexpression of HER2 has been affiliated with poor patient prognosis (Saini et al.,
2013). Moreover, in vitro studies have established PIK3CA mutations are present in up to
50% of breast cancer cell lines (Liedtke et al., 2008). Amplification of AKT2 has also
been observed in breast cancer, presumably contributing to the malignant transformation
of this kinase. In both breast and ovarian cancer, amplification at the genomic level of
several downstream effector molecules, including RSK, has been observed, oftentimes in
conjunction with the neighboring ERBB2 gene (Vivanco and Sawyers, 2002). While
HER2 signaling promotes cellular proliferation through the MAPK pathway, it inhibits
cell death through the PI3K pathway (Yardley and Sliwkowski, 2001).
Similar to the MAPK pathway, PI3K dysfunction resulting in breast tumors may
occur at multiple points along the signaling cascade. Furthest upstream, abnormal growth
factor and RTK activity has been shown to contribute to carcinogenesis. Dysfunction of
insulin and IGF-1 signaling through the PI3K pathway accounts for irregular cellular
metabolism and is often observed in breast cancer (Saini et al., 2013). Feedback
mechanisms also alter PI3K signaling. For example, acting through a negative feedback
loop in breast cancer models, mTORC1/p70S6K regulates IGF-1 receptor (IGF-1R)
function through insulin receptor substrate-1 (IRS-1) and Grb10, ultimately resulting in
the hyperactivation of the PI3K/Akt cascade (García-García et al., 2012).
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Breast tumors have also resulted from constitutive activation of RTKs by
overexpression of FGF and its receptor (FGFR), EGFR gain of function mutations, and
HER2 amplification (Cidado et al., 2012). Downstream of these RTKs, Akt exists in one
of three isoforms; the first two, Akt1 and Akt2, have generally been associated with
breast carcinogenesis. Amplification of the Akt2 gene was found in 4% of breast cancers
assessed and overexpression was observed in 10-20%, resulting in increased kinase
activity in these tumors (Cidado et al., 2012). The data regarding the influence of Akt1 in
breast tumorigenesis, however, remains controversial. In vitro studies have shown that
Akt1 acts to inhibit the invasive migration of breast cancer cells. In an in vivo study of
transgenic mice, Akt1was observed to both promote mammary tumor growth and
represses metastasis, while other studies demonstrated that Akt1-knockout mice display
greater metastases (Chin and Toker, 2011). Though the general consensus agrees on the
involvement of Akt1 in the promotion of breast cancer tumorigenesis and progression,
these reinforce the need for further study.
Mutations in kinases and phosphatases responsible for the modulation of the PI3K
pathway have also been implicated in breast cancer. PTEN loss has been observed in a
number of malignancies due to loss of function mutations, hetero- or homozygous
deletions, and epigenetic silencing. In breast carcinomas, the prevalence of PTEN
mutations is rare, occurring in only about 3% of cases. However, in TNBC, a loss of
PTEN expression occurs in 35-50% of cases, while an assessment of primary TNBC
tumors revealed increased Akt activation as compared to other breast cancer subtypes
(ER+/HER2–, ER+/HER2+, ER–/HER2+), suggesting more studies are necessary to
determine the potential clinical utility of therapeutically targeting PTEN in this patient
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cohort (Saini et al., 2013; Umemura et al., 2007). Another kinase responsible for PI3K
pathway regulation, PDK1, is rarely mutated in human cancer. In breast cancer, however,
PDK1 is amplified or overexpressed in approximately 20% of breast cancers (Brugge et
al., 2007). Particularly in the context of PTEN deficiency, PDK1is critical in the
regulation of cell migration, indicating this kinase may be a viable target for therapeutic
inhibition (Raimondi and Falasca, 2011).
Given the wide variety of potential targets along the pathway, recent attention has
been focused on therapeutically exploiting the PI3K pathway. In cell lines with HER2
amplification, sensitivity to PI3K, Akt, and/or mTORC1/mTORC2 inhibitors was
observed, suggesting that this subtype of breast cancer may rely more heavily on the
PI3K/Akt/mTOR pathway than the Raf/MEK/ERK pathway (Saini et al., 2013). Studies
examining HER2-positive breast cancer demonstrated that a compensatory mechanism
exists whereby PI3K/Akt inhibition resulted in ERK1/2 activation through increased
RTK expression and dimerization (García-García et al., 2012). Such studies suggest the
need for individualized medicine; whereas certain patients would achieve therapeutic
benefits from single pathway inhibitors, other patients may require dual inhibition of the
PI3K/Akt/mTOR and Raf/MEK/ERK pathways. One objective of this study was to begin
to elucidate kinase pathway variations that exist in breast cancer cells exhibiting distinct
hormone receptor profiles in response to age or targeted inhibitors.
1.1.7 Hormonal Influences on the MAPK and PI3K Pathways
The interplay between hormones and kinase expression and activation in breast
cancer, particularly regarding the effect of estrogen and progesterone on ERK1/2, ERK5,
and Akt, remains to be fully elucidated. Recent studies have begun to explore the
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relationship between these critical hormones and the MAPK and PI3K cascades, as well
as the physiological outcomes observed following kinase activation or suppression.
In the ER+ MCF-7 cell line, crosstalk between the MEK1/2-ERK1/2 pathway and
ER increased ERα signaling such that E2-dependent tumor growth was enhanced
(Atanaskova et al., 2002). Furthermore, activation of the G protein-coupled estrogen
receptor 1 (GPER1) by E2 in triple-negative breast cancer cell lines resulted in both
ERK1/2 and Akt activation, in addition to increased invasion and metastasis (Jiang et al.,
2013). It is known that aberrant Akt activation is associated with poor patient outcomes
and endocrine therapy resistance. An assessment of primary breast carcinomas found that
activation of Akt was significantly associated with the overexpression of HER2, and the
clinical efficacy of AIs and SERMs was decreased in patients deemed positive for both
HER2 and pAkt expression. Further, the researchers found an inverse relationship
between pAkt and PR (Tokunaga et al., 2006). These data have important implications
regarding Akt inhibition to enhance patient outcomes with endocrine-based treatments.
A study investigating age-related changes to the ER, ER-inducible genes, and
oxidant stress markers that affect the expression of these genes, including ERK5, were
examined in human breast tumor samples. The data demonstrated that, in addition to an
increase in the number of ER+/PR– breast cancers after the age of 50, increased activation
of ERK5 was positively correlated with age (rP = +0.28, p = 0.03), which the authors
suggested was a result of age-accumulated oxidative stress (Quong et al., 2002). To date,
however, the activation of ERK5 as a function of age in normal, non-diseased, breast
tissue has not been examined. Further, how the observed increase with age affects tumor
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progression has not been elucidated. Moreover, the effect of age on the activation of
familial ERK1/2 and Akt in breast cancer models remains elusive.
Nongenomic ER signaling has also been linked to crosstalk with the ERK1/2 and
PI3K/Akt pathways in obese, postmenopausal women with enhanced tumor growth in
these ER-positive tumors (Bowers et al., 2013). A relationship between Akt and ERα has
also been elucidated through FOXO3a, which is negatively regulated by Akt; FOXO3a
was found to positively correlate with ERα gene transcription (Guo and Sonenshein,
2004). Moreover, a study by Creighton and colleagues (2010) observed hyperactivation
of the PI3K/Akt pathway in luminal B tumors (ER+/PR+/–/HER2+), correlating to low
ERα expression levels. Together, these data have important implications regarding both
ERK1/2 and Akt inhibition to enhance patient outcomes with endocrine-based treatments.
The presence of crosstalk between ER and the ERK1/2 and Akt cascades in
postmenopausal women also warrants further study regarding age-related alterations in
these pathways.
1.1.8 The Effect of Aging on the MAPK and PI3K Pathways
In various cellular and animal models, several studies have examined the role
aging plays on both the MAPK and PI3K pathways. Given the effect these cascades have
on mRNA stability and protein translation, it has been hypothesized that targeted
inhibition of these pathways may prevent cellular aging (Steelman et al., 2011). The
aging process not only results in aberrant cellular communication, but also an attenuation
of these signaling cascades to respond to oxidative and stress stimuli. As breast cancer is
largely age-dependent, a better understanding of these pathways with regard to age will
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facilitate greater mechanistic understanding of changes that occur on a cellular level over
time and may reveal novel therapeutic targets.
It has been well established that the proliferative capacity of cells declines with
age, and further investigation has demonstrated that this is due, in part, to the decreased
activity of the MAPK pathway. A study involving polymorphonuclear neutrophils
demonstrated that decreased ERK1/2 activation resulted in suppressed neutrophil survival
in elderly subjects as compared to younger cohorts (Larbi et al., 2005). In response to
granulocyte macrophage-colony stimulating factor (GM-CSF), ERK1/2 activation was
shown to decrease with age in neutrophils; an age-associated decline in ERK1/2 function
has been found in several other cell types, including T-lymphocytes and duodenal
enterocytes (Tortorella et al., 2004; Li et al., 2000; Gentili and de Boland, 2000). In the
rat brain, the activity of both p38 and the MEK1/2-ERK1/2 pathway were found to be
impaired with age, while a study in rat primary hepatocytes revealed that the activity of
both ERK and p70(S6K), a downstream effector of Akt, declines with age (Zhen et al.,
1999; Hutter et al., 2000).
Moreover, age may also effect the subcellular localization of the MAPKs. In
human granulosa cells, p38 was found to be seven times more activated in older primary
mural granulosa cells as compared to younger counterparts. Further, activated p38 was
more often localized in the cytoplasm of older patients (29.8%) than younger (58.6%),
which the authors conclude may be due to oxidative stress (Ito et al., 2010). To our
knowledge, the effect of age on the cellular localization of ERK1/2 remains to be
determined, yet such data would provide important information regarding the expected
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physiological outcomes, given the diverse roles ERK1/2 plays dependent on its presence
in either the cytosol or nucleus.
Aside from the aforementioned study examining ERK5 activation as it relates to
ERα expression, very few studies have explored the interplay between ERK5 and aging.
Further, whereas the study conducted by Quong and colleagues demonstrated an agerelated increase in ERK5 activation, a study examining miR-143 signaling to ERK5 in
adipose stromal vascular fraction derived cells found that ERK5 expression was higher in
younger rats (6 mo) as compared to older animals (30 mo) (Fei et al., 2013). These
conflicting results warrant further investigation, including an examination regarding the
effect of age on the localization of ERK5 within the cell, as this may have critical
implications regarding physiological outcome.
In a comparison of breast tumor transcriptomes and whole-genome mRNA
expression profiles between young (≤ 45 years), middle-aged (45 to 55 years) and elderly
(≥ 55 years) women, distinct PI3K/Akt pathway alterations were found in the young
patient cohort that were absent from the other age groups (Colak et al., 2013).
Conversely, in skeletal muscle, an age-related increase in Akt phosphorylation was
observed, unexpectedly corresponding with a decrease in mTOR phosphorylation and
PI3K, PTEN, and PDK1 levels (Wu et al., 2009). Overactivation and aberrant Akt
signaling with age has also been deemed as a contributing factor in Alzheimer’s disease
(O’Neill, 2013). Despite these conflicting results, it has been well established that
overexpression of Akt and dysregulation of the PI3K pathway contributes to cancer; yet a
greater mechanistic understanding of how the cascade changes with age may lead to the
development of more efficacious, age-specific therapeutics.
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1.1.9 Crosstalk and Inhibition of the MAPK and PI3K Pathways
The critical roles of the Ras/Raf/MEK/ERK and PI3K/Akt/mTOR pathways in
carcinogenesis have established these cascades as primary focus points of basic research
and as pharmaceutical targets. Multiple points of convergence leading to feedback loops,
cross-activation, and cross-inhibition between the pathways have recently been
elucidated. These feedback loops are not only stimulus-dependent, but also often result in
compensatory mechanisms within one or both of the pathways. While more research is
necessary to fully characterize the underlying modes of interaction, the clinical
implications of such crosstalk, including the potential for consequential resistance,
warrants immediate attention as an increasing number of pathway inhibitors enter into
patient trials.
Crosstalk between the ERK1/2, JNK, and p38 pathways, the most characterized
members of the familial MAPK cascade, has been established in numerous cell types and
results in cross-activation, cross-inhibition, and dysregulated signaling (Fey et al., 2012;
Junttilla et al., 2008; Chiacchiera et al., 2012). Less is known regarding the impact of
ERK5 crosstalk and feedback regulation in the context of other MAPK pathways. In a
study examining the crosstalk between the ERK5 and JNK pathways, Pandurangan and
Gakkhar observed that transient activation of ERK5 occurs in the absence of external
signals as a result of the crosstalk and feedback that exists between the pathways (2010).
The relationship between ERK5 and ERK1/2 is perhaps the most characterized of the
MAPKs, likely due to the large homology that exists between these cascades; still, much
remains to be elucidated regarding the interconnectedness of these pathways.
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The first small molecule MEK1/2 inhibitor, a flavone termed PD98059 (2-(2amino-3-methoxyphenyl)-4H-chromen-4-one), was discovered in 1995 and found to
spare other Ser/Thr kinases (Frémin and Meloche, 2010). PD98059, in addition with
another widely used, commercially available MEK1/2 inhibitor, the conjugated nitrile
U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene), were believed
to be selective for the MEK1/2-ERK1/2 pathway (Figure 7). However, it was later found
that both of these ATP non-competitive drugs were also capable of inhibiting the MEK5ERK5 cascade (Kamakura et al., 1999; Mody et al., 2001). Likely due to the similar
threonine-glutamine-tyrosine (TEY) sequences between ERK5 and both ERK1 and
ERK2, as well as the fact that MEK5 shares 48% relativity with MEK1, the non-specific
inhibition raised questions regarding the distinct roles of the MEK1/2-ERK1/2 and
MEK5-ERK5 cascades and brings to light the need for further characterization of the
functional roles controlled by these pathways.
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Figure 7. Structures of First-Generation MEK1/2 Inhibitors. The commercially available
inhibitors, U0126 and PD98059, have little clinical utility but have proven effective as
research tools to inhibit the MAPK pathway.

A second generation inhibitor, PD184352, later coined CI-1040, was the first
MEK inhibitor that inhibited tumor growth in vivo (Sebolt-Leopold and Herrera, 2009).
Despite being touted as selective for MEK1/2-ERK1/2, PD184352 was also found to
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inhibit MEK5-ERK5 activation at high concentrations (Drew et al., 2012). Interestingly,
in HeLa cells, low concentrations of PD184352 blocked MEK1/2-ERK1/2 activation
while prolonging the activation of the MEK5-ERK5 cascade, suggesting the presence of
crosstalk between the familial pathways through which activation of the ERK1/2 pathway
suppresses ERK5 activity (Drew et al., 2012; Mody et al., 2001). At least twelve
MEK1/2 inhibitors have been tested clinically or are currently undergoing trial evaluation
(National Institutes of Health (NIH), 2013). MEK inhibitors tend to suppress ERK
signaling in all cells, however, and toxicity to non-diseased tissue thereby limits the
dosing and therapeutic effect of these agents (Lito et al., 2012). The effects of the
MEK1/2 inhibitors on the MEK5-ERK5 cascade have not been fully established. With
the growing characterization of the MEK5-ERK5 pathway, comes the advent of novel,
potentially selective inhibitors.
A set of indoline-6-carboxamides, BIX02188 and BIX02189 ((3Z)-3[[[3[dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1Hindole-5-carboxamide and 3-[[[3[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-N,N-dimethyl-2oxo-1H-indole-6-carboxamide), were recently identified as ATP-competitive
pharmacological inhibitors against MEK5 catalytic activity with IC 50 values of 4.3nM
and 1.5nM, respectively (Figure 8) (Tatake et al., 2008). While both compounds dosedependently inhibited ERK5 phosphorylation and MEF2C activity, BIX02189 displayed
a greater potency (59nM vs. 810nM). Importantly, no inhibition of familial MEK1,
MEK2, ERK2, or JNK2 was observed (Tatake et al., 2008; Drew et al., 2012).
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Figure 8. The Structures of BIX02188 and BIX02189. Two novel inhibitors of the
MEK5/ERK5 pathway have recently been identified. While both compounds are efficacious
MEK5 inhibitors, BIX02189 has proven more potent at inhibiting ERK5 catalytic activity.

A compound from a series of benzimidazole-based MEK5 inhibitors that were
originally designed to inhibit cyclin-dependent kinase-5 (CDK5) activity was also
recently found to inhibit EGF-induced MEK5 activation in human embryonic kidney
cells (HEK293) in addition to slowing the growth of MCF-7 breast cancer cells (Figure
9A) (Flaherty et al., 2010). While the compound effectively blocked nearly 88% of
ERK5 phosphorylation, it also inhibited ERK1/2 phosphorylation, though to a lesser
extent. In a follow-up study, the biological activity of a series of 1-isopropyl-4-amino-6ether linked benzimidazole-based compounds was assessed for selective MEK5
inhibition (Figure 9B, Flaherty, et al., 2010b). Interestingly, the results of the NCI-60 cell
line screen indicated that one of the novel inhibitors, coined “compound 2,” proved
effective at reducing cell growth in triple-negative breast cancer cells (MDA-MB-231
and Hs 578T), yet was not selective for MEK5 inhibition. The non-selective inhibition,
combined with the suboptimal results of the NCI-60 cell line screens, warranted an
objective for this study to further characterize novel structural variants of the promising
initial compounds.
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Figure 9. Novel Benzimidazole MEK5 Inhibitors. (A) Based on CDK5 inhibitors,
structural variants of this novel benzimidazole inhibitor were assessed for selective MEK5
inhibition as described in the text. (B) A series of 1-isopropyl-4-amino-6-ether linked
benzimidazole compound were synthesized and assessed for selective inhibition of MEK5.

More recently, an ATP-competitive inhibitor that directly targets ERK5 has been
identified (Figure 10). The compound, termed XMD8-92 (2-((2-ethoxy-4-(4hydroxypiperidin-1-yl)phenyl)amino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4b][1,4]diazepin-6(11H)-one), displayed high selectivity for ERK5 inhibition when tested
in HeLa cells. Researchers found that XMD8-92 was at least 10-fold more selective for
ERK5 as compared to all other kinases expressed in this cell line with an IC50 of 1.5μM
(Yang et al., 2010). Notably, neither MEK5 nor growth factor-induced activation of
ERK1/2 was inhibited by XMD8-92, and the compound effectively suppressed ERK5
both in vitro and in vivo.
Further, the team assessed the ability of the compound to suppress the interaction
of ERK5 with the tumor suppressor promyelocytic leukemia protein (PML), through
which p21 suppression results in enhanced cell proliferation; XMD8-92 did, indeed,
induce p21 expression, thereby reducing cell proliferation (Yang et al., 2010). The recent
determination of the X-ray crystal structure of ERK5 may shed light onto the specificities
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of the MAPK, as well as provide novel target sites for putative inhibitors (Elkins et al.,
2013). Specifically targeting ERK5 may reduce the potential for the inhibition of other
RTK pathways as observed with MEK5 inhibitor treatment. Still, the potential for
upregulation of the PI3K pathway following ERK5 suppression exists and necessitates
further study.
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Figure 10. The Structure of XMD8-92. The novel small molecule inhibitor of ERK5
activity is the first compound to directly target the MAPK and has demonstrated selectivity in
both cellular and animal models.

Two of the most common PI3K pathway inhibitors used in experimental studies
are wortmannin and the synthetic compound, LY294002. A naturally occurring
metabolite of Penicillium funiculosum, wortmannin binds irreversibly to the ATP-binding
site of PI3K with an IC50 value of 3nM. LY294002, meanwhile, was designed based on
the flavonoid, quercetin, and has an IC50 value of approximately 4μM (Wymann and
Schultz, 2012). Though this pan-PI3K inhibitor binds reversibly and displays lower
potency as compared to wortmannin, it is a more stable compound. Despite their
inhibitory effects on PI3Ks, these compounds also inhibit a number of other PI3K
pathway components, including mTOR and DNA-PK, thus limiting their clinical utility
(Walker et al., 2000 and Gharbi et al., 2007).
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First- and second-generation inhibitors of the PI3K/Akt/mTOR pathway include
the allosteric agents: rapamycin, everolimus, and temsirolimus, which interact with the
FK-binding protein 12 (FKBP12) to suppress the mTORC1 complex. Despite initial
clinical efficacy in certain tumor types, the second-generation inhibitors initiate negative
feedback mechanisms and lead to activation of mTORC2, and consequently, Akt, upon
the inhibition of mTORC1, limiting their clinical utility (Britten, 2013). Notably, the use
of allosteric inhibitors to selectively block mTORC1 has proven effective in cancer cell
lines containing PIK3CA mutations, suggesting variations arise based on the presence of
genetic mutations. To circumvent the issue observed with the second-generation drugs,
current inhibitors have been designed to target further upstream in the pathway to avoid
activation of mTORC2. Alternative PI3K pathway inhibitors include the rapamycin
derivatives: CCI-779, RAD001, and AP23573, which are TOR inhibitors that have
demonstrated anti-cancer effects in numerous human malignancies (Cully et al., 2006).
The dual pan-PI3K/mTORC1/2 inhibitor, NVP-BEZ235, has demonstrated oral
bioavailability and the ability to halt tumor growth in several xenograft tumor studies. In
preclinical models, the ATP-competitive imidazoquinoline displayed efficacy against
numerous solid tumors including colorectal, melanoma, and breast (Martini et al., 2013).
The reversible inhibitor acts mechanistically to decrease cell proliferation, promote
autophagy, halt cell cycle progression and suppress angiogenesis. It is currently
undergoing clinical evaluation in both phase I and phase II trials for several malignancies
including glioblastoma, renal cell carcinoma, breast, and pancreatic, either alone or in
combination with other chemotherapeutic agents, including those that elicit their effects
through the PI3K or MAPK pathways.
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Inhibition of either the Raf/MEK/ERK or the PI3K/Akt/mTOR pathway has
resulted in the compensatory activation of the alternate cascade in several cell types
(Figure 11) (Balmanno et al., 2009; Fey et al., 2012; Huang et al., 2013; Hausenloy et al.,
2004). PI3K pathway activation mediates the activation of the MEK/ERK pathway
through Grb-2 associated binding protein (GAB)/IRS/Grb7 pathway, the p21-activated
kinase (PAK), and PDK1. Conversely, activation of Akt and its downstream effectors,
mTOR and p70S6K, negatively regulates the MAPK pathway (Aksamitiene et al., 2012).
Several studies have demonstrated that feedback mechanisms within the PI3K pathway
overcome inhibition of the PI3K/Akt/mTOR system by reactivating upstream effectors in
addition to the Raf/MEK/ERK pathway (García-García et al., 2012). Importantly, the
overactivation of Akt was found to prevent the nuclear translocation of ERK1/2, thereby
affecting the transcription of downstream effector molecules and cell proliferation
(Gervais et al., 2006).
The Raf/MEK/ERK pathway has also been shown to cross-regulate the
PI3K/Akt/mTOR pathway. Notably, ERK1/2 was demonstrated to phosphorylate TSC2
at a site distinct from the Akt phosphorylation site. Such crosstalk ultimately results in
the activation of mTORC1, as phosphorylation by either ERK or Akt inhibits TSC2 (Ma
et al., 2007). In a study with implications for the role of ERK5 in angiogenesis, the novel
kinase was found to be critical for Akt phosphorylation and VEGF-mediated
differentiation of microvascular endothelial cells (Roberts et al., 2010). Similar to the
capability of the PI3K pathway to both positively and negatively regulate the MEK-ERK
pathway, the Raf/MEK/ERK cascade possesses the same potential. ERK-mediated
activation through the GAB/IRS/fibroblast growth factor receptor substrate (FRS) results
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in a negative feedback loop in the PI3K pathway; however, Ras/GTP-induced activation
leads to the activation of the PI3K cascade (Aksamitiene et al., 2012).

Figure 11. Crosstalk Between the PI3K/Akt/mTOR and Raf/MEK/ERK Pathways.
Several areas of convergence exist between the PI3K and MAPK pathways, leading to up- or
down-regulation (as discussed in the text) and resulting in therapeutic sensitivity and
resistance mechanisms against cancer treatment regimens. Adapted from Britten, 2013.

Another study determined MEK inhibitor-induced activation of the PI3K/Akt
cascade occurs through ErbB3 activation, which has important therapeutic implications,
particularly in breast cancer (Turke et al., 2012). These studies suggest that ERK5 may
act to stimulate the PI3K pathway at the RTK level or upstream of Akt (Figure 11).
Similar to ERK1/2, ERK5 has also been shown to be an upstream activator of RSK,
however failure of both wortmannin and rapamycin to inhibit ERK5 activation suggests
ERK5 is not downstream of mTORC2 or PDK1 (Figure 11; Ranganathan et al., 2006;
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Roberts et al., 2010). The exact role of ERK5 on Akt activation and in relation to the
ERK1/2 pathway remains to be fully elucidated.
The recognized crosstalk between these signaling cascades may be responsible for
the modest efficacy observed in trials assessing single pathway inhibitors, thereby
supporting regimens that achieve dual pathway inhibition. Recently, a combination
regimen of BEZ235 with the MEK1/2 inhibitor, MEK162, has entered into phase Ib
clinical trials. A study conducted in genetically engineered mouse models indicated that
the combination of the MEK1/2 inhibitor, AZD6244, with BEZ235 resulted in significant
efficacy and tumor regression in several breast cancer subtypes, including claudin-low,
basal-like, and luminal (Roberts et al., 2012). Furthermore, combination treatment
involving pharmacological inhibitors of EGFR and PI3K/Akt inhibitors resulted in a
synergistic, anti-proliferative effect in cell lines representing the basal-like subtype of
TNBC (Yi et al., 2013). Despite the early success observed in dual-inhibitor pre-clinical
and clinical studies, the potential for resistance and development of compensatory
mechanisms exist. Further, the interplay of the MEK5-ERK5 pathway remains
undetermined.
In summary, the MAPK and PI3K pathways are essential to both normal and
oncogenic cellular function. As inhibitors of these signaling cascades continue to enter
into clinical testing for numerous tumor types, the emergence of nodes of convergence
and crosstalk will necessitate a more thorough understanding of the relationship between
these parallel pathways to subvert modes of resistance and chemosensitivity. Equally
challenging, yet imperative, is the subsequent sparing of the normal physiological
function of these kinase pathways in order to maintain homeostatic regulation.
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1.2

STATEMENT OF THE PROBLEM

1.2.1 Research Objective
Cancer is the second leading cause of death worldwide, resulting in nearly 8
million deaths each year (WHO, 2013). It is expected that over 12 million people will be
diagnosed with the disease this year. In addition to the physical and emotional burden
such a diagnosis incurs on the patient, their family, and caregivers, cancer also imparts a
significant economical toll on society. According to a report from the National Institute
of Health in 2008, the total cost of cancer in the United States totalled $ 201.5 billion,
with total health expenditures from direct medical costs reaching $77.4 billion. Despite
progress in therapeutic intervention and increasing public awareness regarding
preventative measures, the incidence and prevalence of cancer remain largely unchanged
in recent years, and in some cancer types and patient populations, increases were
observed.
For the majority of malignancies, age remains the number one demographic risk
factor. The median age at the time of diagnosis is approaching 70 years and is expected to
continue to increase. Compounding the cancer burden is the fact that, in the United States
alone, the older population (defined as those aged 65 or older) is expected to more than
double from approximately 40 million persons in 2010 to over 90 million by 2060
(Administration on Aging, 2013). With this increase in the elderly population, a
subsequent rise in cancer incidence and prevalence is anticipated. Data from the National
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program suggest
that the number of cancer patients will more than double from nearly 1.4 million in the
year 2000 to almost 3.0 million in 2050.
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Breast cancer rates steadily climb with age. Over 80% of diagnoses occur in
women over the age of 50 and more than one-third in women over the age of 70 (Walker
et al., 2007). Moreover, there is limited data regarding age-related changes in both
diseased and non-diseased breast tissue. Tumor heterogeneity and the hormonal influence
on non-diseased breast tissue and malignant transformation necessitate the need for agerelated studies in an effort to develop efficacious, yet selective, therapeutics for particular
patient populations. For this reason, the present study was designed to assess changes in
two kinase signaling pathways that are typically dysregulated in cancer, including breast
carcinomas. Namely, the expression and activation profiles of the mitogen-activated
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways were
examined in both cellular and animal breast cancer models of aging.
The MAPK and PI3K signaling cascades are critical mediators of numerous
cellular functions, including proliferation, metabolism, differentiation, growth, and
survival. Dysfunction of these pathways has been noted in various cancer types, and
components of these cascades have been the recent target of novel inhibitors aimed at
restoring a homeostatic balance. Despite advancements in drug development, low
bioavailability, insufficient tumor response, off-target toxicities, and therapeutic
resistance have limited the clinical utility of many of these inhibitors that have entered
patient trials. Several points of convergence have been established between the two
cascades, and crosstalk within the familial MAPK network between ERK1/2 and ERK5
and also between the MAPK cascade and PI3K pathways hold the potential for
compensatory mechanisms that may enable sustained tumor growth and progression.
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The relationship between the MAPK and PI3K pathways in breast cancer has not
yet been fully delineated; in particular, to our knowledge, the potential for crosstalk
between the terminal MAPK, ERK5, and the PI3K/Akt pathway has not been explored.
Therefore, an objective of the current study was to explore potential compensation within
the MAPK pathway and between the MAPK and PI3K pathways in breast cancer. The
effect of pathway inhibition on cell proliferation, migration, and invasion were assessed
in breast cancer cell models with varied hormonal profiles.
Numerous pre-clinical studies have examined the role of the MEK5-ERK5
pathway in breast cancer, implicating its enhancement of tumor survival, increased
proliferation, and decreased apoptosis (Drew et al., 2012). Moreover, in analyses of
human breast tumors, MEK5 was found to be overexpressed in more than half, while
ERK5 was overexpressed in one-fifth of the patient samples examined; these findings
were correlated with a decrease in disease-free survival (Montero et al.,2009). In other
tumor types, such as oral squamous cell carcinoma and prostate cancer, elevated ERK5
has been correlated with increased metastatic events (Sticht et al., 2008; Mehta et al.,
2003). Together, these studies indicate the critical role the MEK5-ERK5 pathway plays
in breast carcinomas and indicates it as a viable target for novel anticancer agents.
Inhibitors of the MEK1/2-ERK1/2 pathway previously believed to be specific for
the cascade have since been identified as non-selective and also capable of affecting the
MEK5-ERK5 pathway. With the recent discovery of the MEK5 inhibitors, BIX02188
and BIX02189, and the ERK5 inhibitor, XMD8-92, all touted as specific to this pathway,
came the hope of elucidating the unique MEK5-ERK5 cellular functions. However, in
vitro studies by our laboratory and others has suggested that these inhibitors may be both
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growth-factor and cell-line specific, as results have varied based on the stimulus, model
and selected concentration of inhibitor, suggesting the need for further investigation of
these compounds. Pre-clinical studies and assessments of human breast tumors highlight
the critical impact the MEK5-ERK5 cascade has in malignant transformation and tumor
progression, indicating it as a putative target for potential clinical therapeutics. To that
end, the current study also aimed to characterize a series of novel small molecule
compounds targeting selective MEK5 inhibition in cellular breast cancer models. Sparing
the relative MEK1/2-ERK1/2 pathway while selectively targeting the MEK5-ERK5
and/or PI3K pathways, where appropriate, may reduce off-target toxicity and optimize
treatment regimens.
1.2.2 Hypothesis and Specific Aims
The hypothesis of the study is that ERK5 signaling is upregulated with age in
breast cancer and promotes the proliferation, migration, and invasiveness of breast
cancer cells. To address this hypothesis, the specific aims of the project are:
I.) Determine the expression and activation profiles of ERK1/2, ERK5 and Akt in breast
cancer models with age;
II.) Examine the role of the ERK5 pathway in breast cancer cell proliferation, migration,
and invasion; and
III.) Determine the specificity and activity of novel MEK5 inhibitors in breast cancer
cells.

The overall goal of the study was to determine age-related expression and
activation changes that occur within the MAPK and PI3K pathways in breast cancer and
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assess the physiological outcomes associated with these alterations. In order to first
elucidate the expression and activation profiles of the MAPK and PI3K pathways with
age, two human and one murine cell line were subjected to serial passaging in vitro to
mimic the cellular changes that occur during aging in vivo.
To provide a greater indication of the age-related effects sustained by these kinase
signaling cascades in human breast malignancies, a mouse model of breast cancer was
employed to evaluate kinase activity in both normal mammary and mammary tumor
tissue. To supplement the phenotypic assessment of these pathways, the effect of these
kinases on the proliferative, invasive, and migratory potential of breast cancer cells was
examined (Chapter 3).
Concurrent studies were conducted to explore the effect of dual pathway
inhibition on the activation of each of the kinases to ascertain potential cross-regulation
within and between these signaling modules. These studies are necessary to provide the
foundation for future in vitro and in vivo projects involving the administration of
combination inhibitors to further delineate the oncogenic mechanisms initiated by these
kinases (Chapter 4).
Separately, several series of novel MEK5 inhibitors were synthesized and tested
for both selectivity and potency in both hormonal dependent and independent breast
cancer cell lines. These data provided the groundwork for further in vitro and in vivo
studies in xenograft murine models of human breast cancer to analyze the potential to
decrease tumor growth and examine the effect on the epithelial-to-mesenchymal
transition (Chapter 5 and Appendix A).
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Overall, the results from these studies provide further insight into the relationship
between cancer and aging, particularly at the cellular level. More specifically, the
preliminary findings from this project indicate a hormonal influence on ERK5 activity in
breast cancer and on the relationship between the MAPK and PI3K pathways, warranting
further investigation. The cellular characterization of putative, selective MEK5 inhibitors
provides insight regarding the synthetic variations necessary for ERK5 inhibition to
ultimately reduce tumor growth and progression while sparing familial kinase activity. In
summary, these studies provide novel information regarding the role of ERK5 in breast
cancer with age and in association with the PI3K pathway.
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CHAPTER 2
MATERIALS AND METHODS
2.1

Cell Culture

2.1.1 BT-474 Cell Line
In 1978, the BT-474 cell line was derived from a 60-year-old Caucasian female
with an invasive ductal carcinoma of the breast with a luminal B classification. The cells
are epithelial and aneuploid with a modal chromosome number of 55; the cells are also
capable of producing tumors in nude mice. In addition to highly expressing the estrogen
receptor, BT-474 cells express HER2 and demonstrate high specificity for epidermal
growth factor (EGF) (Imai et al., 1982).
The BT-474 breast cancer cell line (ER+/PR–/HER2+) was obtained from
American Type Culture Collection (ATCC, Manassas, VA). The cells were cultured in
1X Hybri-Care media (ATCC) containing NaHCO 3 (0.15%). The culture media were
supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO). Cell cultures were
maintained in a humidified 37° C incubator supplied with 5% CO2-95% air.
2.1.2 MDA-MB-231 Cell Line
The MDA-MB-231 cell line was derived from the metastatic pleural effusion of a
51 year old Caucasian female with an adenocarcinoma of the breast, classified as claudinlow. The cells are epithelial, adherent, and display a triple-negative hormonal profile.
Capable of forming tumors in both nude and ALS-treated BALB/c mice, the MDA-MB231 cells are hypotriploid with a modal chromosome number of 65.
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The MDA-MB-231 cell line (ER–-/PR–/HER2–) was purchased from American
Type Culture Collection (ATCC, Manassas, VA). The hormone independent cell line was
cultured in Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s F-12 Nutrient
Mixture (both Invitrogen, Carlsbad, CA) in a 1:1 ratio. The culture medium was
supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO). Cell cultures were
maintained in a humidified 37° C incubator supplied with 5% CO2-95% air.
2.1.3 MMC Cell Line
The mouse mammary carcinoma (MMC) cell line (ER–/PR–/HER2+) was
provided as a gift from the laboratory of Dr. Mary L. Disis (University of Washington,
Seattle, WA). The transplantable cell line was derived from a spontaneous mammary
tumor from a neu-tg mouse; the hormonal profile of MMC cells mimics premenopausal
breast cancer in humans.
The MMC cell line was cultured in HyClone medium (ThermoScientific,
Pittsburgh, PA) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals,
Lawrenceville, GA) and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO).
Cell cultures were maintained in a humidified 37° C incubator supplied with 5% CO295% air.
2.1.4 HEK293 Cell Line
The human embryonic kidney (HEK) 293 cell line was utilized to test novel
MEK5 inhibitors within the benzimidazole and diphenylaniline classes that were
synthesized in the laboratory of Dr. Patrick Flaherty. The HEK293 cell line was cultured
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in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA),
supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO). Cell cultures were
maintained in a humidified 37°C incubator supplied with 5% CO2-95% air.
2.2

In vitro cell aging
To mimic aging in vitro, a method of serial passaging was performed. The method

of serially passaging cells in culture to mimic natural aging in vivo has been established
in several different cell types, including fibroblasts, osteoprogenitor, kidney proximal
tubule, endothelial, and epithelial cells (Schneider et al., 1976; Peterson et al., 2004;
Pinho et al., 2011; Merkle et al., 2005; Berdyyeva et al., 2005). These studies
demonstrated that prolonged time in culture led to functional differences that were
accompanied by increased total, membrane, and cytosolic protein content. To assess age
related changes in kinase expression and activation, the cell lines of young (lower)
passage were assessed compared to middle and old (higher) passage breast cancer cells in
vitro. Based on similar studies, “young” cells included those of passages 12-15, “middle”
included cells in passages 24-27, and “old” included cells of passages 30-36. The BT474, MDA-MB-231, and MMC cell lines were maintained in culture in 10 cm2 plates in a
humidified 37°C incubator supplied with 5% CO2-95% air. For each cell line, the
medium (10 mL/plate) was replenished every 2-3 days and the cells were passaged
approximately every 4-5 days (once cells reached 70-80% confluence). Cells were
monitored daily and any observed morphological changes were noted. Once the cells
reached passage number 12 (the first to correspond to “young,” age) and continuing until
the cells reached passage number 36 (the “oldest” cells collected), cell lysates were
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collected at every third passage. One passage prior to collection, the cells were split into
35 mm plates (2 mL media/plate). Lysates were collected once the cells reached 70-80%
confluence.
2.3

Animal Model

To determine ERK1/2, ERK5, and Akt expression and activation in normal
mammary tissue and mammary tumor tissue with age, MMTV-neu transgenic mice were
employed. To obtain transgenic female mice for the study, homozygous Tg
((MMTV/neu) 202Mul) male mice were bred with wild-type FVB/N-Tg ((MMTV/neu)
202Mul/J) female mice (Jackson Laboratories, Bar Harbor, ME). The MMTV/neu mice
express the ErbB2 (c-neu) proto-oncogene under the control of the mouse mammary
tumor virus (MMTV) promoter, as previously described (Guy et al., 1992; Andrecheck et
al., 2000). At weaning, ear punches were used to designate animal number.
After 4 mo, female offspring began receiving weekly manual palpations. Once a
tumor was detected manually, the date and physical location of the tumor were recorded
and hand-held calipers were used to measure the linear dimensions of the tumor. Animals
were monitored daily and weighed on a weekly basis. The mice were double-housed in a
12:12 light:dark cycle and provided with water and an isoflavone-free soy diet, a
modified AIN-93G diet containing corn oil (20% protein, 16% fat, 64% carbohydrates,
and 3713 kcal/kg) (Harlan Teklad Laboratories, Madison, WI) ad libitum. Once a tumor
reached 20 mm, or the health or motility of the animal became compromised, the animal
was sacrificed by carbon dioxide asphyxiation. All efforts were made to minimize animal
suffering. All procedures were conducted in accordance with the guidelines for the NIH
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Care and Use of Laboratory Animals and approved by the Duquesne University
Institutional Animal Care and Use Committee.
2.4

Cell Lysate Collection
To generate cell lysates, cells were placed on ice and the media was aspirated.

The cells were washed 2× with ice-cold Dulbecco’s 1X phosphate-buffered saline (PBS).
Homogenation lysis buffer was prepared as follows; all reagents were purchased from
Sigma-Aldrich (St. Louis, MO) and added to 1% Triton X-100 buffer: 20 mM Tris (pH
6.8), 137 mM NaCl, 25 mM β-glycerophosphate (pH 7.14), 2 mM NaPPi, 2 mM EDTA,
1 mM Na3VO4, 10% glycerol, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 2 mM benzamidine,
0.5 mM DTT, and 1 mM PMSF. Cells were incubated with lysis buffer (150 µL/plate) on
ice for 10 min prior to physical disaggregation with a cell scraper. Total cell homogenates
were centrifuged at 10,000 rpm for 10 min at 4º C and the supernatant was collected and
stored at -80° C until analysis.
2.5

Tissue Collection and Homogenization
Following euthanization, all mammary glands were observed for the presence of

tumors. The number and physical location of any observed tumors were then recorded on
a necropsy sheet. Tumor and adjacent normal mammary tissues were isolated from the
animals and weighed; one half of the tissue was flash-frozen in liquid nitrogen (LN2) and
stored at -80° C, while the remaining tissue was fixed in 4% paraformaldehyde (PFA)
until further analysis. While both solid and cystic tumors were collected, only solid
tumors were included in the study for consistency purposes, as the integrity of some of
the cystic tumor tissue became compromised during necropsy. Tumors derived from both
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upper and lower mammary glands were utilized for the study. Though noted, variations in
tumor size, latency, and aggressiveness between animals were not controlled for as they
were not endpoints in the current study. The uteri and ovaries were also collected and
weighed. One half of the uterus was flash frozen while the other half was fixed in 4%
PFA; all ovarian tissue was fixed in 4% PFA. All tissues that were fixed in 4% PFA were
transferred to 70% ethanol after 72 h and maintained at 4° C until further processing.
To generate tissue lysates for western blot analysis, tissues were weighed and
placed in ice-cold 1% Triton X-100 homogenation lysis buffer (10 µL/1 mg) containing:
20 mM Tris (pH 6.8), 137 mM NaCl, 25 mM β-glycerophosphate (pH 7.14), 2 mM
NaPPi, 2 mM EDTA, 1 mM Na3VO4, 10% glycerol, 5 μg/ml leupeptin, 5 μg/ml
aprotinin, 2 mM benzamidine, 0.5 mM DTT and 1 mM PMSF (all Sigma-Aldrich, St.
Louis, MO). The tissue was physically disaggregated via sonication. Total tissue
homogenate was centrifuged at 11,000 rpm for 30 min at 4º C and the supernatant was
collected and stored at -80° C until analysis.
2.6

Western Blotting

2.6.1 Cell Lines
Total protein content was assessed by the Bradford protein assay (Bio-Rad, Cat.
#500-0001, Hercules, CA) and equal amounts of protein (30 μg) were separated on an 8%
polyacrylamide gel by standard sodium dodecyl sulfate (SDS)-gel electrophoresis and
transferred to a nitrocellulose membrane (LI-COR Biosciences, Lincoln, NE). Blots were
blocked in casein blocking buffer (LI-COR Biosciences) for 1 h prior to incubation
overnight at 4° C in primary antibody in casein blocking buffer + 0.2% Tween-20. The
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following antibodies were purchased from Cell Signaling Technology: pERK1/2 (#9101),
pERK5 (#3371), pAkt (Ser473, #4051), pAkt1 (Ser473, #9018), total Akt (#9272), and
total ERK1/2 (#9107). Total ERK5 (#sc-81460) was purchased from Santa-Cruz
Biotechnology (Santa Cruz, CA). All primary antibodies were prepared at a concentration
of (1:1000) except pERK5 (1:500). The following day, blots were washed three times in
Dulbecco’s 1X PBS solution with 0.1% Tween-20 (1X PBS-T) and incubated with goat
anti-rabbit (LI-COR Biosciences, Cat. #926-68021) and goat anti-mouse (LI-COR
Biosciences, Cat. #926-32210) secondary antibodies (both 1:10000) for 1 h at room
temperature. After washing the membranes with 1X PBS-T, the protein bands were
visualized on an Odyssey Infrared Imager (model #9201-01, LI-COR) and quantified
with Odyssey software (Version 3.0, LI-COR Biosciences). Phosphorylated proteins were
expressed as a fraction of their respective total protein levels and total proteins were
expressed as a fraction of either mouse anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, clone 6C5, Cat. #MAB374, Billerca, MA) or mouse anti-α-tubulin (SigmaAldrich Cat. #T5168) to control for differences in protein loading across experimental
groups. The resultant infrared protein bands were pseudocolored green or red.
2.6.2 Tissue Samples
Total protein content of the tissue homogenates was determined by the Bradford
protein assay and 60 μg of protein was separated on an 8% polyacrylamide gel by SDSgel electrophoresis and transferred to a nitrocellulose membrane (LI-COR Biosciences,
Lincoln, NE). Blots were blocked in casein blocking buffer (LI-COR Biosciences) for 1 h
prior to overnight incubation at 4° C in primary antibody in casein blocking buffer +
0.2% Tween-20. The following antibodies were purchased from Cell Signaling
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Technology: pERK1/2 (#9101), pERK5 (#3371), pAkt (Ser473, #4051), pAkt1 (Ser473,
#9018), total Akt (#9272), and total ERK1/2 (#9107). Total ERK5 (#sc-81460) was
purchased from Santa-Cruz Biotechnology (Santa Cruz, CA). All primary antibodies
were prepared at a concentration of (1:1000) except pERK5 (1:500). The following day,
blots were washed three times in Dulbecco’s 1X PBS solution with 0.1% Tween-20 (1X
PBS-T), then incubated with goat anti-rabbit (LI-COR Biosciences, Cat. #926-68021)
and goat anti-mouse (LI-COR Biosciences, Cat. #926-32210) secondary antibodies (both
1:10000) for 1 h at room temperature. After washing the membranes with 1X PBS-T, the
protein bands were visualized on an Odyssey Infrared Imager (model #9201-01, LI-COR)
and

quantified

with Odyssey software

(Version 3.0,

LI-COR

Biosciences).

Phosphorylated proteins were expressed as a fraction of their respective total protein
levels or as a fraction of the loading control, where appropriate; total proteins were
expressed as a fraction of either mouse anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, clone 6C5, Cat. #MAB374, Billerca, MA) or mouse anti-α-tubulin (SigmaAldrich Cat. #T5168) to control for differences in protein loading across experimental
groups. The resultant infrared protein bands were pseudocolored green or red.
2.7

Kinase Inhibitors
The LY294002 and U0126 inhibitors were purchased from Cell Signaling

Technology (Cat. #9901 and #9903, Danvers, MA). The BIX02189 compound was
purchased from Selleck Chemicals (Cat. #S1531, Houston, TX). The XMD8-92 inhibitor
was provided as a gift from the laboratory of Dr. Nathanael Gray (Harvard Medical
School, Boston, MA) or purchased from Tocris Bioscience (Cat. #4132, Minneapolis,
MN). Wortmannin was provided as a gift from the laboratory of Dr. Rehana Leak
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(Duquesne University). All inhibitors were prepared as 10 mM stocks in dimethyl
sulfoxide (DMSO) and stored at -20° C until in vitro use at the final concentrations
indicated.
2.8

Novel MEK5 Inhibitor Treatment
The HEK293 cell line, BT-474 breast cancer cell line, or MDA-MB-231 breast

cancer cell line were grown in culture as previously described (Section 2.1). Twenty-four
h prior to inhibitor treatment, the media were replaced to provide serum-free culture
conditions. The cells were pretreated with novel MEK5 inhibitor compounds (10 µM) for
30 min followed by stimulation with epidermal growth factor (EGF, 50 ng/mL) for 15
min. Vehicle-treated cells were pretreated with DMSO for 30 min prior to EGF
stimulation for 15 min. Protein visualization and quantification analysis was performed
using LI-COR Odyssey Imager as described (Section 2.6.1).
2.9

MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay
Subconfluent monolayer cultures were trypsinized and cells were plated in 96-

well plates at a density of 3,000 per well (Costar, Corning, NY). Cultures were allowed to
attach overnight prior to treatment with vehicle (DMSO), BIX02189, U0126, LY294002,
PD98059 (all 10 µM, Selleck Chemicals and Cell Signaling Technologies), or
Wortmannin (50 nM) for 1 hr prior to treatment with epidermal growth factor (EGF, 50
ng/mL). Cell proliferation was analyzed at 24 and 48 h by an MTT-based assay (SigmaAldrich CGD-1, St. Louis, MO). The MTT assay is a colorimetric assay that measures the
activity of living cells via mitochondrial dehydrogenase activity. The assay is utilized as a
measure of viability and proliferation based on cellular mitochondrial function.
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Following treatment with the inhibitors and EGF, MTT was added at 5 mg/mL and plates
were returned to the incubator for 3 h. The medium-MTT was then removed and 100 µl
of MTT Solvent (0.1 N HCl in anhydrous isopropanol) was added to each well. The plate
was kept for 15 min in the dark to dissolve the MTT-formazan crystals. The absorbance
of the samples was then recorded at 570 nm. Luminescence was measured on a
microplate reader (VICTOR3 1420 multilabel counter, Perkin Elmer, Waltham, MA).
Five wells were analyzed for each condition, and wells containing medium plus MTT (no
cells) were used as blanks.
2.10

Invasion Assay
Invasion assays were performed using BD BioCoat™ Matrigel Invasion

Chambers (BD Biosciences, San Jose, CA) as per the manufacturer’s instructions. Cells
were grown to 70% confluent monolayers in 10 cm2 plates, then seeded at a density of 35
× 105 cells/well in the upper chamber of the Matrigel basement membrane-coated insert
(8.0µm) in DMEM/F12 + 0.1% penicillin-streptomycin (MDA-MB-231 cells) or HybriCare + 0.1% penicillin-streptomycin (BT-474 cells) +/- dimethyl sulfoxide (DMSO,
vehicle), XMD8-92, LY294002, or U0126 (5 or 10 µM). No FBS was added to the apical
chambers. Media containing the chemoattractant (10% FBS) was added to the lower
chambers. Cells were incubated for 22 h at 37° C and supplied with 5% CO2. Cells
remaining in the upper chamber were gently removed with a cotton swab, while cells on
the lower surface of the membrane were fixed and stained with the Hema-3 Staining
System (Fisher Scientific, Pittsburgh, PA). The total number of invading cells was
determined by counting the cells on the underside of the insert from triplicate wells (five
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fields per insert) at 10x or 20x magnification using the Olympus SC30 digital camera and
cellSens digital imaging software (Version 1.8, Olympus).
2.11

Migration Assay
To investigate the effect of MAPK and PI3K inhibition on cell migration, the

wound healing, or “scratch,” assay was employed. This assay has been validated in
several cell lines as a method to mimic the migration of cells in vivo. Further, it allows
for the regulation of cell-cell and cell-ECM interaction that is disrupted in other methods
used to assess cell migration, including the Boyden chamber assay. Cells were seeded, in
triplicate, into 12-well plates and grown to a confluent monolayer. The cells were serumstarved for 24 h prior to the induction of the wound (scratch). After removal of the media,
a wound was created by scraping the cells with a 200 µL plastic pipette tip at the 0 h time
point. The cells were then washed 1× with 1X PBS to remove any cellular debris or
detached cells, and then replenished with media containing the vehicle and/or inhibitor (5
or 10 µM final concentration). The cells were allowed to migrate for 24 h. Images were
taken at 6, 12, 18 and 24 h with the EVOS digital inverted fluorescence microscope
(Model #AMF-4301-US, Advanced Microscopy Group (AMG), Bothell, WA) to assess
the cell migration into the wound area. The area of the scratch from cell border to cell
border was quantified for each timepoint and analyzed as a percentage of the area at
baseline, or the 0 h timepoint (set at 100%). ImageJ Software (Version 1.46r, software
developed by Wayne Rasband, National Institutes of Health, Bethesda, MD) was used to
quantify the wound area. Statistical analysis was performed using GraphPad Prism
software (GraphPad, San Diego, CA).
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2.12

Immunohistochemistry
At necropsy, the animals were euthanized by CO2 inhalation. Tissues to be

processed for immunohistochemical analysis were fixed in 4% PFA at the time of
necropsy, then transferred to 70% ethanol after 72 h and maintained at 4° C until further
processing. Paraffin-embedded mammary tumor and normal mammary tissues were first
sectioned and then stained for total ERK5 (Catalog #C-20: sc-1284; Santa Cruz
Biotechnology, Inc, Santa Cruz, CA) or Ki67 by Mass Histology Service, Inc.
(Worcester, MA). For staining, sections were heated for 20 min followed by incubation
with hydrogen peroxide for 15 min. Sections were blocked with rabbit serum for 20 min
prior to overnight incubation in the appropriate primary antibody at 4° C. The next day,
sections were incubated in a biotinylated rabbit anti-goat secondary antibody (1:250) for
1 h. Avidin-biotin complex (ABC) staining was employed for 45 min. The
immunostaining was scored by a researcher blinded to the samples’ age. The number of
Ki67 and ERK5 positive cells was estimated in three separate fields (20x magnification)
for each tumor. Results were classified according to the following scale: 4 (≥ 75%); 3
(50–75%); 2 (25–50%); 1 (≤ 25%); and 0 (no or weak staining in a few cells).
2.13

Statistical Analysis

The results are representative of two or three independent experiments performed
in at least triplicate, as specified, and are expressed as the means ± SEM. Grubbs’ test
was performed to determine significant outliers ( p < 0.05) within the experimental groups
(GraphPad® Prism Software, San Diego, CA). Statistical analysis of the data was
performed using GraphPad® Prism Software (Versions 5.01 and 6.02, San Diego, CA) or
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IBM SPSS Statistics Software (Version 2.0, Armonk, NY). A Student’s unpaired t-test or
one- or two-way analysis of variance (ANOVA) followed by a multiple comparison posthoc Bonferroni, Tukey-Kramer, Newman-Keuls, or Dunnett analysis was employed, as
specified. The Bonferroni and Newman-Keuls tests were employed when all pair-wise
comparisons were being assessed among groups containing equal sample sizes. Unlike
the Bonferroni correction, the Newman-Keuls test considers the alpha of each
comparison separately, and was therefore used to determine very small differences
between groups. The Tukey-Kramer post-hoc test was utilized to make pair-wise
comparisons in experiments where the sample sizes were unequal. Finally, the Dunnett
analysis was used when comparisons were being made against one group (control).
Significance was set at * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** p = 0.0001.
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CHAPTER 3
AGE-ASSOCIATED CHANGES IN THE EXPRESSION AND ACTIVATION OF THE
MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) AND PHOSPHATIDYLINOSITOL 3KINASE (PI3K) SIGNALING PATHWAYS IN CELLULAR AND ANIMAL MODELS OF
BREAST CANCER

3.1

Hypothesis
The activation of ERK5 increases with age to promote cell proliferation,

migration, and invasion in breast cancer.
3.2

Rationale
The most common demographic risk factor associated with breast cancer is aging

(Edwards et al., 2002; Balducci and Ershler, 2013; Garbe et al., 2012; Jemal et al., 2013;
NCI, 2013). Several changes at both the organismal and cellular levels have been
associated with aging, including altered cellular signaling, telomere shortening,
epigenetic shifts, and genomic instability. Many of these contributing factors have also
been implicated in cancer initiation, maintenance, and progression; thereby, the
transformed cells are enabled to evade cell death, sustain cell proliferation, and activate
metastatic processes. Despite the overlapping characteristics between aging and cancer,
the effect of age on distinct cellular mechanisms that underlie crucial processes necessary
for tumor growth and progression remain elusive.
Two kinase signaling pathways critical for maintaining numerous cellular
processes that are often aberrant in tumors are the mitogen-activated protein kinase
(MAPK) and phosphatidylinositol 3-kinase (PI3K) cascades. It has been demonstrated
that activation of ERK5 positively correlates with age in human breast tumor samples
(Quong et al., 2002), yet both the age-associated mechanistic basis of kinase stimulation
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and the physiological consequences of the resultant ERK5 activity remain to be
determined. Moreover, the effect of aging on ERK1/2 expression and activation is
undetermined, while contradictory findings involving Akt activity with age warrant
further investigation. Therefore, one aim of the current study was to determine the agerelated expression and activation changes that occur in these signaling kinases and how
these alterations translate to physiological outcomes in breast cancer cells. It was
hypothesized that as ERK5 activation increases with age, a compensatory decrease in
ERK1/2 and Akt activation will occur.
3.3

Results

3.3.1 Age-Associated Changes in Kinase Expression and Activation in Breast
Cancer Cells
Numerous studies have demonstrated the contribution of the MAPK and PI3K
pathways to breast cancer initiation and progression (Santen et al., 2002; Saini et al.,
2013; Bartholomeusz et al., 2012; Liu et al., 2009; Campbell et al., 2004; Ligresti et al.,
2009). In addition, age is the most common demographic risk factor associated with the
onset of breast cancer (Pirone et al., 2012; NCI, 2013). Taken together, these data suggest
potential overlap between age and an increase in kinase activity to promote breast cancer.
In fact, an age-related increase in ERK5 activation was observed in a study examining the
ER and ER-inducible genes in human breast tumors (Quong et al., 2002). However, no
studies have examined changes to the kinase at middle-age, and, to date, the few data that
do exist regarding the relationship between age and ERK5 provide inconsistent
conclusions (Fei et al., 2013; Quong et al., 2002). Moreover, age-associated alterations in
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expression and activation of the familial kinase, ERK1/2, and the parallel signaling
kinase, Akt, expression and activation remain to be determined in breast cancer.
Furthermore, the potential influence of disparate hormonal profiles on age-related kinases
changes in breast cancer cells has not been explored.
To first examine how kinase expression and activation vary over time, the BT474, MDA-MB-231, and MMC breast cancer cell lines were “aged” in culture as
described (Chapter 2). Based on the findings in the ER+ tumors assessed by Quong and
colleagues (2002), where the ERK5 activation positively correlated with age, similar
results were expected in the ER+ BT-474 cell line. Constitutive activation of ERK5 has
been previously established in this cell line and in breast tumors where HER2 is
overexpressed (Esparís-Ogando et al., 2002; Montero et al., 2009). Taken together, these
data suggest that in the current study, ERK5 activation will increase with age in this ER+
and HER2+ cell line. Such results might suggest E2 and the ER participate in agedependent crosstalk with the MEK5-ERK5 pathway, resulting in heightened activation;
however, further investigation into the relationship between ERK5 and the ER would be
required to elucidate this potential mechanistic link.
In the present study, age-related ERK5 activation would support the involvement
of ERK5 in the observed increase in hormone-dependent breast cancers that occur with
age (Anderson et al., 2006). In fact, a significant increase in phospho-ERK5 was
observed in the BT-474 cell line in middle-aged cells as compared to young cells (Figure
12A). No significant change in ERK5 activation was observed between the old-aged cells
as compared to either young or middle-aged cells. Whereas a previous study determined
total ERK5 protein expression was higher in young rats as compared to older animals
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(Fei et al., 2013), in the current study, no significant alterations were observed in the total
expression of ERK5 (Figure 12A).
As previously discussed, ERK1/2 activation and function have been shown to
decline with age in the rat brain as well as in human neutrophils, T-lymphocytes, and
duodenal enterocytes (Tortorella et al., 2004; Li et al., 2000; Gentili and de Boland,
2000; Zhen et al., 1999; Hutter et al., 2000). Therefore, a decrease in the phosphorylation
of ERK1/2 was anticipated with age. Despite this expected outcome, no significant
changes in ERK1/2 activation or expression were observed in this cell line, though total
ERK1/2 expression was highest at middle-age as compared to both young- and old-aged
cells (p = 0.14 and p = 0.12, respectively, by two-tailed, unpaired t-test, GraphPad
Prism®).
Increased activation of Akt has been previously found to correspond to
overexpression of HER2 in primary breast carcinomas (Tokunaga et al., 2006). Similarly,
in cell lines where HER2 is amplified, an observed sensitivity to PI3K, Akt, and/or
mTORC1/mTORC2 inhibitors suggests that these cells rely on this pathway (Saini et al.,
2013). Furthermore, as an inverse relationship was observed between Akt activation and
PR expression (Tokunaga et al., 2006), we anticipate high activation of Akt in the PR–
/HER2+ BT-474 cells.
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Figure 12. MAPK and PI3K Pathway Expression and Activation in Aged BT-474 Breast
Cancer Cells. The expression and activation of ERK5, ERK1/2 and Akt were assessed by
western blot analysis in aged BT-474 cells as described in the Methods section. (A) A
significant (*) increase in ERK5 activation was observed in middle-aged cells as compared to
young cells. (B) No significant changes were observed in ERK1/2 expression or activation
with age. (C) A significant decrease in total Akt levels was observed in old-aged cells as
compared to young (**) and middle-aged (#) cells. Results represent the mean ± SEM of two
independent experiments, n=3/group. Significance was defined as * = p ≤ 0.05, ** = p ≤
0.01, and # p ≤0.05 by one-way ANOVA followed by Tukey-Kramer post-hoc analysis
(GraphPad® Prism software).
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Conflicting data exist, however, regarding age-related changes within the Akt
signaling cascade. While a study of primary breast carcinomas found alterations to the
pathway exclusively in young patient cohorts, studies in other anatomical regions,
including the brain and skeletal muscle, indicate overexpression of Akt increases with
age. These data suggest that activation of this signaling cascade may be tissue and
disease-state specific, with upregulation occurring in response to cellular needs. In this
model, no significant changes in the activation of Akt with age were observed (Figure
12C). An age-related decrease in total Akt protein expression, however, was observed. As
compared to both young- and middle-aged cells, old-aged cells (higher passage)
displayed a decrease in total Akt protein levels (Figure 12C).
Numerous recent studies have focused on gaining a better mechanistic
understanding of TNBC owing to the paucity of therapeutic options available and high
mortality rate associated with this disease, particularly in younger women. TNBCs are
characterized by a lack of estrogen and progesterone receptors and amplification of the
HER2 gene. In cancer, the MAPK and PI3K signaling pathways are oft-aberrant. The
presence of PIK3CA mutations (10-21%), in addition to the enhanced expression of the
MAPKs observed in this breast cancer subtype, support the importance of these pathways
in TNBC (Engebraaten et al., 2013; Saini et al., 2013; Perez-Madrigal et al., 2012). To
assess how these cascades change with age, the human triple-negative MDA-MB-231 cell
line (ER–/PR–/HER2–) was aged in vitro as described in the Methods section (Chapter 2).
Derived from a metastatic pleural effusion of a 51-year-old woman, the MDA-MB-231
cell line provides insight regarding the expression and activation changes that occur in
middle-aged women with this particular claudin-low subtype of breast cancer. As
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previously described, hormone-negative breast cancers are more typical in younger
women with an increased rate up to age 50 (Anderson et al., 2006).
While the MEK5-ERK5 pathway has been linked to TNBC in terms of controlling
cell proliferation (Perez-Madrigal et al., 2012), little is known regarding expression and
activation levels of ERK5 in TNBC, particularly with age. In the present study, an agedependent decrease in ERK5 activation was observed, as middle-aged cells has
significantly less ERK5 activation as compared to young cells. Furthermore, old-aged
cells demonstrated significantly less ERK5 activation as compared to young and middleaged animals (Figure 13A).
The MEK1/2-ERK1/2 pathway is activated in TNBC (Bartholomeusz et al.,
2012); however, as previously mentioned, ERK1/2 function and activation have been
shown to decrease with age. As ERK5 activation decreases with age in these animals, it
was expected that ERK1/2 activation would increase to compensate for the loss of ERK5
activity. In fact, ERK1/2 activation decreased with age in this model, as a significant
reduction of p-ERK1/2 was observed in middle-aged cells as compared to young (Figure
13B). There was not a significant difference in the ERK1/2 activation of old-aged cells as
compared to middle-aged cells, however the difference was close to significance as
compared to young cells (p = 0.058, by two-tailed, unpaired t-test, GraphPad Prism®).
Meanwhile, no significant differences were observed in total ERK1/2 expression with
age, by one-way ANOVA, though a significant decrease was determined between
middle- and old-aged cells (p ≤ 0.05 by two-tailed, unpaired t-test, GraphPad Prism®)
and the difference between middle and young cells was close to significance (p = 0.08 by
two-tailed, unpaired t-test, GraphPad Prism®) (Figure 13B).
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In a study investigating signal transduction pathways in TNBC, activation of Akt
was found to be significantly higher in patient samples devoid of hormone receptors
(Umemura et al., 2007). The aforementioned discrepancies regarding how Akt expression
and activation change with age, however, provide little insight as to the age-related
changes that may occur with this receptor-negative cell line. Similar to observations with
ERK1/2 activation, a significant decrease in Akt activation was observed in middle-aged
cells as compared to both young- and old-aged cells (Figure 13C). Conversely, an agedependent increase in total Akt expression was observed in middle-aged cells as
compared to both young- and old-aged cells (Figure 13C).
The murine tumor-derived MMC cell line represents a unique hormonal profile as
compared to the two human cell lines assessed in the current study. The MMC cells are
both ER- and PR-negative, but HER2-positive (ER–-/PR–/HER2+). Though not as
clinically relevant as the human cell lines examined, the data revealed from the kinase
profiling analysis provides valuable data as the cell line was derived from the tumor of an
MMTV-neu mouse, the same animal model used for in vivo aging study. The expression
and activation of ERK1/2 and Akt were higher in mammary tumors derived from this
animal model as compared to normal mammary tissue (Lee et al., 2010). The rodents
used for the study were 6-7 weeks old, however, providing little indication of how these
kinases may change with age. Furthermore, ERK5 expression and activation have not yet
been examined in these cells or with the MMTV-neu mouse model.
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Figure 13. MAPK and PI3K Pathway Expression and Activation in Aged TripleNegative Breast Cancer Cells. The expression and activation of ERK5, ERK1/2 and Akt
were assessed by western blot analysis in aged MDA-MB-231 cells as described in the
Methods section. (A) A significant (*) decrease in ERK5 activation was observed in middleaged cells as compared to young cells and in old cells as compared to both young and middle
passages. No significant changes were observed in total ERK5 expression. (B) A significant
decrease was observed in ERK1/2 activation in middle-aged cells as compared to young. No
significant changes were observed in total ERK1/2 levels. (C) A significant decrease in Akt
activation was observed in middle-aged cells as compared to both young and old passages.
Akt expression was significantly increased as compared to both young and old cells. Results
represent the mean ± SEM of two independent experiments, n=3/group. Significance was
defined as * = p ≤ 0.05, ** = p ≤ 0.01, *** p ≤ 0.001, # p ≤ 0.05, and $ p ≤ 0.01 by one-way
ANOVA followed by Tukey-Kramer post-hoc analysis (GraphPad® Prism).
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Following a similar pattern to that observed in the triple-negative MDA-MB-231
cell line, the activation of ERK5 appears to decrease with age in the MMC cell line,
though the results were not significant (Figure 14A). Interestingly, the inverse pattern
was observed in total ERK5 expression; though not statistically significant, total ERK5
protein levels appear to increase with age (Figure 14A). Similarly, no significant changes
were observed in the activation or expression of ERK1/2 (Figure 14B).
HER2 overexpression has been associated with increased activation of Akt in
breast cancer (Tokunaga et al., 2006) though how this kinase changes with age has not
been previously examined in this animal model. As shown in Figure 14C, activation of
Akt increased with age, with a significant increase observed between young cells as
compared to both middle- and old-aged cells. No significant changes were observed in
total Akt protein expression with age (Figure 14C).
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Figure 14. MAPK and PI3K Pathway Expression and Activation in Aged Murine MMC
Cells. The expression and activation of ERK5, ERK1/2 and Akt were assessed by western
blot analysis in aged MMC cells as described in the Methods section. (A) No significant
changes were observed in the expression or activation of ERK5 in MMC cells with age in
vitro. (B) As observed with ERK5, no significant changes occurred in ERK1/2 expression or
activation. (C) A significant increase in Akt activation was observed in middle- and old-aged
cells as compared to young. Akt expression did not change. Results represent the mean ±
SEM of two independent experiments, n=3/group. Significance was defined as * = p ≤ 0.05
by one-way ANOVA followed by Tukey-Kramer post-hoc analysis (GraphPad® Prism).
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3.3.2 Age-Associated Changes in Kinase Expression and Activation in Normal
Mammary and Mammary Tumor Tissue
The in vitro study assessing age-related changes in the MAPK and PI3K pathways
revealed variability between cell lines regarding kinase expression and activation.
Furthermore, the presence of age-associated changes within each of the cell lines was
observed. These data provided valuable information regarding the role of aging on
ERK1/2, ERK5, and Akt expression and activation and warrant further investigation in
breast cancer cells exhibiting unique hormonal profiles. However, to more closely mimic
how these pathway nodes are altered with age, the transgenic MMTV-neu mouse model
was employed. Homozygous transgenic (MMTV/neu, 202Mul) male mice were bred with
wild-type FVB/N-Tg (MMTV/neu, 202Mul/J) female mice to generate female offspring
to be aged for the study. These animals spontaneously develop focal tumors within the
epithelium of mammary fat pad following a prolonged latency period, mimicking middleage in humans. The hormonal profile of the tumors that develop in these animals (ER–
/PR–/HER2+) provides an indication of how age-related changes affect kinase expression
and activation in the presence of HER2 gene amplification.
The MMC cell line, derived from the tumor of an MMTV/neu transgenic mouse,
provided an in vitro indication of how the ERK1/2, ERK5, and Akt pathways may be
altered with age in the MMTV/neu animal model. As previously described, no significant
changes were observed in ERK1/2 or ERK5 expression or activation in the MMC cell
line (Figure 14B and C). However, a significant age-related increase in Akt activation
was observed. Similar results were expected in the in vivo aging study, though tumor
heterogeneity, individual animal differences, and the influence of the tumor
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microenvironment may result in alterations in the MAPK and PI3K pathways that were
not noted in vitro.
Mammary tumor (MT) tissue and normal adjacent mammary (NM) tissue were
harvested and analyzed from animals spanning 9-15 mo of age (n=5 animals/age/tissue).
An age-related increase in ERK5 activation was observed in MT tissue as compared to
NM tissue in animals aged 13 and 14 mo (Figure 15A). An assessment of age-related
changes in ERK5 activation in MT tissue alone revealed activation largely increased with
age, particularly when comparing animals at 9 mo vs. 14 mo (p = 0.06 by unpaired t-test),
though the difference was not statistically significant (results not shown). In nearly all
age subsets, the activation of ERK5 was higher in MT than NM tissue. Conversely, in an
assessment of total ERK5 expression, in all aged cohorts, higher ERK5 was observed as
compared to MT tissue. A significant decrease in ERK5 expression occurred in animals
aged 11, 12, 14, and 15 mo (Figure 15B).
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Figure 15. Expression and Activation of ERK5 in an Aged Murine Model of Breast
Cancer. The expression and activation of ERK5 were assessed by western blot analysis in
normal mammary (NM) and mammary tumor (MT) tissue as described in the Methods
section. (A) A significant difference in ERK5 activation was observed between MT and NM
tissue in animals at 13 and 14 mo of age. (B) Total ERK5 protein expression in MT tissue
was significantly decreased in animals aged 11, 12, 14, and 15 mo as compared to NM tissue.
Results represent the mean ± SEM, n=5/tissue/age. Significance was defined as * = p ≤ 0.05;
** = p ≤ 0.01; *** = p ≤ 0.001 vs. NM tissue by two-way ANOVA followed by Bonferroni
post-hoc analysis (GraphPad® Prism and IBM SPSS Statistics Software).
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Next, the expression and activation of ERK1/2 were examined in MT and NM
tissues of aged MMTV/neu mice. Data from the in vitro aging study in MMC cells
determined there were no significant changes in ERK1/2 expression or activation with
age (Figure 16B). However, in vivo studies in rodents and humans demonstrated an agerelated decline in function and activation of ERK1/2 (Zhen et al., 1999; Hutter et al.,
2000; Tortorella et al., 2004; Li et al., 2000; Gentili and de Boland, 2000). In animals at
9, 10, and 12 mo of age, ERK1/2 activation was significantly higher in the NM tissue as
compared to MT tissue (Figure 16A). Similar to the results observed in the MMC cell
line, no significant age-related changes in total ERK1/2 protein expression were observed
when comparing NM and MT tissue (Figure 16B).
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Figure 16. Expression and Activation of ERK1/2 in an Aged Murine Model of Breast
Cancer. The expression and activation of ERK1/2 were assessed by western blot analysis in
normal mammary (NM) and mammary tumor (MT) tissue as described in the Methods
section. (A) A significant difference in ERK1/2 activation was observed between MT and
NM tissue in animals at 9, 10, and 12 mo of age. (B) No significant differences were
observed at any age between total ERK1/2 protein expression in NM and MT tissue. Results
represent the mean ± SEM, n=5/tissue/age. Significance was defined as * = p ≤ 0.05; ** = p
≤ 0.01; *** = p ≤ 0.001 vs. MT tissue by two-way ANOVA followed by Bonferroni post-hoc
analysis (GraphPad® Prism and IBM SPSS Statistics Software).
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In addition to the MAPK pathway, the expression and activation of Akt provided
information regarding age-related changes in vivo in the PI3K pathway. Previous studies
in primary breast tumors have found that overamplification of HER2 was correlated with
increased Akt activation (Tokunaga et al., 2006); therefore, it was expected that in these
HER2-positive tumors, high activity of Akt would be observed. The in vitro assessment
of kinase activity in the MMC cells revealed that, in fact, activation of Akt was increased
in an age-dependent manner (Figure 14C). No significant changes were observed, with
age, in total Akt expression (Figure 14C). In the MMTV/neu mouse model, a significant
increase in Akt activation was observed in MT tissue as compared to NM tissue in
animals at 15 mo of age (Figure 17A). However, no statistically significant age-related
changes in phosphorylated Akt were observed within either tissue type. No significant
changes in total Akt protein expression were observed with age or in a comparison
between MT and NM tissue (Figure 17B), supporting the results obtained from the in
vitro study (Figure 14C).
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Figure 17. Expression and Activation of Akt in an Aged Murine Model of Breast
Cancer. The expression and activation of Akt were assessed by western blot analysis in
normal mammary (NM) and mammary tumor (MT) tissue as described in the Methods
section. (A) A significant difference in Akt activation was observed between MT and NM
tissue in animals at 15 mo of age. (B) No significant differences were observed at any age
between total Akt protein expression in NM and MT tissue. Results represent the mean ±
SEM, n=5/tissue/age. Significance was defined as ** = p ≤ 0.01 vs. NM tissue by two-way
ANOVA followed by Bonferroni post-hoc analysis (GraphPad® Prism and IBM SPSS
Statistics Software).
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3.3.3 Analysis of Kinase Expression and Proliferation in an Aged Mammary
Tumor Model
To assess how age-related alterations in kinase expression and activation translate
into functional outcomes, the first goal was to examine whether kinase expression
correlates to age-related changes in cell proliferation. ERK5 has been previously
associated with increased proliferation in several cell models of breast cancer (PerezMadrigal et al., 2012; Esparís-Ogando et al., 2002). A link between aging and
proliferation in breast malignancies has not been explored. To begin to examine the
potential association between ERK5 and aging to promote proliferation, MMTV/neu
mice were aged and mammary tumor and non-tumor adjacent mammary tissue were
collected for immunohistochemical analysis as described in the Methods section (Chapter
2). Animals were delineated into age groups as follows: young (8-9 mo); middle (10-12
mo); and old (13-15 mo) (n=3-7 animals/group). The immunostaining of ERK5 was
analyzed by an independent researcher blinded to the study and the age of the animals.
Using an intensity scale to assess ERK5 staining, the observer examined three
representative images of each tumor, as described in Chapter 2. Representative images
for each age cohort are shown in Figure 18. Expression of ERK5 in tumors progressively
increased with age, with a significant difference observed between the tumors of young
and old animals (Figure 19). Interestingly, irrespective of age, localization of ERK5 was
also observed in the tumors; the majority of ERK5 staining, regardless of intensity, was
found in peripherally located cells (indicated by white arrows in Figure 20).
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Figure 18. ERK5 Expression in Aged Murine Mammary Tumor Tissue. The expression
of ERK5 was examined by immunohistochemical analysis in mammary tumors extracted
from the MMTV/neu mouse model as described in the Methods section. Panel A illustrates
representative ERK5 staining in tumors extracted from young (8-9 mo) animals. Panel B
represents tumors extracted from middle-aged animals (10-12 mo) and Panel C is
representative of two animals from the old aged cohort (13-15 mo). All histological sections
(5µm thick) were stained using an antibody specific for total ERK5 expression. All images
are shown at 20x magnification.

99

Figure 19. ERK5 Expression Increases with Age in Murine Mammary Tumor Tissue.
The expression of ERK5 was assessed by immunohistochemical analysis in mammary tumor
sections derived from MMTV/neu mice as described in the Methods section. A significant
increase in total ERK5 expression was observed in tumors of old-aged (13-15 mo) as
compared to the tumors of young animals (8-9 mo). No significant differences in ERK5
expression were observed in tumors from middle-aged animals as compared to young- or oldaged animals. Results represent the mean ± SEM, n=3-7. Significance was defined as * = p ≤
0.05 by one-way ANOVA followed by Tukey post-hoc analysis (GraphPad® Prism).
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Figure 20. Localization of ERK5 in Murine Mammary Tumor Tissue. The expression of
ERK5 was assessed by immunohistochemical analysis in mammary tumor sections derived
from MMTV/neu mice as described in the Methods section. Upon microscopic observation,
the majority of ERK5 staining was found to occur within the periphery of tumors (marked by
white arrows) regardless of age. A representative tumor image is provided for each age
cohort: young (8-9 mo)- Panel A; middle-aged (10-12 mo)- Panel B; and old-aged (13-15
mo)- Panel C. All histological sections (5µm thick) were stained using an antibody specific
for total ERK5 expression. All images are shown at 20x magnification.
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After establishing that an age-associated increase in ERK5 expression occurs in
mammary tumors, the expression of Ki67 was assessed to provide an indication of
whether aging affects tumor proliferation in this model of breast cancer (Figure 21).
Mammary tumors and non-tumor adjacent mammary tissue derived from the same
MMTV/neu mice used for the assessment of ERK5 expression were utilized for
immunohistochemical analysis of Ki67 as described in the Methods section (Chapter 2).
Animals were again delineated into age groups as follows: young (8-9 mo); middle (1012 mo); and old (13-15 mo) (n=3-7 animals/group). The same paradigm for scoring the
intensity of Ki67 staining was used as that described for the assessment of ERK5
(Chapter 2). Following scoring, no significant age-related changes in Ki67 expression
were observed (Figure 22).
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Figure 21. Ki67 Expression in Aged Murine Mammary Tumor Tissue. The expression of
Ki67 was assessed by immunohistochemical analysis in mammary tumor sections derived
from MMTV/neu mice as described in the Methods section. Two representative tumor
images are provided for each age cohort: Panel A- young (8-9 mo); Panel B- middle-aged
(10-12 mo); and Panel C- old-aged (13-15 mo). All histological sections (5µm thick) were
stained using an antibody specific for total Ki67 expression. All images are shown at 20x
magnification.
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Figure 22. Quantification of Ki67 Expression in Aged Murine Mammary Tumor Tissue.
The expression of Ki67 was assessed by immunohistochemical analysis in mammary tumor
sections derived from MMTV/neu mice as described in the Methods section. No significant
differences in Ki67 expression were observed in mammary tumors when comparing any of
the age groups. Results represent the mean ± SEM, n=3-7. Data were analyzed by one-way
ANOVA followed by Tukey post-hoc analysis (GraphPad® Prism Software).

3.3.4 The Influence of the MAPK and PI3K Pathways on Breast Cancer Cell
Proliferation and Migration
3.3.4.1 BT-474 Cell Line
Several studies have indicated that ERK1/2 and Akt influence tumor progression
by promoting cancer cell migration (Li et al., 2010; Krishna and Narang, 2008; Brugge et
al., 2007; Raimondi and Falasca, 2011; Guvakova et al., 2002), yet few studies have
explored the effect of ERK5 activation on cell migration, particularly in breast cancer
(Shukla et al., 2013; Ramsay et al., 2011, Castro and Lange, 2010). Further, age-related
effects on kinase modulation of cell migration has not been previously examined. Having
observed that ERK5 increases with age in mammary tumors, the next goal was to assess
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if this age-related rise translates to greater cell migration in aged and non-aged breast
cancer cells. To assess this outcome, the BT-474, MDA-MB-231, and MMC cell lines
were employed. Kinase inhibition was achieved using the following commercially
available inhibitors: the MEK inhibitor, U0126 (10 µM); the Akt inhibitor, LY294002(10
µM); and the novel ERK5 inhibitor, XMD8-92 (5 µM), as previously described (Chapter
2). Building upon previous reports that linked ERK5 to cell proliferation prior to the
synthesis of the touted MEK5-specific BIX series of inhibitors (Esparís-Ogando et al.,
2002), the effect of pharmacological inhibition on the ERK5 pathway was analyzed in the
current study using the same ER-dependent cell line as these findings were first reported.
To ensure that treatment of these cells resulted in kinase inhibition, western blot
analysis was performed as previously described. The hormone-dependent BT-474 cell
line was first treated with BIX02189, XMD8-92, LY294002, and U0126 to assess kinase
inhibition in basal conditions after 24 h of treatment (Figure 23). Following treatment
with the purportedly specific MEK5 and ERK5 inhibitors, BIX02189 and XMD8-92, the
activation of ERK5 was assessed (Figure 23A).
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Figure 23. MAPK and PI3K Pathway Activation following Kinase Inhibitor Treatment
in BT-474 Cells. The activation of ERK5, ERK1/2 and Akt was assessed in the ER-positive
BT-474 breast cancer cell line by western blot analysis. (A) ERK5 activation was assessed as
a ratio over total ERK5 protein expression following treatment with BIX02189 and XMD892. No statistical decrease in activation was observed by one-way ANOVA followed by
Dunnett post-hoc analysis. (B) ERK1/2 activation was examined as a ratio over total ERK1/2
protein expression following treatment with U0126. A statistically significant decrease was
observed as compared to vehicle (DMSO)-treated BT-474 cells by an unpaired t-test. (C) Akt
activation was assessed as a ratio over total Akt protein expression following treatment with
LY294002.The activation of Akt was significantly decreased as compared to vehicle treated
cells by an unpaired t-test. All data are expressed as a percentage of the control (vehicle
(DMSO)-treated cells). Results represent the mean ± SEM, n=3. Significance was defined as
* = p ≤ 0.05; *** = p ≤ 0.001 (GraphPad® Prism software).

Significant inhibition of ERK5 phosphorylation was not observed following
treatment with either inhibitor, though a modest decrease was observed following
XMD8-92 exposure (p = 0.15 by unpaired t-test). Moreover, at earlier timepoints,
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BIX02189 treatment resulted in activation of ERK5 (data not shown). Treatment of the
BT-474 cells with the MEK1/2 inhibitor significantly decreased ERK1/2 activation, as
anticipated (Figure 23B). Further, treatment with LY294002 significantly decreased
activation of Akt (Figure 23C).
Having established the effect of these inhibitors on kinase activation in the BT474 cell line, the effect on cell proliferation was assessed by the MTT assay as described
in the Methods section (Chapter 2). To examine proliferation following pharmacological
inhibition of the MAPK and PI3K pathways, cells were treated with the specified
inhibitors for either 24 or 48 h (Figure 24). As shown previously, treatment with
BIX02189 fails to inhibit ERK5 activation in this cell line (Figure 23). The MTT assay
revealed BIX02189 treatment had no effect on reducing cell proliferation (Figure 24).
Moreover, no significant changes in cell proliferation were observed following any
inhibitor treatment after either 24 or 48 h of exposure (Figure 24).
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Figure 24. Effect of Kinase Inhibition on Cell Proliferation in BT-474 Breast Cancer
Cells. Cell proliferation in the BT-474 cell line was examined following kinase inhibition of
ERK5, ERK1/2 and Akt. Cells were treated with the following: DMSO (vehicle), BIX02189,
U0126, PD98059, LY294002, or Wortmannin. No significant changes in proliferation were
observed at either the 24 h (left) or 48 h (right) timepoints following exposure to any
inhibitor. Results represent the mean ± SEM, of three independent experiments, n=5.
Treatment groups were compared to the vehicle group for the respective timepoint. Statistical
analysis was performed using a one-way ANOVA followed by post-hoc Dunnett analysis
(GraphPad® Prism software).

To assess cell migration, the wound-healing or “scratch” cell migration assay was
employed as described (Chapter 2). The assay allowed for the in vitro assessment of cells
migration by examining the scratched area over time as the cells move to close the
“wounded” area. The migration of cells treated with kinase inhibitors (XMD8-92 (5µM),
U0126 (10µM), or LY294002 (10µM)) was examined as a function of the cells receiving
vehicle-treatment at 12 and 24 h timepoints following the induction of the scratch.
Migration assays were not performed with BIX02189 as it resulted in activation, not
inhibition, of ERK5.
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The BT-474 cells were first treated with XMD8-92, an inhibitor indicated for
specific reduction of ERK5, while sparing the familial ERK1/2 kinase. As shown in
Figure 25, there was not a significant reduction in cell migration following XMD8-92
treatment. However, western blot analysis revealed that treatment with this inhibitor did
not significantly reduce activation of ERK5 (Figure 23A). Studies recently demonstrated
the involvement of ERK1/2 in breast cancer cell migration (Ma et al., 2012), though a
different methodology was employed. Following treatment with U0126, no changes were
observed at early timepoints, but a similar decrease in cell migration was observed after
24 h of inhibitor exposure (Figure 25).
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Figure 25. Effect of Kinase Inhibition on Cell Migration in BT-474 Breast Cancer Cells.
Cell migration in the BT-474 cell line was examined following kinase inhibition of ERK5,
ERK1/2 and Akt. (A) Representative light microscopy images of the BT-474 cell migration
assay after treatment with the following: DMSO (vehicle), XMD8-92, LY294002, or U0126
at baseline (top row) and 24 h following wound induction (bottom row). All images are
presented at 20x magnification. (B) Quantification of cell migration following inhibitor
treatment. White bars indicate the area of the scratch at baseline (0hr); gray bars represent the
area of the scratch 12 h following injury; black bars represent the area of the scratch at the
completion of the assay (24 h). After 12 h, inhibition with LY294002 resulted in a significant
reduction in cell migration as compared to control. After 24 h, inhibition with both
LY294002 and U0126 led to a significant decrease in cell migration compared to vehicle
control. For all treatments, quantified data are presented for both the 12 and 24 h timepoints
as a percentage of control (defined as the baseline, or the area of the scratch at 0 hr). Results
represent the mean ± SEM, of two independent experiments in triplicate. Significance was
defined as * = p ≤ 0.05; *** = p ≤ 0.001 by two-way ANOVA followed by Dunnett post hoc
analysis (GraphPad® Prism software).
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Finally, the effect of Akt inhibition on cell migration was assessed. Previous
studies have linked Akt activation to cell migration in this cell line (Zhang et al., 2012),
though the researchers examined receptor activator for nuclear factor κB ligand
(RANKL)-induced cell migration and focused mainly on the MCF-7 cell line, whereas
the current study assessed un-induced BT-474 cell migration. At both early and late
timepoints, exposure to LY294002 resulted in a significant reduction in cell migration
(Figure 25).
3.3.4.2 Triple-Negative MDA-MB-231 Cell Line
Triple-negative breast cancer is characterized as highly aggressive with high
patient mortality and limited treatment options. To assess potential pathways involved in
the migration of this breast cancer subtype, the MDA-MB-231 cell line was examined
following treatment with MAPK and PI3K pathway inhibitors, including BIX02189,
XMD8-92, U0126, and LY294002 (all 10µM, except XMD8-92, 5µM). Similar to the
paradigm utilized in the BT-474 cell line studies (Figures 23 and 25), western blot
analysis was performed in the MDA-MB-231 cell line to ensure decreased kinase
activation was achieved following inhibitor treatment (Figure 26).

111

(A)

(B)

(C)

Figure 26. MAPK and PI3K Pathway Activation following Kinase Inhibitor Treatment
in MDA-MB-231 Cells. The activation of ERK5, ERK1/2 and Akt was assessed in the
triple-negative MDA-MB-231 breast cancer cell line by western blot analysis. (A) ERK5
activation was assessed as a ratio over total ERK5 protein expression following treatment
with BIX02189 and XMD8-92. No change was observed in the cells following BIX02189
treatment, however, a statistically significant decrease in ERK5 activation was observed with
XMD8-92 treatment by one-way ANOVA followed by Dunnet post-hoc analysis. (B)
ERK1/2 activation was examined as a ratio over total ERK1/2 protein expression following
treatment with U0126. A statistically significant decrease was observed as compared to
DMSO (vehicle)-treated MDA-MB-231 cells by an unpaired t-test. (C) Akt activation was
assessed as a ratio over total Akt protein expression following treatment with LY294002.The
activation of Akt was significantly decreased as compared to DMSO-treated cells by an
unpaired t-test. All data are expressed as a percentage of the control (DMSO (vehicle)-treated
cells). Results represent the mean ± SEM, n=3. Significance was defined as ** = p ≤ 0.01 and
*** = p ≤ 0.001 (GraphPad® Prism software).

The receptor-negative cells were first treated with the MEK5 inhibitor,
BIX02189, or the ERK5 inhibitor, XMD8-92, and then analyzed for activation of ERK5.
No change was observed in kinase activation following BIX02189 treatment (Figure
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26A). Therefore, BIX02189 was not employed during the cell migration assay. Following
treatment with XMD8-92, however, ERK5 activation was significantly reduced in the
cells (Figure 26A). Similarly, following inhibition of MEK1/2 with U0126 treatment, a
significant decline in ERK1/2 activation was observed (Figure 26B). In addition, a
significant decrease in Akt activation was found following treatment with LY294002
(Figure 26C). Though the effect of ERK1/2 and Akt inhibition has been previously
examined in cell migration with this cell line, migration and motility were examined by
different assays; more importantly, the role of ERK5 on cell migration has not been
previously explored in these cells. Therefore, the next goal was to evaluate the influence
of these kinases on cell migration in this triple-negative cell line.
The wound-healing, or “scratch” assay, was again employed as a measure of cell
migration in the MDA-MB-231 cell line, as outlined previously (Chapter 2). Following
inhibition of ERK5 activation upon treatment with XMD8-92, a significant reduction in
cell migration was observed after both 12 and 24 h of treatment as compared to vehicletreated cells (Figure 27B). Similarly, migration was decreased in these cells following
ERK1/2 inhibition at both timepoints (Figure 27C). These data support previous studies
with this cell line that indicate treatment with U0126, and subsequent ERK1/2 inhibition,
lead to decreased cell migration. A significant decrease in cell migration was also
achieved at both timepoints upon PI3K inhibition by LY294002, in support of previous
reports that have examined the effect of Akt on motility in these TNBC cells.
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Figure 27. Effect of Kinase Inhibition on Cell Migration in Triple-Negative Breast
Cancer Cells. The effect of ERK5, ERK1/2 and Akt inhibition on cell migration was
assessed in the triple-negative MDA-MB-231 breast cancer cell line. (A) Representative light
microscopy images of the MDA-MB-231 cell migration assay after treatment with the
following: DMSO (vehicle), XMD8-92, LY294002, or U0126 at baseline (top row) and 24 h
following wound induction (bottom row). All images presented at 20x magnification. (B)
Quantification of cell migration following inhibitor treatment. White bars indicate the area of
the scratch at baseline (0hr); gray bars represent the area of the scratch 12 h following injury;
black bars represent the area of the scratch at the completion of the assay (24 h). After 12 and
24 h, kinase inhibition by XMD8-92, LY294002, and U0126 resulted in a significant
reduction in cell migration as compared to control (vehicle). For all treatments, quantified
data are presented for both the 12 and 24 h timepoints as a percentage of control (defined as
the baseline, or the area of the scratch at 0 hr). Results represent the mean ± SEM, of two
independent experiments, n=3. Significance was defined as *** = p ≤ 0.001 and **** = p ≤
0.0001 by two-way ANOVA followed by Dunnett post hoc analysis (GraphPad® Prism
software).

3.3.4.3 Age-Related Effects of Cell Migration in the Murine MMC Cell Line
The murine MMC cells (ER–/PR–) were derived from the in vivo model in which
age-related changes in ERK5 activation were previously observed (Figure 15A). To
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assess if this increased activation causes differential effects on cell migration with age,
the MMC cells were employed for in vitro assessment. Following a similar paradigm to
that utilized to age cells in vitro (Chapter 2), young (passage 12) and old (passage 36)
MMC cells were first assessed by western blot analysis to determine kinase activation
profiles following inhibitor treatment.
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Figure 28. MAPK and PI3K Pathway Activation following Kinase Inhibitor Treatment
in Young MMC Cells. The activation of ERK5, ERK1/2 and Akt was assessed in young
murine MMC cells (passage 12) by western blot analysis. (A) ERK5 activation was assessed
as a ratio over total ERK5 protein expression following treatment with BIX02189 and
XMD8-92. No change was observed in the cells following BIX02189 treatment, however, a
near statistically significant decrease in ERK5 activation was observed with XMD8-92
treatment by one-way ANOVA followed by Dunnett post-hoc analysis (p = 0.07). (B)
ERK1/2 activation was examined as a ratio over total ERK1/2 protein expression following
treatment with U0126. A statistically significant decrease was observed as compared to
DMSO (vehicle)-treated MMC cells by an unpaired t-test. (C) Akt activation was assessed as
a ratio over total Akt protein expression following treatment with LY294002.The activation
of Akt was significantly decreased as compared to DMSO-treated cells by an unpaired t-test.
Results represent the mean ± SEM, n=3, of at least two independent experiments.
Significance was defined as * = p ≤ 0.05 (GraphPad® Prism software).
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Young MMC cells were first treated with the MEK5 inhibitor, BIX02189, the
ERK5 inhibitor, XMD8-92. While no decrease in ERK5 activation was achieved
following BIX02189 treatment, XMD8-92 treatment nearly significantly reduced ERK5
activation (p = 0.07 by one-way ANOVA followed by Dunnett post-hoc analysis; p =
0.052 by unpaired t-test) (Figure 28A). Treatment of the lower passage MMC cells with
the MEK1/2 inhibitor, U0126, and Akt inhibitor, LY294002, resulted in a significant
decrease in both ERK1/2 and Akt activation, respectively (Figure 28B and C).
To assess the differential effects of age on kinase activation and cell migration,
young MMC cells were then treated with pharmacological inhibitors of MEK1/2, ERK5,
and Akt and analyzed via the wound healing/scratch assay (Figure 29). As previously
described (Chapter 2), the MMC cells were aged in vitro, and then treated with one of the
following inhibitors: XMD8-92 (5µM), U0126, or LY294002 (both 10µM) for a
maximum duration of 24 h. Light microscopy images were taken 12, 18, and 24 h
following wound induction (Figure 29A). Following treatment with any of the inhibitors,
no significant reductions in cell migration were observed after 12 h post-wound as
compared to vehicle (DMSO) control (Figure 29B). After 24 h following treatment with
XMD8-92, however, significantly fewer cells had migrated into the wound area as
compared to control. In a similar patter, treatment with the PI3K inhibitor, LY294002, or
with the MEK1/2 inhibitor, U0126, resulted in a significant reduction in cell migration
after 24 h (Figure 29B).
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Figure 29. Effect of MAPK and PI3K Pathway Inhibition on Cell Migration in Young
MMC Cells. The effect of ERK5, ERK1/2 and Akt inhibition on cell migration was assessed
in young murine MMC cells (passage 12). (A) Representative light microscopy images of
young MMC cells treated with DMSO (vehicle), XMD8-92, LY294002, or U0126 after the
initial scratch (baseline, top row) or 24 h following the wound induction (bottom row). All
images presented at 20x magnification. (B) Quantification of the migration assay depicted in
panel A. Following ERK5 inhibition with XMD8-92, a significant decrease in MMC cell
migration was observed 24 h after wound induction. Similarly, a significant decrease in cell
migration was observed after 24 h following treatment with LY294002 or U0126 as
compared to vehicle-treated cells at that timepoint. No significant changes in cell migration
were observed 12 h following wound induction with any of the inhibitor treatments. For all
treatments, quantified data are presented for both the 12 and 24 h timepoints as a percentage
of control (defined as the baseline, or the area of the scratch at 0 hr). Results represent the
mean ± SEM, n=3, of two independent experiments performed in triplicate. Significance was
defined as * = p ≤ 0.05; ** = p ≤ 0.01 by two-way ANOVA followed by Dunnett post-hoc
analysis (GraphPad® Prism software).
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To examine if the age-associated changes in MAPK and PI3K pathway activity
related to changes in cell migration, aged (higher passage) MMC cells were also analyzed
in the cell migration assay. As with the young MMC cells, western blot analysis was first
employed to ensure a decrease in kinase activity resulted following inhibitor treatment.
As observed previously in the young (passage 12) MMC cells (Figure 28A), treatment
with BIX02189 did not decrease ERK5 activation in the aged (passage 36) MMC cells
(Figure 30A). However, ERK5 activation significantly declined following treatment with
XMD8-92 (Figure 30A). The treatment of old MMC cells with the MEK1/2 inhibitor,
U0126, also reduced ERK1/2 activation (Figure 30B). However, while exposure of cells
with LY294002 led to a decline in Akt activation, the reduction was not significant
(Figure 30C). Next, the effect of kinase inhibition on migration in the aged cells was
measured using the wound-healing assay previously described (Chapter 2).
In the young MMC cells, kinase inhibition of the MAPK and PI3K pathways
resulted in fewer cells migrating into the wound area. To examine if aged cells followed a
similar trend, the cells were exposed to the various kinase inhibitors for a maximum
duration of 24 h.
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Figure 30. MAPK and PI3K Pathway Activation following Kinase Inhibitor Treatment
in Aged MMC Cells. The activation of ERK5, ERK1/2 and Akt was assessed in aged murine
MMC cells (passage 36) by western blot analysis following inhibitor treatment for 24 h. (A)
ERK5 activation was assessed as a ratio over total ERK5 protein expression following
treatment with BIX02189 and XMD8-92. No change was observed in the cells following
BIX02189 treatment, however, a significant decrease in ERK5 activation was observed with
XMD8-92 treatment by one-way ANOVA followed by Dunnett post-hoc analysis. (B)
ERK1/2 activation was examined as a ratio over total ERK1/2 protein expression following
treatment with U0126. A significant decrease was observed as compared to DMSO (vehicle)treated MMC cells by an unpaired t-test. (C) Akt activation was assessed as a ratio over total
Akt protein expression following treatment with LY294002. A non-significant decrease in
Akt activation was observed. Results represent the mean ± SEM, n=3, of at least two
independent experiments. Significance was defined as * = p ≤ 0.05; ** = p ≤ 0.01
(GraphPad® Prism software).
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Figure 31. MAPK and PI3K Pathway Inhibition on Cell Migration in Aged MMC Cells.
The effect of ERK5, ERK1/2 and Akt inhibition on cell migration was assessed in old murine
MMC cells (passage 36). (A) Representative light microscopy images of old MMC cells
treated with DMSO (vehicle), XMD8-92, LY294002, or U0126 after the initial scratch
(baseline, top row) or 24 h following the wound induction (bottom row). (B) Quantification
of the migration assay depicted in panel A. Following ERK5 inhibition with XMD8-92, a
significant decrease in MMC cell migration was observed 24 h after wound induction.
Similarly, a significant decrease in cell migration was observed after 24 h following
treatment with LY294002 or U0126 as compared to vehicle-treated cells at that timepoint. No
significant changes in cell migration were observed 12 h following wound induction with any
of the inhibitor treatments. For all treatments, quantified data are presented for both the 12
and 24 h timepoints as a percentage of control (defined as the baseline, or the area of the
scratch at 0 hr). Results represent the mean ± SEM, n=3, of two independent experiments
performed in triplicate. Significance was defined as * = p ≤ 0.05; ** = p ≤ 0.01 by two-way
ANOVA followed by Dunnett post-hoc analysis (GraphPad® Prism software).
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The migration assay in aged MMC cells revealed no significant changes
following any inhibitor treatment at either of the timepoints assessed (Figure 31B). These
data are in contrast to the migration changes observed in the young MMC cells (Figure
29); thereby, the role of the MAPK and PI3K pathways in cell migration may be agedependent. In addition to cell migration, the effect of these signaling cascades on cell
invasion and the potential for age-related regulation on this process, were examined.
3.3.5 The Influence of the MAPK and PI3K Pathways on Breast Cancer Cell
Invasion
Several cellular processes contribute to cancer metastasis, including motility,
migration, and invasion. Further, both the MAPK and PI3K have been associated with
increased metastasis in cancer, including breast cancer (Frémin and Meloche, 2010;
Sticht et al., 2008; Sawhney et al., 2009; Castro and Lange, 2010; Chin and Toker, 2011).
However, the underlying cellular signaling mechanisms responsible for the enhanced
tumor spread and the role of aging in this occurrence remain to be fully examined.
In order to assess the involvement of the MAPK and PI3K pathways in breast
cancer cell invasion, the ER-positive BT-474 cell line and the triple-negative MDA-MB231 cell line were employed as in the cell migration study. Additionally, to examine
potential age-associated phenotypic effects related to the observed changes in kinase
expression and activation (Figures 12-14), the MMC cell line was utilized. For
pharmacological kinase inhibition, BIX02189, XMD8-92, U0126, and LY294002 were
again employed for these studies. Following treatment with these inhibitors, the
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invasiveness of unstimulated BT-474 cells was first examined using a matrigel invasion
chamber assay previously described (Chapter 2).
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Figure 32. The Effect of the MAPK and PI3K Pathways on Cell Invasion in BT-474
Breast Cancer Cells. The effect of ERK5, ERK1/2 and Akt inhibitor treatment on cell
invasion was assessed in the BT-474 cell line. (A) Representative light microscopy images of
BT-474 cells treated with the following (clockwise, from the left): DMSO (vehicle),
BIX02189, XMD8-92, U0126, or LY294002 for 22 h prior to analysis. (B) Quantification of
the cell invasion assay after treatment with BIX02189. As compared to control cells, an
increase in cell invasion was observed following treatment, though the rise was not
significant. (C) Treatment with XMD8-92 resulted in a significant increase in cell invasion as
compared to vehicle control. (D) No significant changes in cell invasion were observed
following treatment with the Akt inhibitor, LY294002. (E) Treatment with the MEK1/2
inhibitor, U0126, had no change on cell invasion in these cells. Data are presented as a
percent of the control (vehicle), n=3, of two independent experiments. Significance was
defined as * = p ≤ 0.05 by unpaired t-test (GraphPad® Prism software).
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Following the cell invasion assay, it was determined that treatment with both the
BIX02189 and XMD8-92 compounds enhanced the invasive capacity of these cells
(Figure 32B and C). In fact, a significant increase in cell invasion was observed following
exposure to XMD8-92 in these cells as compared to vehicle-treated control cells (Figure
32C). Inhibitor treatment with either LY294002 or U0126 also had no significant effect
on cell invasion in this cell line (Figure 32D and E).
To investigate the underlying cellular mechanisms attributing to the enhanced
deadly phenotype of TNBC, the MDA-MB-231 cell line was utilized to examine the
involvement of the MAPK and PI3K pathways in cell invasion.
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Figure 33. The Effect of the MAPK and PI3K Pathways on Cell Invasion in TripleNegative Breast Cancer Cells. The effect of ERK5, ERK1/2 and Akt inhibitor treatment on
cell invasion was assessed in the MDA-MB-231 cell line. (A) Representative light
microscopy images of MDA-MB-231 cells treated with the following (clockwise, from the
left): DMSO (vehicle), BIX02189, XMD8-92, U0126, or LY294002 for 22 h prior to
analysis. (B) Quantification of the cell invasion assay after treatment with BIX02189. No
significant changes in cell invasion were observed following treatment with the MEK5
inhibitor. (C) Treatment with XMD8-92 nearly significantly decreased cell invasion as
compared to vehicle control. (D) A significant decrease in cell invasion was achieved
following treatment with the Akt inhibitor, LY294002. (E) Cell invasion was significantly
reduced after exposure to U0126 as compared to control. Data are presented as a percent of
the control (vehicle), n=3, of two independent experiments. Significance was defined as ** =
p ≤ 0.01 and *** = p ≤ 0.001 by unpaired t-test (GraphPad® Prism software).
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The triple-negative MDA-MB-231 cell line displayed diverse invasive effects
following kinase inhibitor treatment as compared to the ER-positive BT-474 cell line.
Aside from a similar slight increase in cell invasion following treatment with BIX02189
(Figure 33B), exposure to the other inhibitors resulted in decreased cell invasion. When
treated with the ERK5 inhibitor, XMD8-92, the cells exhibited a nearly significant
decrease in cell invasion (Figure 33C). Further, treatment with both LY294002 and
U0126 also resulted in significant declines in the invasiveness of this cell line (Figure
33D and E), suggesting that the MAPKs, ERK1/2 and ERK5, and Akt each play a
contributing role in the invasive property of these cells.
As with cell migration in breast cancer cells, the effect of aging on cell invasion
has not been fully examined. In order to assess potential differential outcomes of aging
on cell signaling pathways known to affect cell invasion, pharmacological kinase
inhibitors of components of the MAPK and PI3K pathways were again employed.
Murine MMC cells aged in vitro were utilized as a model to assess potential ageassociated changes between young (lower passage) and old (higher passage) in cell
invasion.
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Figure 34. The Effect of the MAPK and PI3K Pathways on Cell Invasion in Young
MMC Cells. The effect of ERK5, ERK1/2 and Akt inhibitor treatment on cell invasion was
assessed in the murine MMC cell line. (A) Representative light microscopy images of MDAMB-231 cells treated with the following (clockwise, from the left): DMSO (vehicle),
BIX02189, XMD8-92, U0126, or LY294002 for 22 h prior to analysis. All images are
presented at 20x magnification. (B) No changes in cell invasion were observed following
treatment with BIX02189. (C) Treatment with the ERK5 inhibitor, XMD8-92, resulted in a
significant decrease in cell invasion. (D) Akt inhibition reduced cell invasion in these young
cells, but the decrease was not significant. (E) No significant changes in cell invasion were
observed following treatment with the Akt inhibitor, LY294002. (E) Treatment with the
MEK1/2 inhibitor, U0126, demonstrated a trending decrease in cell invasion as compared to
vehicle-treated cells. Data are expressed as the mean ± SEM of two independent experiments.
Significance was defined as * = p ≤ 0.05 by unpaired t-test (GraphPad® Prism software).
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The cell invasion assay demonstrated that inhibiting the ERK5 pathway with
XMD8-92 reduces the invasive capacity of young MMC cells (Figure 34C). Though not
significant, a trend toward inhibition of invasiveness occurred in the presence of the
ERK1/2 inhibitor (Figure 34E). No changes in the invasive property of these cells
occurred following treatment with either BIX02189 or LY294002 (Figure 34B and D),
though previous studies revealed BIX02189 failed to inhibit ERK5 activation in these
cells (Figure 28A).
In the aged MMC cells, no significant effects were observed in the cell invasion
assay following treatment with any of the MAPK or PI3K pathway inhibitors (Figure 35).
These data suggest that the influence of the MAPK signaling cascade on cell invasion
may be age-dependent.
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Figure 35. The Effect of the MAPK and PI3K Pathways on Cell Invasion in Aged MMC
Cells. The effect of ERK5, ERK1/2 and Akt inhibitor treatment on cell invasion was assessed
in the murine MMC cell line. (A) Representative light microscopy images of MDA-MB-231
cells treated with the following (clockwise, from the left): DMSO (vehicle), BIX02189,
XMD8-92, U0126, or LY294002 for 22 h prior to analysis. All images are presented at 20x
magnification. (B) No changes in cell invasion were observed following treatment with
BIX02189. (C) Treatment with XMD8-92 resulted in a significant increase in cell invasion as
compared to vehicle control. (D) No significant changes in cell invasion were observed
following treatment with the Akt inhibitor, LY294002. (E) Treatment with the MEK1/2
inhibitor, U0126, had no effect on cell invasion in these cells. Data following treatment with
XMD8-92, LY294002, and U0126 are all presented as a percent of the control (vehicle). Data
are expressed as the mean ± SEM of two independent experiments.
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3.4

Discussion
Age remains the principle demographic risk factor associated with all cancer

types, including breast cancer. Numerous cellular and systemic factors have been
suggested to explain the relationship between age and cancer risk, including accumulated
genetic mutations, telomere shortening, and an overall physiological decline in immune
and defense mechanisms against toxins and oxidative stressors. Few studies have focused
on the mechanistic cellular signaling changes that occur with age and how these
alterations may attribute to tumor initiation and progression. The overall aim of the
current study was to evaluate how two of the most commonly dysregulated cellular
signaling pathways function in aging cellular and animal models of breast cancer.
The aging process results in several physiological and functional changes within
the breast that have yet to be fully elucidated. A recent study of normal mammary
epithelial cells derived from organoids of aged patients revealed an age-associated
decline of myoepithelial cells, which act as tumor suppressors; in addition, the
researchers observed an increase in defective multipotent progenitor cells that give rise to
incompletely differentiated luminal and epithelial cells in the breast (Garbe et al., 2012).
These data are among the first to suggest that age-associated changes at the cellular level
promote malignant transformation in the breast.
The mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase
(PI3K) pathways are involved in several crucial cellular processes required for
homeostatic function, including cell growth, proliferation, differentiation, and survival.
Aberrations in these cascades, resulting from genetic mutations or accumulated stressors
and lead to chronic upregulation, often results in carcinogenesis. While the involvement
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of these pathways in cancer has been widely studied over the past several decades,
relatively few studies have examined age-associated changes that may potentially alter
the function of these cascades, despite the fact that age is the most common risk factor in
cancer. Moreover, in breast cancer, the influence of age-related hormonal fluctuations on
these signaling pathways remains understudied.
The MAPK pathway has been widely implicated in cancer, though the newest
member of this kinase family, ERK5 remains largely unexamined. A study investigating
age-related changes in hormone receptors and oxidative stressors in human primary
breast tumors correlated age with an increase in ERK5 activation (Quong et al., 2002). In
another investigation involving aging and ERK5, it was revealed that total ERK5 protein
expression was higher in adipose stromal vascular fraction derived cells of younger rats
as compared to older animals (Fei et al., 2013). These disparate results indicate the need
for further study to delineate how this novel MAPK changes with age in normal tissue
and how these mechanistic alterations lead to malignant transformation. Though far more
studies have examined the involvement of ERK1/2 in breast cancer, to our knowledge,
age-related changes within this pathway have not been previously explored. In various
human and rodent cellular models, the majority of relevant studies have indicated both
function and activation of the MEK1/2-ERK1/2 cascade decline with age (Zhen et al.,
1999; Hutter et al., 2000; Tortorella et al., 2004; Li et al., 2000; Gentili and de Boland,
2000).
The PI3K/Akt pathway is the most commonly dysregulated pathway in breast
cancer, yet little is known regarding potential age-related shifts in the expression and
activation of this cascade. While a clinical study of breast cancer determined Akt
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activation is nearly equivalent regardless of patient age, (52.4% positive (≥ 50) vs. 47.6%
positive (≤ 50)), an analysis of breast cancer transcriptomes and mRNA expression
revealed age-associated dysregulation of the PI3K pathway in young patients but not in
either middle-aged or older patient groups (Yangb et al., 2010; Colak et al., 2013).
In addition to the modest understanding that exists regarding these signaling
pathways with age, several inherent factors that influence breast cancer, including ethnic
and racial disparities combined with variant hormonal profiles of tumors, further
complicate the field. To begin to elucidate age-related and the influence of hormones on
the expression and activation MAPK and PI3K pathways, namely the ERK1/2, ERK5,
and Akt cascades, three cell lines with distinct hormonal profiles were examined. The
inclusion of a middle-age group is often absent from aging studies and results are often
drawn based on a comparison of young versus older cohorts. Particularly in breast cancer,
however, incidence rises around middle-age and tumor subtypes vary based on patient
age, with more aggressive and inflammatory disease types occurring in younger women
(NCI, 2013; Anderson et al., 2006).
Employing an in vitro method of aging, young-, middle-, and old-aged cells were
obtained by a method of serial passaging previously validated in several cell types
(Schneider et al., 1976; Peterson et al., 2004; Pinho et al., 2011; Merkle et al., 2005;
Berdyyeva et al., 2005). The ER+/PR–/HER2+ BT-474 cell line demonstrated an increase
in ERK5 activation in middle age as compared to young (Figure 12A). Based on the
study by Quong and colleagues (2002) and that ERK5 has been previously shown to be
constitutively active in this cell line (Esparís-Ogando et al., 2002), an age-dependent
increase in ERK5 activation was anticipated. Moreover, it was hypothesized that as
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ERK5 activation increased, ERK1/2 activation would decrease, as this phenomenon has
been observed in other models (Cavanaugh et al., 2001). No significant changes were
observed in total ERK5 expression or in ERK1/2 activation or expression, however
(Figure 12A and B). Though somewhat in contrast to the results observed in primary
breast tumors, where an increase in ERK5 activation was correlated with age, the results
of the current in vitro study suggested changes in the MAPK pathway may be observed in
middle-aged animals of the in vivo study.
Further, while no changes were observed in Akt activation, a significant decline in
total Akt expression was observed (Figure 12C). Previous reports indicated that with age,
Akt activation increases, leading to skeletal muscle decline and an increase in
Alzheimer’s disease; therefore, the results of the present study indicate that alterations in
Akt activation may be cell-type specific (O’Neill, 2013; Wu et al., 2009).
Triple-negative breast cancer (TNBC), as compared to hormone-receptor positive
tumors, demonstrates a highly aggressive phenotype and incidence is elevated in younger
women. Despite the lack of estrogen and progesterone receptors, E 2 has displayed activity
in TNBC cell lines through the G protein-coupled estrogen receptor 1 to increase ERK1/2
and Akt activation (Jiang et al., 2013). Furthermore, an established inverse relationship
between PR expression and Akt activation suggests that, in these receptor-negative cells,
Akt activation would be enhanced (Tokunaga et al., 2006).
In the TNBC cells, an age-dependent decrease in ERK5 activation was observed
(Figure 13A); however, the expected decrease in ERK1/2 and Akt activation was not
found (Figure 13B and C). Rather, both ERK1/2 and Akt activation also declined with
age, specifically in the middle-age. These data again support that specific changes to the
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MAPK and PI3K pathways occur in this particular age subset. While no changes in total
MAPK expression occurred, a significant increase of Akt protein expression was noted in
middle-aged cells. The significant increase in total Akt expression but decrease in the
phosphorylation of this protein suggests impaired signaling at this particular age whereby
amplified translation of the protein may be counteracted by deficient post-translational
modification resulting in decreased phosphorylation and activation of this kinase.
In an effort to gain preliminary insight for the in vivo aging study, the murine
MMC cell line was employed. These cells, derived from the tumor of a transgenic
MMTV/neu mouse, are both ER and PR-negative, but HER2-positive. In a study of the
hormonally comparable SKBR3 cells (ER–/PR–/HER2+), ERK5 displayed constitutive
activation (Esparís-Ogando et al., 2002). However, no significant expression or activation
changes were observed in the MAPK pathway (Figure 14A and B). The increase in Akt
activation may be due to the amplification of HER2 in these cells as previous studies of
primary breast tumors demonstrated a positive correlation between the two (Tokunaga et
al., 2006).
Despite the valuable information provided from this study, aging cells in vitro
provides only a slight representation of the cellular changes that occur with age.
Dependent on subcultivation, the process of aging cells in culture may result in clonal
selection for certain populations of cells, which may skew the representation provided
regarding kinase expression and activation. Though rare in cancer cells, replicative
senescence may occur following serial passaging of cells. This halt in cellular growth
may lead to a host of aberrant cellular functions or loss of function that could also distort
the results of the aging study.
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An analysis of mammary tumor tissue as compared to age-matched adjacent
normal mammary tissue revealed that ERK5 activation increases with age in mammary
tumor tissue but not in normal mammary tissue (Figure 15A). In addition to the tissue
specificity observed, the age-related changes in ERK5 activation in MT tissue alone
suggest that further study is warranted regarding the effect of specifically targeting this
kinase in elderly cohorts, thereby sparing normal mammary tissue function through this
pathway.
Antithetically, total ERK5 protein was found to be higher in normal mammary
tissue as opposed to mammary tumor tissue, particularly with increasing age (Figure
15B). These data suggest that upon the synthesis of ERK5 in tumor tissue, cells are
commandeered to phosphorylate, and thereby activate, the protein, while such signals are
absent in normal mammary tissue. Further, immunohistochemical analysis of
physiologically similar mammary tumors revealed an age-related increase in total ERK5
expression (Figure 19), though this was not demonstrated in western blot analysis where
animals aged 9-15 mo were evaluated by individual month (Figure 15B). These results
suggest that alterations in kinase signaling cascades may occur in short intervals,
warranting further immunohistochemical analyses of ERK5 in tissues derived from
animals of each age.
In contrast to that observed with ERK5, ERK1/2 activation was higher in normal
mammary tissue as compared to mammary tumor tissue, particularly in younger animals
(Figure 16A). In an assessment of ERK1 and ERK2 activation as distinct kinases,
phosphorylated ERK1 in mammary tumor tissue was significantly reduced in middleaged animals as compared to younger cohorts (9 and 10 mo) and to the oldest animals
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examined (15 mo), while no changes in ERK2 activation was observed (data not shown).
ERK1, known to antagonize the effects of ERK2, has been established as a negative
modulator of cell proliferation; these data suggest the age-related decrease in ERK1
activation may contribute to enhanced tumor growth in an age-dependent manner in
breast cancer (Lefloch et al., 2008; Vantaggiato et al., 2008).
Akt expression and activation changes with age were not seen in either mammary
tumor or normal mammary tissue (Figure 17), diverging from the age-associated increase
in Akt activation observed in the MMC cell line (Figure 14C). A significant increase in
Akt activation was observed in mammary tumor tissue derived from old animals (15 mo)
when compared to normal tissue (Figure 17A). A significant difference was observed
between ERK5 and Akt activation in tumor tissues at this age (p = 0.009 by unpaired ttest, GraphPad Prism). These results may indicate that in old animals, when activation of
the MAPK pathway declines (Figures 15A and 16A), Akt becomes activated in a possible
compensatory manner.
The current study also sought to uncover how age-related changes in the MAPK
and PI3K pathways translate to oncogenic progression in breast cancer. Thereby, several
cellular processes, including proliferation, migration, and invasion were examined
following inhibition of these pathways in hormonally varied breast cancer subtypes. In
the current study, pharmacological inhibition of the MAPK and PI3K pathways failed to
reduce cell proliferation in vitro (Figure 24). As previous reports have linked ERK5 to
enhanced proliferation (Esparís-Ogando et al., 2002; Perez-Madrigal et al., 2012;
McCracken et al., 2008), the results of the present study further indicate that BIX02189
may act in a cell-specific manner, as inhibition of ERK5 activation was not achieved
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following exposure to this inhibitor (Figure 23). Furthermore, no age-related proliferative
changes were observed by Ki67 expression in mammary tumors (Figure 22); while it may
be that age does not affect proliferation in mammary tumors, it is also possible that no
age-associated alterations were found due to the heterogeneity of the tumor sections
examined. This was supported by the observed localization of ERK5 in the highly
proliferative periphery of tumors (Figure 20), which supports previous reports that link
the MAPK to enhanced tumor growth. It is possible that examining the peripheral portion
of the tumor separately from the inner core would reveal age-related changes in Ki67 and
ERK5 expression. The increase in both total and phosphorylated ERK5 with age (Figures
15A and 19) indicate that targeting the novel kinase in elderly subjects may act to
decrease tumor progression in these aged patients, by reducing alternate dysregulated
cellular processes, such as migration and invasion, warranting further investigation.
The effect of novel MEK5 and ERK5 inhibitors on cell migration was evaluated
in the two hormonally distinct human breast cancer cell lines. In the ER +/PR– BT-474 cell
line, treatment with XMD8-92 did not result in reduced migration (Figure 25), though
western blot analysis revealed that higher concentrations of this ERK5-specific inhibitor
may be necessary to elicit an effect as inhibition of ERK5 activation was not fully
achieved (Figure 23). Unlike that observed in the hormone-dependent BT-474 cell line,
examination of the triple-negative MDA-MB-231 cell line demonstrated ERK5 inhibition
reduces cell migration (Figure 27). In a study by Locatelli and Lange (2011), the
researchers found that cell migration in these cells occurs independently of ERK1/2, but
requires ERK5-Sam68 signaling.
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The current study indicates that selective inhibition of the MEK5-ERK5 pathway
at the level of ERK5 may be sufficient to reduce cell migration, while sparing the related
MEK1/2-ERK1/2 cascade. Notably, in both cell lines Akt and ERK1/2 inhibition resulted
in declined cell migration (Figures 25 and 27), though the reduction occurred earlier and
to a higher degree following Akt inhibition. Together, these data suggest dual inhibition
of the ERK5 and Akt pathways may sufficiently reduce migration of breast cancer cells
regardless of subtype; sparing the MEK1/2-ERK1/2 cascade may lessen toxicity and offtarget cell death.
Cell migration and invasion are precursor cellular events that increase the
likelihood of metastatic progression in cancer. The results of the cell migration assay in
young and aged cells (Figures 29 and 31) may be a manifestation of the general decline in
cellular function that occurs with age, or signify that higher concentrations of inhibitors
and/or longer periods of exposure are necessary to achieve the desired reduction in cell
migration in aged cells. An examination of kinase inhibition on cell invasion in the BT474 and MDA-MB-231 cell lines displayed dissimilar results that suggest hormonally
distinct breast cancer subtypes may uniquely respond to such inhibitors. In the BT-474
cell line, exposure to the ERK5 inhibitor increased the invasive capacity of these cells
(Figure 32B).
As discussed previously, the inability of these inhibitors to reduce ERK5
activation suggest higher concentrations or longer treatment duration may be required to
lessen cell migration and invasion in these cells. Supporting the cell-specificity of these
inhibitors is the finding that in the triple-negative MDA-MB-231 cells, both ERK1/2 and
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Akt inhibition reduced cell invasion (Figure 33C and D), but no effect was observed in
the BT-474 cells (Figure 32C and D).
The inherent aggressive nature of triple-negative breast cancer cells may also
contribute to the effectiveness of kinase inhibitors; for example, previous reports have
demonstrated that ERK1/2 is increased in TNBC as compared to breast cancer tumors
expressing alternate hormonal profiles (Umemura et al., 2007). The findings of the
current study suggest the importance of evaluating the upregulation of the ERK5 and Akt
pathways in TNBC as compared to tumors with varied hormonal profiles.
As in the cell migration study with aging, the MMC cells were again employed to
assess the effect of the MAPK and PI3K pathway inhibition on cell invasion. A similar
age-related trend was observed regarding the effect of kinase inhibition on cell invasion
as was demonstrated with cell migration. Whereas young MMC cells responded to ERK5
inhibition by demonstrating a reduction in cell invasion (Figure 34), no change was
observed in aged MMC cells (Figure 35). Notably, though a trend toward a decline in
invasion was observed following ERK1/2 inhibition in young cells, the results were not
significant, and no change occurred with Akt inhibition. Combined with the results
obtained in the triple negative MDA-MB-231 cells, these data strongly support the
critical role ERK5 in promoting metastasis in this breast cancer subtype, as TNBC most
often occurs in younger patients. Furthermore, the current study indicates that selectively
targeting ERK5, while sparing the ERK1/2 and Akt pathways, may be sufficient to
reduce cell migration and invasion in age-specific patient cohorts.
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CHAPTER 4
ASSESSMENT OF CROSSTALK AND DUAL KINASE INHIBITION OF THE MAPK AND PI3K
PATHWAYS IN BREAST CANCER

4.1

Hypothesis
Crosstalk between the MAPK and PI3K pathway exists such that inhibition of one

pathway leads to activation of the alternate cascade in breast cancer.
4.2

Rationale
Both the Ras/Raf/MEK/ERK and PI3K/Akt/mTOR pathways have been focal

points of anti-cancer agents for several years, with numerous drugs entering into patient
trials and a few already indicated for clinical use (Sebolt-Leopold and Herrera, 2009;
Cully et al., 2006; Roberts et al., 2012; Britten, 2013; Martini et al., 2013). Despite the
strides that have been made in targeting these pathways in various solid tumor types,
limited efficacy combined with the development of resistance mechanisms necessitate
further study and indicate adjuvant treatment options may be required to achieve optimal
therapeutic outcomes. In breast cancer, one clinical arterial has been completed to assess
the efficacy of dual inhibition of the MEK and PI3K/mTOR/Akt pathways in breast
cancer, with two more currently being conducted and two in the active recruitment phase
(www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01337765, NCT01155453,
NCT01476137, NCT01390818, NCT01363232).
Crosstalk between the MEK5-ERK5 cascade and the PI3K/Akt pathways has only
recently become the focus of investigation in cancer (Ramos-Nino et al., 2008). As such,
the aforementioned trials involving MEK inhibitors targeted against the MEK1/2ERK1/2 cascade fail to account for the contribution of the MEK5-ERK5 pathway in
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tumor progression. As crosstalk within the MAPK pathway and between the MAPK and
PI3K pathways has not yet been fully evaluated, in the current study, the influence of
single and dual pathway inhibition on the expression and activation of the ERK1/2,
ERK5, and Akt pathways was investigated. To date, the effect of pharmacological
inhibitors of MEK5 or ERK5 on the relative MEK1/2-ERK1/2 and PI3K/Akt pathways
has not been examined, nor has MEK5-ERK5 activity been assessed following MEK1/2
or Akt inhibition. These studies suggest potential mechanisms of resistance against kinase
inhibitors and underscore the importance of targeting multiple components within the
MAPK family in addition to the PI3K/Akt cascade to achieve clinical success.
4.3

Results

4.3.1 Inhibition of the MEK5-ERK5 Pathway in Hormonally Distinct Breast Cancer
Cell Lines
To begin to elucidate the relationship between the MAPK and PI3K pathways in
breast cancer, the pharmacological inhibitors XMD8-92 (5µM), BIX02189, LY294002,
and U0126 (all 10µM) were again employed in the BT-474, MDA-MB-231, and MMC
cell lines. Various durations of exposure were selected to examine the transient nature of
inhibition exhibited by these kinase pathways. Western blot analysis was utilized to
investigate the effect of these inhibitors on total protein expression and activation as
described in Chapter 2. To analyze the effect on the largely understudied MEK5-ERK5
cascade, cells were first treated with the MEK5 inhibitor BIX02189 or the ERK5
inhibitor, XMD8-92 (Figures 36, 37, and 38).
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Figure 36. The Impact of MEK5 and ERK5 Inhibition on the MAPK and PI3K
Signaling Cascades in BT-474 Cells. The effect of MEK5 and ERK5 inhibition on ERK5,
ERK1/2, and Akt expression and activation after 30 min, 60 min, and 24 h of treatment was
assessed in the BT-474 cell line. (A) BIX02189 treatment resulted in increased activation of
Akt after 30 min of treatment. (B) No changes in total protein expression were observed
following exposure to BIX02189 at any timepoint. (C) Treatment with XMD8-92 resulted in
a significant increase in Akt activation after 30 and 60 min. (D) ERK5 expression was
significantly increased after 24 h of XMD8-92 treatment. Results represent the mean ± SEM,
n=3, of at least two independent experiments. Significance was defined as * = p ≤ 0.05 and
*** = p ≤ 0.001 by two-way ANOVA followed by Bonferroni post-hoc analysis (GraphPad®
Prism software).

Treatment of BT-474 cells with BIX02189 failed to inhibit ERK5 activation at
any time point and had no effect on ERK1/2 activation. After 30 min of exposure to the
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MEK5 inhibitor, a significant increase in Akt activation was observed (Figure 36A). No
changes in the expression of ERK1/2, ERK5, or Akt were observed at any time point
following BIX02189 treatment (Figure 36B). As with BIX02189 exposure, Akt activation
was increased after 30 min following treatment with the ERK5 inhibitor, XMD8-92;
phosphorylated Akt was also increased after 60 min of XMD8-92 treatment (Figure 36C).
One-way ANOVA analysis revealed a significant reduction in ERK1/2 activation after 30
and 60 min of XMD8-92 exposure (p < 0.0001 and p = 0.002, respectively) (Figure 36C).
Exposure to the ERK5 inhibitor reduced ERK5 activation only after 24 h, as indicated by
an unpaired t-test (p = 0.0003, GraphPad Prism). A significant increase in total ERK5
expression was observed after 24 h of treatment with the XMD8-92 compound. Though
two-way ANOVA analysis demonstrated XMD8-92 treatment failed to decrease ERK5
activation, a significant decrease was detected by an unpaired t-test (p = 0.001, GraphPad
Prism).
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Figure 37. The Impact of MEK5 and ERK5 Inhibition on the MAPK and PI3K
Signaling Cascades in MDA-MB-231 Cells. The effect of MEK5 and ERK5 inhibition on
ERK5, ERK1/2, and Akt expression and activation after 30 min, 60 min, and 24 h of
treatment was assessed in the MDA-MB-231 cell line. (A) BIX02189 treatment increased
ERK1/2 activation after 30 min and 24 h of treatment. (B) No changes in total ERK1/2,
ERK5, or Akt protein expression were observed following exposure to BIX02189 at any
timepoint. (C) Treatment with XMD8-92 resulted in a significant increase in ERK1/2
activation after 24 h. (D) ERK5 expression was significantly increased after 24 h of XMD892 treatment. Results represent the mean ± SEM, n=3, of at least two independent
experiments. Significance was defined as ** = p ≤ 0.01, *** = p ≤ 0.001 and **** p ≤ 0.0001
by two-way ANOVA followed by Bonferroni post-hoc analysis (GraphPad® Prism
software).
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In the triple-negative MDA-MB-231 cell line, BIX02189 treatment significantly
increased ERK1/2 activation after 30 min and 24 h of inhibitor treatment (Figure 37A). A
statistical comparison of ERK1/2 activation following 60 min of treatment as compared
to vehicle treatment revealed a significant increase by an unpaired t-test that was not
detected by two-way ANOVA (p = 0.02, GraphPad Prism). No changes in total ERK1/2,
ERK5, or Akt protein levels was observed in this cell line following BIX02189 treatment
(Figure 37B). After 24 h of treatment, XMD8-92 led to a significant increase in ERK1/2
activation (Figure 37C) and total ERK5 protein expression (Figure 37D).
The murine MMC cell line is both ER- and PR-negative, but HER2-positive.
Treatment with BIX02189 increased both ERK1/2 and Akt activation in a transient
manner following both 30 and 60 min of exposure (Figure 38A). An unpaired t-test
revealed a significant decrease in ERK5 activation as compared to vehicle-treated cells
after 30 min (p = 0.003). No changes in kinase activation were observed in any of the
pathways following 24 h of BIX02189 treatment. Contrastly, a significant increase in
total ERK5 protein expression was observed at all timepoints assessed (Figure 38B).
Treatment of MMC cells with XMD8-92 led to a significant increase in ERK1/2
activation after 30 min and in Akt activation after 30 and 60 min of treatment, however
no changes in either of these pathways were observed following 24 h of exposure (Figure
38C). Notably, ERK5 activation was decreased at all timepoints according to unpaired ttest analysis (30 min: p = 0.02; 60 min: p = 0.003; 24 h: p = 0.04; GraphPad Prism). A
transient increase in ERK5 expression was observed after 30 min and 24 h of XMD8-92
treatment, though no increase in any of the pathways was observed after 60 min,
indicating this kinase inhibitor also acts in a transient manner (Figure 38D).
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Figure 38. The Impact of MEK5 and ERK5 Inhibition on the MAPK and PI3K
Signaling Cascades in MMC Cells. The effect of MEK5 and ERK5 inhibition on ERK5,
ERK1/2, and Akt expression and activation after 30 min, 60 min, and 24 h of treatment was
assessed in the MMC cell line. (A) BIX02189 treatment increased ERK1/2 and Akt
activation after 30 and 60 min of treatment. (B) Total ERK5 protein expression was
significantly increased at all timepoints following exposure to BIX02189. (C) Treatment with
XMD8-92 resulted in a significant increase in ERK1/2 activation after 30 min and in Akt
activation after both 30 and 60 min of treatment. (D) ERK5 expression was significantly
increased after 30 min and 24 h of XMD8-92 treatment. Results represent the mean ± SEM,
n=3, of at least two independent experiments. Significance was defined as * = p ≤ 0.05, ** =
p ≤ 0.01, and *** = p ≤ 0.001 by two-way ANOVA followed by Bonferroni post-hoc
analysis (GraphPad® Prism software).
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4.3.2 Inhibition of the MEK1/2-ERK1/2 Pathway in Hormonally Distinct Breast
Cancer Cell Lines
After examining the effect of MEK5 and ERK5 inhibition on the MAPK and
PI3K pathways, the MEK1/2 inhibitor, U0126, was utilized to analyze how inhibition of
this kinase affected the MEK5-ERK5 and PI3K/Akt pathways in breast cancer cell lines
under basal conditions.
Treatment of the BT-474 cell line with U0126 led to a significant decrease in pERK1/2 expression after 30 min, 60 min, and 24 h of exposure (Figure 39A). In addition,
a subsequent increase in Akt activation was observed at early timepoints, but was not
found after 24 h of treatment (Figure 39A). Total ERK5 expression was decreased after
30 min of U0126 treatment, however, similar changes were not observed at later
timepoints and total ERK1/2 and Akt protein expression remained unchanged at all
timepoints (Figure 39B).
Variations in protein expression and activation were observed in the MDA-MB231 cell line following MEK1/2 inhibition as compared to the ER-positive BT-474 cell
line. After treatment with U0126, ERK1/2 activation was decreased after 60 min by twoway ANOVA statistical analysis (Figure 39C). However, analysis by one-way ANOVA
revealed that p-ERK1/2 expression was, in fact, statistically reduced at all timepoints (p =
0.0001, analysis not shown). No changes in total ERK1/2, ERK5, or Akt protein
expression were observed in the triple-negative cell line at any timepoint (Figure 39D).
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Figure 39. The Impact of MEK1/2 Inhibition on the MAPK and PI3K Signaling Cascades in
Breast Cancer Cells. The effect of MEK1/2 inhibition on ERK5, ERK1/2, and Akt expression and
activation after 30 min, 60 min, and 24 h of treatment was assessed. (A) Treatment with U0126
decreased ERK1/2 activation at all timepoints and increased Akt activation after 30 and 60 min of
exposure in BT-474 cells. (B) Total ERK5 protein expression was reduced following U0126
treatment at an early timepoint in BT-474 cells. (C) In the MDA-MB-231 cell line, U0126 decreased
ERK1/2 activation after 60 min of treatment. (D) U0126 had no effect on ERK1/2, ERK5, or Akt
total protein expression at any timepoint in the MDA-MB-231 cell line. (E) Akt activation was
increased following U0126 treatment in MMC cells after 30 min. (F) Total ERK5 protein expression
was increased after 30 min of treatment with the MEK1/2 inhibitor in the MMC cell line. Results
represent the mean ± SEM, n=3, of at least two independent experiments. Significance was defined
as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** p ≤ 0.0001 by two-way ANOVA followed
by Bonferroni post-hoc analysis (GraphPad® Prism software).
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Inhibition of MEK1/2 corresponded to an increase in Akt activation at an early
timepoint in the murine MMC cell line (Figure 39E). After both 30 and 60 min of U0126
exposure, ERK1/2 activation was decreased (unpaired t-test, 30 min: p = 0.008; 60 min:
p < 0.0001, GraphPad Prism). Total ERK5 protein expression was increased after 30 min
of U0126 treatment (Figure 39F), while ERK5 activation was found to be significantly
decreased at this timepoint (p = 0.007, unpaired t-test, data not shown, GraphPad Prism).
In contrast, a significant loss of ERK5 protein was observed after 24 h of U0126
treatment (p = 0.01; GraphPad Prism). No changes were observed in either total ERK1/2
or total Akt expression (Figure 39F).
4.3.3 Inhibition of the PI3K/Akt Pathway in Hormonally Distinct Breast Cancer
Cell Lines
In addition to assessing the effect of MAPK inhibition in the three hormonally
unique cell lines, the result of PI3K/Akt pathway inhibition was examined. The PI3K
inhibitor, LY294002, was employed to examine the effect of PI3K pathway inhibition on
ERK1/2, ERK5, and Akt expression and activation.
Treatment of BT-474 cells with LY294002 led to no change in kinase activation
in the ERK1/2, ERK5, or Akt pathways by two-way ANOVA (Figure 40A). Analysis by
an unpaired t-test, however, revealed that ERK1/2 activation was, in fact, significantly
reduced after both 30 and 60 min of exposure to the Akt inhibitor (p = 0.002, GraphPad
Prism, analysis not shown). A significant increase in total ERK5 expression was observed
after 24 h of treatment (Figure 40B).
No changes in the activation of ERK1/2, ERK5, or Akt were observed in the
MDA-MB-231 cell line following treatment with LY294002 by two-way ANOVA
148

analysis (Figure 40C). Assessment of Akt activation by one-way ANOVA followed by
Dunnett post-hoc analysis, however, revealed that following both 30 and 60 min of
treatment with LY294002, p-Akt was significantly reduced (p ≤ 0.05, analysis not
shown). Total ERK5 protein expression was increased following 24 h of LY294002
administration in the triple negative breast cancer cell line (Figure 40D).
In the MMC cell line, treatment with LY294002 led to a significant, transient
increase in ERK1/2 activation after 30 min and 24 h of exposure (Figure 40E). Though
no significant change in p-Akt expression was observed following inhibitor treatment by
two-way ANOVA, one-way ANOVA analysis demonstrated a significant decrease at all
timepoints (30 and 60 min treatment: p ≤ 0.0001; 24 h treatment: p ≤ 0.001, GraphPad
Prism). No changes in total kinase expression were observed in the MMC cells following
Akt inhibition (Figure 40F).
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Figure 40. The Impact of PI3K Inhibition on the MAPK and PI3K Signaling Cascades in
Breast Cancer Cells. The effect of PI3K inhibition on ERK5, ERK1/2, and Akt expression and
activation after 30 min, 60 min, and 24 h of treatment was assessed in the BT-474, MDA-MB-231,
and MMC cell lines. (A) Treatment with LY294002 had no effect on kinase activation in the BT-474
cells. (B) Total ERK5 protein expression was increased after 24 h of exposure in the BT-474 cells.
(C) In the MDA-MB-231 cell line, no changes in kinase activation were observed at any timepoints.
(D) Total ERK5 expression was increased after 24 h of treatment. (E) ERK1/2 activation was
increased after 30 min and 24 h treatment in the MMC cell line. (F) No changes in total kinase
expression were observed at any timepoint in the MMC cell line. Results represent the mean ± SEM,
n=3, of at least two independent experiments. Significance was defined as * = p ≤ 0.05 and ** = p ≤
0.01by two-way ANOVA followed by Bonferroni post-hoc analysis (GraphPad® Prism software).
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4.3.4 Dual Inhibition of the MAPK and PI3K Pathways in Breast Cancer Cell Lines
To investigate the potential synergistic effect on the MAPK and/or PI3K
pathways following exposure to dual kinase inhibitors, the BT-474, MDA-MB-231, and
MMC cell lines were again employed. Under basal conditions, cells were treated with
one of the following combinations of inhibitors (each 10µM): (1) U0126 + LY294002,
(2) XMD8-92 + LY294002, or (3) XMD8-92 + U0126 for 30 min prior to lysate
collection and western blot analysis.
4.3.4.1 Influence of Dual Kinase Inhibition in the BT-474 Cell Line
Treatment with each combination of dual inhibitors in the BT-474 cell line led to
a decrease in ERK5 activation (Figure 41A, left panel). Notably, inhibitor combinations
that included the ERK5 inhibitor, XMD8-92 led to a significant increase in total ERK5
protein expression (Figure 41A, right panel). While all combinations of inhibitors
decreased ERK1/2 activation, only when U0126 was present did a significant reduction
occur (Figure 41B, left panel). No changes were observed in total ERK1/2 protein levels
following treatment; however, in regimens involving XMD8-92, a non-significant
increase was observed (Figure 41B, right panel). The dual inhibition of the ERK5 and
Akt pathways, resulting from XMD8-92 + LY294002 treatment, significantly reduced
Akt activation (Figure 41C, left panel). Combinatorial inhibition had no significant effect
on Akt protein expression by one-way ANOVA analysis (Figure 41C, right panel).
However, an unpaired t-test revealed that the combination of XMD8-92 + LY294002,
which leads to a significant decline in Akt activation, causes a significant increase in total
Akt protein levels (p = 0.03, GraphPad Prism).

151

(A)

(B)

(C)

Figure 41. Dual Kinase Inhibition on MAPK and PI3K Signaling in BT-474 Breast
Cancer Cells. The effect of dual kinase inhibitor treatment on ERK1/2, ERK5, and Akt
expression and activation in the BT-474 cells was assessed by western blot analysis. (A)
Treatment with each inhibitor combination decreased ERK5 activation in the BT-474 cells
(left), while combination treatment including XMD8-92 increased total ERK5 expression
(right). (B) Combination treatment with U0126 decreased ERK1/2 activation (left), but no
changes in total ERK1/2 protein expression were observed with any treatment (right). (C)
The combination of XMD8-92 + LY294002 decreased Akt activation (left). No changes in
total Akt expression were observed as a result of any treatment combinations (right). Results
represent the mean ± SEM, n=3. Significance was defined as * = p ≤ 0.05, ** = p ≤ 0.01, ***
= p ≤ 0.001, and **** p ≤ 0.0001 by one-way ANOVA followed by Dunnett post-hoc
analysis (GraphPad® Prism software).
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4.3.4.2 Influence of Dual Kinase Inhibition on the Triple-Negative MDA-MB-231
Cell Line
Each dual inhibitor combination (U0126 + LY294002, XMD8-92 + LY294002,

and XMD8-92 + U0126) decreased ERK5 activation in the triple-negative MDA-MB-231
cell line (Figure 42A, left panel). As compared to vehicle (DMSO) treatment, each
combination increased total ERK5 expression, though none significantly (Figure 42A, right
panel). ERK1/2 activation was significantly reduced as a result of each treatment
combination (Figure 42B, left panel), while total ERK1/2 protein expression was slightly
increased, though not significantly, as compared to control (Figure 42B, right panel). Oneway ANOVA analysis indicated that there were no significant changes in Akt activation
following dual inhibitor exposure (Figure 42C, left panel). Statistical analysis by an unpaired
t-test, however, reveals a significant decrease in total cellular p-Akt expression following the
combination treatment of XMD8-92 + LY294002 when taken as a ratio over GAPDH (data
not shown, p = 0.02, GraphPad Prism). Similarly, while no changes were observed by oneway ANOVA analysis in total Akt expression, an unpaired t-test indicates a significant loss
in total Akt expression following the same combination of inhibitors (XMD + LY) (Figure
42C, right panel).
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Figure 42. Dual Kinase Inhibition on MAPK and PI3K Signaling in Triple-Negative
Breast Cancer Cells. The effect of dual kinase inhibitor treatment on ERK1/2, ERK5, and
Akt expression and activation in the MDA-MB-231 cell line was assessed by western blot
analysis. (A) Treatment with each inhibitor combination decreased ERK5 activation in the
MDA-MB-231 cells (left), yet no changes in total ERK5 expression were observed in any
treatment group (right). (B) All inhibitor combinations decreased ERK1/2 activation (left).
No changes in total ERK1/2 protein expression were observed with any treatment (right). (C)
Dual inhibitor treatments caused no change in Akt activation (left) or in total Akt protein
expression (right). Results represent the mean ± SEM, n=3. Significance was defined as * = p
≤ 0.05, ** = p ≤ 0.01 and *** = p ≤ 0.001 by one-way ANOVA followed by Dunnett posthoc analysis (GraphPad® Prism software).
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4.3.4.3 Influence of Dual Kinase Inhibition on the Murine MMC Cell Line
In the MMC cell line, no significant changes were observed in ERK5 activation
following any of the grouped inhibitor treatments (Figure 43A, left panel). Further
analysis by an unpaired t-test revealed that the combination of U0126 + LY294002 nearly
significantly increased ERK5 activation (p = 0.1), while treatment with XMD8-92 +
LY294002 significantly reduced p-ERK5 expression (p = 0.002, GraphPad Prism). No
changes in total ERK5 protein expression was observed following inhibitor treatments
involving XMD8-92, however, an unpaired t-test revealed a significant decrease in ERK5
expression following treatment with U0126 + LY294002 (p = 0.002, GraphPad Prism)
(Figure 43A, right panel). ERK1/2 activation was not affected by dual inhibitor
treatments as compared to control and analyzed by one-way ANOVA; unpaired t-test
analysis, however, indicated a near significant decrease in p-ERK1/2 following
combination treatments with U0126 (U0126 + LY294002, p = 0.06; U0126 + XMD8-92,
p = 0.1; GraphPad Prism; Figure 43B, left panel). No changes in total ERK1/2 expression
were observed in any of the treatment groups (Figure 43B, right panel). Activation of Akt
resulted from dual inhibition of the MAPK pathway (Figure 43C, left panel). While no
significant changes were observed in total Akt expression, a near significant decrease was
seen in cells treated with the combination of XMD8-92 + U0126 (p = 0.09, unpaired ttest, GraphPad Prism) (Figure 43C, right panel).
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Figure 43. Dual Kinase Inhibition on MAPK and PI3K Signaling in Murine MMC
Cells. The effect of dual kinase inhibitor treatment on ERK1/2, ERK5, and Akt expression
and activation in the murine MMC cell line was assessed by western blot analysis. (A) No
changes in ERK5 activation (left panel) or expression (right panel) were observed following
treatment with any of the combinations of inhibitors. (B) ERK1/2 activation (left panel) and
total ERK1/2 expression (right panel) were unchanged by dual inhibitor exposure. (C)
MAPK inhibition significantly increased Akt activation (left panel). Total Akt protein
expression was unaffected by dual kinase inhibition (right panel). Results represent the mean
± SEM, n=3. Significance was defined as *** = p ≤ 0.001 by one-way ANOVA followed by
Dunnett post-hoc analysis (GraphPad® Prism software).
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4.4 Discussion
Both the Ras/Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways regulate
crucial cellular processes, including proliferation and survival, and are highly
dysregulated in solid malignancies (Britten, 2013; Liu et al., 2009; Santarpia et al.,
2012). Alterations within these cascades have been also been implicated in resistance to
anticancer therapies. To date, few studies have focused on the influence of the MEK5ERK5 cascade on the familial MEK1/2-ERK1/2 or Ras-related PI3K/Akt pathways. The
current study focused on assessing the effect of both single and dual kinase pathway
inhibition to characterize the expression and activation profiles of the MAPK and PI3K
pathways in hormonally distinct breast cancer cell lines.
The effect of single pathway inhibition was first examined to investigate the
relationship between the MEK1/2-ERK1/2, MEK5-ERK5, and PI3K/Akt signaling
cascades in breast cancer. Due to the recognized transient activation profiles of these
kinases, three timepoints, ranging from 30 min to 24 h, were assessed. In the (ER+/PR–
/HER2+) BT-474 cell line, treatment with the MEK5 inhibitor, BIX02189, led to a highly
significant increase in Akt activation at an early timepoint (Figure 36A), while no
changes in total ERK1/2, ERK5, or Akt protein expression were observed (Figure 36B).
The presence of crosstalk between the PI3K and MEK5-ERK5 pathways has not been
previously explored in this cell line. While ERK5 activation was not inhibited following
BIX02189 treatment at early timepoints (30 and 60 min), once ERK5 inhibition is
achieved after 24 h of exposure, the increase in Akt activation dissipates. Future studies
involving breast cancer cells in which Akt and/or ERK5 are constitutively-active will
further elucidate the cross-regulation between these kinase pathways.
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Treatment with the downstream ERK5 inhibitor, XMD-92 also increased Akt
activation in a transient manner. In contrast, the ERK5 inhibitor decreased ERK1/2
activation at the early timepoints (Figure 36C). After 24 h of XMD8-92 treatment, total
ERK5 protein levels were significantly increased (Figure 36D). The decline in
phosphorylated ERK5 in opposition to the increase in total ERK5 protein expression may
indicate that an upregulation of protein synthesis occurs in response to blocked kinase
activation in these cells (Figures 36C and D). Moreover, at early timepoints, the inability
of XMD8-92 to inhibit ERK5 activation but decrease ERK1/2 activation suggests
transient non-specificity of the inhibitor within the MAPK pathway. These data are in
contrast to related studies where XMD8-92 demonstrated 10-fold higher specificity for
ERK5 inhibition as compared to other kinases (Yang et al., 2010). Furthermore, these
data may suggest a compensatory upregulation of the PI3K/Akt pathway in response to
inhibition of the MEK1/2-ERK1/2 pathway in these ER-positive cells following
treatment with XMD8-92 (Figure 36C).
A distinct pattern of upregulation in response to BIX02189 treatment was
observed in the triple-negative MDA-MB-231 cell line as compared to the BT-474 cells.
Transient ERK1/2 activation was observed in these cells following both 30 min and 24 h
of exposure to BIX02189 (Figure 37A), while no changes in total ERK1/2, ERK5, or Akt
expression were observed (Figure 37B). Following XMD8-92 treatment, p-ERK1/2
expression was again increased after 24 h. A similar trend in ERK1/2 activation was
observed after shorter timepoints (30 and 60 min) with XMD8-92 as seen with
BIX02189, indicating that, in this cell line, use of these MEK5-ERK5 pathway inhibitors
causes transient activation of the related MEK1/2-ERK1/2 pathway. Notably, an increase
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in total ERK5 protein expression occurred after 24 h of XMD8-92 exposure, similar to
that observed in the luminal B-type BT-474 cell line. These data provide an early
indication that this ERK5 inhibitor acts to decrease ERK5 activation in breast cancer
regardless of the hormonal receptor profile of the cell; future in vitro studies involving
multiple hormonally distinct cell lines and in vivo analyses are necessary to fully
characterize the utility of this inhibitor.
In order to characterize the effect of MEK5-ERK5 inhibition on the MAPK and
PI3K pathways in HER2-type breast cancer, the MMC cell line was utilized. Short
exposures of BIX02189 resulted in activation of both ERK1/2 and Akt (Figure 38A),
while ERK5 activation was decreased after 30 min of treatment. Unlike the BT-474 and
MDA-MB-231 cells, in which no changes in total ERK5 protein levels were observed, in
the MMC cell line, ERK5 protein expression was increased at all timepoints examined
(Figure 38B). These data may indicate that in HER-2 type MMC breast cancer cells,
BIX02189 inhibits ERK5 activation in a transient manner, subsequently causing an
upregulation of the familial ERK1/2 and parallel PI3K signaling cascades. Treatment
with XMD8-92 also led to activation of the ERK1/2 and Akt pathways that was sustained
to 60 min in the PI3K/Akt cascade (Figure 38C).
Unique patterns of inhibition and upregulation were also observed in these cell
lines as a result of treatment with the MEK1/2 inhibitor, U0126. In the BT-474 cell line,
early durations of exposure led to an increase in Akt activation (Figure 39A), similar to
that observed following administration of both BIX02189 and XMD8-92 (Figure 36A
and C), further suggesting a compensatory mechanism between the MAPK and PI3K
pathways in these ER-positive cells. No changes in the ERK5 or Akt pathways were
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observed following p-ERK1/2 inhibition in the MDA-MB-231 cell line (Figure 39C and
D). As detected in the BT-474 cell line, MEK1/2 inhibition in the HER2-positive MMC
cells also upregulated Akt at early timepoints (Figure 39E), suggesting inhibition of the
MEK1/2-ERK1/2 cascade in cells overexpressing HER2 is compensated for by activation
of the PI3K/Akt pathway. These data are in support of clinical studies that found HER2
and Akt are positively correlated in primary breast tumors and may have mechanistic
implications regarding the finding that HER2 overexpression and Akt activation
negatively affect the clinical efficacy of both AIs and SERMS (Tokunaga et al., 2006).
In addition, at an early timepoint, total ERK5 protein expression was significantly
increased in the MMC cells, corresponding to a decrease in p-ERK5 expression. After 24
h of U0126 treatment, however, total ERK5 protein levels were again significantly
reduced (p = 0.01, unpaired t-test, GraphPad Prism), while p-ERK5 expression had
returned to basal levels (Figure 39E and F). These results indicate the non-specific and
transient activity of U0126 in these cells. Moreover, in addition to the aforementioned
compensatory response of Akt to ERK1/2 inhibition, the temporal fluctuations in both
total and phosphorylated ERK5warrant further investigation and indicate ERK5 may play
a role in the early activation of Akt.
Inhibition of the Akt pathway has been shown to elicit feedback mechanisms
within the PI3K pathway that overcome inhibition by reactivating both upstream
effectors and the MEK-ERK pathway (García-García et al., 2012). In the BT-474 cell
line, however, treatment with LY294002 failed to inhibit Akt activation. A higher
concentration of inhibitor or longer exposure times may be needed to achieve Akt
inhibition and enable for the assessment of Akt inhibition on the alternate pathways in
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this cell line. In the MDA-MB-231 cell line, however, Akt inhibition was achieved at
early time points. In accordance with previous findings by García-García and colleagues
(2012), decreased Akt activation corresponded to an increase in p-ERK1/2 expression
after 30 min of LY294002 exposure (Figure 40C). Similarly, in the HER2-type MMC
cell line, a decline in Akt phosphorylation corresponded to an increase in ERK1/2
activation at both early and extended timepoints (Figure 40E). These findings support
previous data in the MMC cell line, whereupon inhibition of the MEK1/2-ERK1/2
cascade by U0126 resulted in increased phosphorylation of Akt (Figure 39E).
Notably, total ERK5 protein levels were significantly increased after 24 h of
LY294002 treatment in all three cell lines evaluated (Figure 40B, D, and F). A study by
Roberts and colleagues (2010) demonstrated that ERK5 activation is critical for Akt
phosphorylation in human dermal microvascular endothelial cells. Further, the authors
concluded that the inability of the PI3K inhibitor, wortmannin, or the mTOR inhibitor,
rapamycin, to inhibit VEGF-induced ERK5 activation indicated ERK5 was not
downstream of either PDK1 or mTORC2. Taken together, the upregulation of total ERK5
protein levels in the present study may be in response to the inhibition of Akt
phosphorylation by LY294002. As the current study assessed the effect of kinase
inhibitors in unstimulated cells, further investigation is required to determine the effect of
PI3K inhibition on ERK5 activation. The preliminary findings herein, however, indicate
that treatment with LY294002 acts to prevent activation of ERK5 despite the
upregulation of the protein under basal conditions.
In numerous cell lines, crossregulation between the MEK1/2/ERK1/2 and
PI3K/Akt pathways has been established (Balmanno et al., 2009; Fey et al., 2012; Huang
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et al., 2013; Hausenloy et al., 2004; Serra et al., 2011); the involvement of the
MEK5/ERK5 pathway, however, remains to be elucidated. Moreover, combination
therapies that target both RTKs and either the PI3K or MEK pathways are often
overcome by resistance mechanisms to the receptor-targeted therapy that cannot be
surmounted by the PI3K or MEK inhibitor (Britten, 2013). Recent clinical trials have
demonstrated the importance of targeting both the MEK/ERK and PI3K/Akt pathways in
several tumor types in order to achieve efficacious results (Britten, 2013; Roberts et al.,
2012). Combination therapies to date, however, largely ignore the influence of the
MEK5-ERK5 pathway. Herein, preliminary findings indicate the importance of assessing
the effect of dual PI3K/MEK inhibition on this novel kinase to circumvent potential
resistance.
Combined inhibition of the ERK1/2 and PI3K pathways reduced ERK5 activation
in both the BT-474 and MDA-MB-231 cell lines (Figures 41A and 42A). In contrast, a
nearly significant increase in ERK5 activation occurred in response to similar treatment
in the HER2-type MMC cell line (Figure 43A). These findings suggest that inhibition of
the MEK1/2-ERK1/2 and PI3K/Akt pathways in HER2-type breast cancer may lead to
activation of the MEK5-ERK5 pathway, necessitating further study. Additionally, dual
MEK1/2/ERK5 inhibition in this cell line led to a highly significant increase in Akt
activation, underscoring the importance of combination MAPK/PI3K inhibition in these
cells. In contrast to the near upregulation of ERK5 in the HER2-type cells following
MEK1/2/Akt inhibition, dual inhibition of the ERK5 and Akt pathways was sufficient to
prevent MEK1/2-ERK1/2 activation in all cell lines assessed (Figures 41-43B).
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Moreover, a significant loss of pERK1/2 expression was achieved in the triple-negative
MDA-MB-231 cell line with this inhibitor combination (Figure 42B).
A comparison of the combination treatments XMD8-92 + LY294002 vs. U0126 +
LY294002 reveals that inhibition of ERK5 and Akt may have a more synergistic effect
on blocking Akt activation than the dual inhibition of ERK1/2 and Akt. Whereas
treatment with U0126 + LY294002 was unable to prevent phosphorylation of Akt in all
three cell lines, only the combination of XMD8-92 + LY294002 decreased Akt activation
in both the BT-474 and MDA-MB-231 cell lines (Figures 41 and 42C). These results
support the link established between the MEK5-ERK5 and PI3K pathways in malignant
mesothelioma whereby MEK5-ERK5 is suggested to act downstream of PI3K; further
downstream, negative feedback regulation is modulated by Fra-1 (Ramos-Nino et al.,
2008). In addition to Fra-1, ERK5 has also been shown to activate and stabilize c-Fos
(Terasawa et al., 2003). The suggested role of these immediate early gene products on
cell invasion in mammary cancers (Milde-Langosch et al., 2004) warrant further
investigation regarding the influence of the upstream PI3K and ERK5 pathways in breast
cancer.
Collectively, the results of these single and dual inhibitor studies reveal the
importance of characterizing the MEK5-ERK5 pathway when targeting either the
MEK1/2-ERK1/2 and/or PI3K/Akt pathways (Figure 44). In the BT-474 cell line,
inhibition of both the ERK1/2 and ERK5 pathways resulted in increased activation of Akt,
suggesting the ERKs may act downstream of Akt. However, inhibition of Akt did not result
in any change in ERK1/2 or ERK5 activation; therefore, the three kinases may also act
independently (Figure 44A). Inhibition of ERK5 in the MMC cell line resulted in an increase
in ERK1/2 and Akt activation, suggesting the novel kinase may act downstream of ERK1/2
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and Akt in this cell line (Figure 44B). An increase in activation of Akt and ERK1/2,
respectively, was observed following inhibition of the opposite kinase, suggesting these
kinases may act in a compensatory parallel manner (Figure 44B). In the MDA-MB-231 cell
line, following ERK5 inhibition, ERK1/2 activation was observed, indicating the novel
ERK5 may function downstream of ERK1/2 in these cells. The absence of ERK5 activation
following ERK1/2 inhibition, however, suggests ERK5 may also act independently of
ERK1/2 (Figure 44C).

In breast cancer, combinations of kinase inhibitors may demonstrate varied
synergistic effects in vivo specific to the tumor subtype. The kinase inhibitors evaluated
in the present study demonstrate both cell-type and temporal specificity. Moreover, the
non-specific inhibition observed within the MAPK pathway indicates the necessity of
inhibitors possessing higher selectivity to achieve desired outcomes while minimizing
off-target regulation and toxicity.
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Figure 44. Proposed PI3K/Akt and MAPK Signal Transduction Pathways in Distinct
Breast Cancer Cell Lines. (A) In the BT-474 cell line, inhibition of both the ERK1/2 and
ERK5 pathways resulted in increased activation of Akt, suggesting the ERKs may act
downstream of Akt or inhibit the activity of Akt via crosstalk. (B) Inhibition of ERK5 in the
MMC cell line resulted in an increase in both ERK1/2 and Akt activation, suggesting the
novel kinase may act downstream of ERK1/2 and Akt or that ERK5 inhibits ERK1/2 and Akt
via cross-talk mechanisms in this cell line. (C) ERK5 inhibition resulted in an increase in
ERK1/2 activation, suggesting ERK1/2 may act upstream of ERK5 or that ERK5 inhibits
ERK1/2's activity via cross-talk mechanisms in these triple-negative cells.
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CHAPTER 5
CHARACTERIZATION OF NOVEL MEK5 INHIBITORS IN BREAST CANCER CELLS

5.1

Hypothesis
Novel compounds containing structural variations to established CDK5 and

MEK1 inhibitors will provide specific inhibition of MEK5 in breast cancer cells.
5.2

Rationale
The MEK5-ERK5 pathway is upregulated in a number of solid tumors, including

breast cancer. While one group found ERK5 was activated in 20% of patients, another
study observed MEK5 overexpression in over half of the breast tumors evaluated (Hseih
et al., 2005). As such, the MEK5 cascade has recently become the focus of investigation,
yet few selective inhibitors of the pathway exist (Flaherty et al., 2010; Tatake et al.,
2008; Yang et al., 2010). The most commonly targeted MEK to date has been MEK1
(Sebolt-Leopold and Herrera, 2004). Inhibitors of the MEK1/2-ERK1/2 cascade
previously thought to be pathway-specific, such as PD98059, PD184352, and U0126,
have also been found to affect the MEK5-ERK5 pathway (Drew et al., 2012). Though not
surprising due to the sequence homology between MEK1 and MEK5 in addition to the
similar TEY motif present on ERK1, 2, and 5, the non-specificity of these MEK1/2
inhibitors has, however, provoked questions regarding the relevance of ERK1/2 in certain
biological contexts that may, in fact, be attributed to ERK5.
The series of indoline-6-carboxamides, BIX02188 and BIX02189, are ATPcompetitive inhibitors that were found to effectively inhibit ERK5 phosphorylation and
catalytic activity while having no inhibitory effect on MEK1, MEK2, ERK2, or JNK2
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(Tatake et al., 2008). In the present study, treatment of the BT-474 and MDA-MB-231
human breast cancer cells with BIX02189 has resulted in little ERK5 inhibition and, at
varying times of exposure, an increase in ERK1/2 activation (Figures 36 and 37). More
recently, the ATP-competitive inhibitor, XMD8-92, synthesized to specifically target the
MAPK, ERK5, demonstrated high selectivity and effectively reduced ERK5 activity in
vitro and in vivo (Yang et al., 2010). In the present study, however, treatment of the BT474 and MDA-MB-231 cell lines again revealed activation of the ERK1/2 and Akt
pathways in response to XMD8-92 exposure (Figures 36 and 37). Therefore, despite the
advances in synthetic chemistry, the need remains for selective, potent inhibitors of the
MEK5-ERK5 pathway in breast cancer.
In the present study, a panel of putative MEK5 inhibitors have been assessed for
their pathway selectivity and efficacy in the human embryonic kidney cell line, HEK293,
in addition to the BT-474 and MDA-MB-231 cell lines. Several series of compounds
have been tested, including benzimidazoles, diphenyl anilines, non-steroidal antiinflammatory (NSAIDs) compounds, and flavones. The benzimidazole-based inhibitors
were originally synthesized to target the proline-directed serine/threonine kinase, cyclindependent kinase-5 (CDK5)/p25; notably, the oxindole series of BIX compounds were
originally targeted against CDK2.
The non-specific MEK1/2 inhibitor, PD98059, served as the basis of the flavone
series of compounds, while an unexpected finding with a substituted methyl anthranilate
derivative that demonstrated specificity for MEK1/2, but not MEK5 inhibition, in the
MDA-MB-231 cell line led to the testing of a series of NSAIDs. Most recently, the
diphenyl aniline series of compounds have been synthesized based on the allosteric, non-
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ATP-competitive MEK1/2 inhibitor, PD0325901. After compounds were observed to
preferentially inhibit MEK5 while sparing MEK1/2 activity, proliferation assays and
studies assessing the epithelial-to-mesenchymal transition, both crucial processes
involved in tumor progression, were performed to further characterize these novel
inhibitors (studies in progress, data not shown). The results of the characterization studies
are presented herein and in Appendix A.
5.3

Results

5.3.1 Assessment of Novel Flavone Compounds as Specific MEK5 Inhibitors
In preliminary studies, a benzimidazole compound was observed to inhibit EGFinduced MEK5 activation in the HEK293 cells while also slowing the growth of MCF-7
breast cancer cells (Flaherty et al., 2010). Though the compound inhibited nearly 88% of
ERK5 activation, it also inhibited ERK1/2, necessitating further investigation. Based on
the commercially available PD98059, a series of flavone compounds were assessed for
their ability to specifically inhibit MEK5. The triple-negative MDA-MB-231 cells were
exposed to the compounds (as described in Chapter 2) and western blot analysis was
performed to assess MEK1/2 and MEK5 inhibition.
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(A)

(B)

Figure 45. Assessment of Novel Flavone Compounds as Specific MEK5 Inhibitors.
MDA-MB-231 cells were exposed to several flavone inhibitors prior to western blot analysis.
(A) No changes in ERK5 activation were observed following exposure to any compound. (B)
Activation of ERK1/2 was not inhibited following treatment with the flavone series of
inhibitors. Data represent the mean ± of two independent experiments, n=3, by one-way
ANOVA and Dunnett post-hoc analysis (GraphPad Prism® software).

Compounds
Vehicle
SQ-2-11
SQ-1-32
SQ-1-36 (II)

pERK5 relative
activity (%)
100
16.6
63.8
79.1

pERK5
pERK1/2 relative
pERK1/2
decrease (%)
activity (%)
decrease (%)
0
100
0
83.4
104.5
-36.2
125.3
-20.9
17.8
82.2

Table 2. Quantification of MEK1/2 and MEK5 Inhibition with Flavone Inhibitors.
Based on western blot analysis (Figure 45), the relative activity of ERK1/2 and ERK5
phosphorylation were quantified as a percentage of the vehicle (DMSO)-treated control.

Treatment of the TNBC cell line, MDA-MB-231, with a series of flavone
inhibitors did not elicit MEK5-specific inhibition (Figure 45A). ERK1/2 inhibition was
also not observed following inhibitor treatment and analysis by one-way ANOVA. A
significant decrease in ERK1/2 activation was observed following exposure to SQ-1-36
(II), however, by unpaired t-test (p = 0.04, GraphPad Prism).
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5.3.2 Examination of Diphenyl Aniline Compounds on the MEK5 Pathway
Based on the known allosteric MEK1/2 inhibitor, PD0325901, a series of
diphenyl aniline compounds containing structural variations to the side chains and to the
central and terminal arenes were synthesized.

(A)

(B)

(C)

Figure 46. Assessment of Novel Diphenyl Aniline Compounds as Specific MEK5
Inhibitors. MDA-MB-231 cells were exposed to diphenyl aniline compounds prior to
western blot analysis. (A) Representative western blot image assessing ERK1/2 and ERK5
activation. (B) Treatment with SC-1-177 and SC-1-181 decreased ERK5 inhibition in these
cells. (C) Exposure to the following compounds resulted in a decline in ERK1/2 activation:
SC-1-69, SC-1-72 (amide), SC-1-72 (ester), SC-1-75, SC-1-79, SC-1-80, SC-1-122, SC-1177, and SC-1-180. Results are expressed as a percentage of the control, or vehicle (DMSO)treated cells, set at 100%. Data are expressed as the mean ± of three independent experiments
performed in triplicate. Significance was defined as ** = p ≤ 0.01; *** = p ≤ 0.001; and ****
= p ≤ 0.0001 by one-way ANOVA and Dunnett post-hoc analysis (GraphPad Prism®
software).
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Compounds
Vehicle
SC-1-24
SC-1-65
SC-1-69
SC-1-72 (amide)
SC-1-72 (ester)
SC-1-75
SC-1-79
SC-1-80
SC-1-122
SC-1-177
SC-1-180
SC-1-181
U0126

pERK5 relative
pERK5
pERK1/2 relative
pERK1/2
activity (%)
decrease (%)
activity (%)
decrease (%)
100
69.1
107.9
98.8
78.8
87.7
93.5
104.4
119
91
29
79.9
17.6
102.1

0
30.9
-1.2
21.2
12.3
6.5
--9
71
20.1
82.4
--

100
66.9
95.6
13.1
0.4
1.07
29.5
1.01
1.37
71.8
70.7
1.48
108.5
0.28

0
33.1
4.4
86.9
99.6
98.93
70.5
98.99
98.63
28.2
29.3
98.52
-99.72

Table 3. Quantification of MEK1/2 and MEK5 Inhibition by Diphenyl Aniline
Inhibitors. Based on western blot analysis (Figure 46), the relative activity of ERK1/2
and ERK5 phosphorylation were quantified as a percentage of the vehicle (DMSO)treated control.

Treatment of MDA-MB-231 cells with SC-1-177 and SC-1-181 significantly
reduced ERK5 activation by 71% and 82.4%, respectively, as compared to DMSO
(vehicle)-treated control cells (Figure 46B). While SC-1-177 also inhibited ERK1/2
activation (29.3%), a slight increase in p-ERK1/2 expression (8.5%) was observed
following SC-1-181 treatment (Figure 46C, Table 3). Several other compounds, including
SC-1-69, SC-1-72 (amide), SC-1-72 (ester), SC-1-75, SC-1-79, SC-1-80, SC-1-122, SC1-177, and SC-1-180, also decreased ERK1/2 activation (Figure 46C), but did not inhibit
ERK5 activation (Figure 46B).
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5.3.3 Assessment of Non-Steroidal Anti-Inflammatory Compounds on the MEK5
Pathway
The effect of tolfenamic acid, indomethacin, sulindac, and meloxicam on ERK1/2
and ERK5 activation was assessed by western blot analysis as described previously
(Chapter 2).

(A)

(B)

Figure 47. Assessment of Non-Steroidal Anti-Inflammatory Agents as Specific MEK5
Inhibitors. MDA-MB-231 cells were treated with a panel of NSAIDs prior to western blot
analysis. (A) Treatment with the NSAID compounds had no effect on ERK5 activation. (B)
ERK1/2 activation was unaffected by exposure to the NSAIDs. Results are expressed as a
percentage of the control, or vehicle (DMSO)-treated cells, set at 100%. Data are expressed
as the mean ± of three independent experiments performed in triplicate by one-way ANOVA
and Dunnett post-hoc analysis (GraphPad Prism® software).
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Compounds

pERK5 relative
activity (%)

pERK5
decrease (%)

pERK1/2 relative
activity (%)

pERK1/2
decrease (%)

Vehicle
Tolfenamic Acid
Indomethacin
Sulindac
Meloxicam

100
87.2
100.1
89.2
86.5

0
12.8
-10.8
13.5

100
76.1
79.4
78.2
71.4

0
23.9
20.6
21.8
28.6

Table 4. Quantification of MEK1/2 and MEK5 Inhibition by Non-Steroidal AntiInflammatory Compounds. Based on western blot analysis (Figure 47), the relative activity
of ERK1/2 and ERK5 phosphorylation were quantified as a percentage of the vehicle
(DMSO)-treated control.

Exposure of the MDA-MB-231 cell line with the NSAIDs failed to reduce ERK5
activation (Figure 47A). Similarly, ERK1/2 inhibition was not indicated by one-way
ANOVA analysis, however, an unpaired t-test revealed treatment with tolfenamic acid or
meloxicam significantly reduced ERK1/2 activation (p = 0.004 and p = 0.02,
respectively; GraphPad Prism).
5.4

Discussion
Dysregulation of the RAS-Raf-MEK-ERK pathway, which transmit signals from

surface receptors to nuclear transcription factors, has been noted in numerous solid tumor
types, including prostate, bladder, liver, and breast (Al-Azayzih et al., 2002; RodriguezBerriguete et al., 2012; Whitaker et al., 2010; Frey et al., 1997; Saini et al., 2013). The
mitogen-activated protein kinase (MAPK) signal transduction cascade consists of
serine/threonine kinases that play crucial roles in numerous intracellular signaling events,
including proliferation, survival, and apoptosis, and presents a promising target for the
development of anticancer agents. In particular, the MEK1/2-ERK1/2 pathway is the
most studied in breast cancer (Santen et al., 2002). A growing number of inhibitors of the
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MEK-ERK cascade, including sorafineb and CI-1040, have recently entered into clinical
trials for the treatment of solid tumors, including breast carcinomas. However, related
toxicities compounded by the development of resistance to these therapies in both
preclinical and clinical models, necessitate further investigation (Saini et al., 2013; Dai et
al., 2011; Hatzivassiliou et al., 2012).
The least characterized member of the MAPK family of protein kinases, ERK5, is
structurally and physiologically similar to ERK1/2 and likewise plays a role in cell
survival, differentiation, proliferation, and apoptosis (Kato et al., 1997; Suzaki et al.,
2002; Nishimoto and Nishida, 2006; Li et al., 2008). As compared to other mammalian
MAP kinases, however, ERK5 has a distinct C-terminal and loop-12 structure that could
potentially be exploited by novel inhibitors (Lee et al., 1995). To date, ERK5 is the only
known substrate for MEK5; therefore, targeting this unique pathway may minimize side
effects and reduce toxicity by sparing other MAP kinase activity critical for the
homeostasis and survival of healthy cells.
ERK5 has been found to mediate the effects of a number of oncogenes, including
Ras and Src, and its role in tumor development and progression continues to be
elucidated (Kamakura et al., 1999; English et al., 1999; Barros and Marshall, 2005;
Lockhead et al., 2012). The MEK5/ERK5 pathway is constitutively active in numerous
cancer types as compared to normal cells (Drew et al., 2012). In oral squamous cell
carcinoma, ERK5, but not ERK1, was correlated with advanced tumor stage and lymph
node metastasis (Sticht et al., 2008). Additionally, in breast cancer, MEK5
overexpression was observed in over 50% of tumors analyzed and ERK5 in over 20% of
patients; patients whose tumors contained higher levels of ERK5 expression had reduced
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disease-free survival time as compared to patients with lower expression of the kinase
(Hseih et al., 2005; Montero et al., 2009).
The commercially available and widely used PD98059 flavone compound
effectively inhibits activation of ERK1/2. The non-specificity of this compound,
however, introduced the possibility that cellular processes previously attributed to the
MEK1/2-ERK1/2 cascade may instead be a consequence of MEK5-ERK5 activity. While
the current study of novel flavone compounds failed to selectively inhibit ERK5
activation (Figure 45, Table 2), further structural variations to these putative inhibitors
are planned for future assessment in breast cancer cell lines.
Epithelial-mesenchymal transitions (EMT) occur during normal embryonic
development and under several other physiological conditions, including carcinogenesis,
enabling tumors to develop an invasive phenotype (Kang and Massague, 2004; Grunert et
al., 2003). A recent study in keratinocytes has indicated a role of ERK5 in
reepithelialization during wound healing, suggesting the kinase is involved in cell
motility and cytoskeletal organization, characteristics associated with EMT (Arnoux et
al., 2008). Furthermore, the MEK5-ERK5 pathway was found to promote EMT in a
proteomic analysis of breast cancer, indicating this pathway as a viable target to reduce
tumor invasiveness and prevent potential metastatic spread (Zhou et al., 2008).
The diphenyl aniline series of small molecules was constructed based on a revised
homology model of MEK5 that was originally based on the X-ray crystal structure of
MEK-1 (PDB ID: 3EQC). The panel of these Type III inhibitors has presented the most
promise regarding MEK5 specificity (Figure 46, Table 3), cell proliferation, and
reversion of the epithelial-to-mesenchymal transition. Animal studies utilizing xenograft
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mouse models of triple-negative breast cancer indicate that one compound from this
series, IC-3-99 (Appendix A), attenuates tumor growth and prevents metastatic spread,
consistent with in vitro data (data not shown). These studies suggest that selectively
inhibiting MEK5 reverts the EMT in vitro and reduces tumor growth and metastasis in
vivo, warranting further investigation to delineate the underlying mechanism of action of
the inhibitor.
The assessment of the diphenyl aniline compounds led to an unexpected finding
following treatment with SC-1-72 (ester), whereby ERK1/2 activation was selectively
inhibited (98.9% decline) while little effect was observed on the ERK5 pathway (12.3%
decrease in activation, Figure 46). The structural similarities between the Type III (nonATP-competitive) MEK inhibitors and non-steroidal anti-inflammatory agents (NSAIDs)
led to the hypothesis that MEK1/2 and MEK5 inhibition may be mediated via
cyclooxygenase. A comprehensive search of NSAIDs with the potential to inhibit MEK
activity based on stereochemistry identified four compounds that were analyzed herein.
Though none of the NSAIDs examined presented selective MEK5 inhibition (Figure
47A), both tolfenamic acid and meloxicam reduced ERK1/2 activation (Figure 47B).
Amide variations to the four NSAIDs examined are currently being assessed for MEK
inhibition.
In summary, few, specific MEK5 inhibitors are currently available and inhibitors
of the MEK5-ERK5 cascade have not yet produced effective in vivo results worthy of
progression to clinical assessment. A large proportion of the MEK1/2 inhibitors available
and being tested clinically also non-specifically inhibit the MEK5-ERK5 cascade. As
such, the specific involvement of ERK5 has yet to be determined, while non-specific
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inhibition increases the likelihood of toxic side effects. The role of ERK5 in cancer
progression, including breast cancer, urges the development of pathway specific
inhibitors of this cascade in order to fully elucidate the underlying mechanisms of this
kinase and to potentially provide clinical benefits while reducing off-target toxicities.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

Increasing age remains the principle risk factor for developing breast cancer,
though the mechanistic basis for this association remains to be elucidated. Several
theories involving hormonal fluctuations on tumor initiation have been proposed, while
other hypotheses have focused on the accumulated genetic damage and chromosomal
instability that occur with age. At a genetic level, variations may be attributed to either
environmental exposures or inherited mutations. In both cases, the interplay of an agerelated shifting endocrine system likely contributes to the heightened incidence of breast
cancer that increases with age in women. To date, however, few studies have centered on
investigating the cellular mechanistic underpinnings responsible for the age-associated
risk of developing breast malignancies. The mounting rise in the elderly population both
in the U.S. and worldwide has recently shifted focus to age-related disease management
and prevention due to the potential devastating outcomes regarding both global health
and socioeconomic perspectives.
In an effort to begin to delineate the cellular contributions related to the ageassociated rise in breast cancer, the focus of this dissertation centered on two signal
transduction pathways that are oft aberrant in tumors, including breast cancers. The
mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)
pathways control numerous cellular processes crucial for normal homeostatic function,
including proliferation, growth, differentiation, and survival. Herein, one aim of the
current study was to elucidate shifts in the expression and activation of components of
these pathways with age. Determining the age-related activation profiles of the ERK1/2,
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ERK5, and Akt kinases may aid in the development of more targeted preventative and
therapeutic interventions while enhancing patient specificity. In the present study, three
in vitro models were selected based on the hormonal profile attributed to each cell line.
Importantly, distinct patterns of expression and activation were observed in the cells with
age, suggesting the hormone receptor profile of the tumor may influence the cellular
requirements and recruitment of the kinase pathways being investigated.
Particularly in the subset of cells aged in vitro to mimic middle-age, unique
patterns of kinase activation emerged in each cell line investigated. Whereas ERK5
activation was increased with age in the ER/HER-2-positive BT-474 cell line, a marked
decrease in ERK1/2, ERK5, and Akt activation was observed in the triple-negative
MDA-MB-231 cell line within this group. These data suggest that, in hormone-dependent
cancers, upregulation of kinases may play a greater role in the age-related onset of tumors
than in patients whose tumors are devoid of these receptors. The implications of this
study warrant further investigation involving a more extensive panel of cell lines
exhibiting distinct hormone receptor profiles to better understand the association between
receptor expression and the MAPK and PI3K signaling pathways with age. Moreover,
studies involving estradiol administration would help to further elucidate the impact both
the presence and activity of hormone receptors on age-related kinase activity in breast
cancer.
In addition to the valuable information gained from the in vitro assessment of the
kinases with age, in vivo studies were employed to more closely mimic human aging. The
influence of the tumor microenvironment and effect of endocrine and immune
modulation enabled for a more complete investigation of how the signaling pathways are
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altered with age. Further, comparison to age-matched non-malignant mammary tissue
provided an indication of the specific oncogenic upregulation that occurs in these
signaling cascades with age. The results of the in vivo study indicate that, of the kinases
examined in this particular HER-2 breast cancer subtype, ERK5 demonstrated the
greatest age-related shift in activation. Moreover, the age-associated upregulation of this
pathway occurred specifically in tumor tissue, but not in age-matched normal mammary
tissue, indicating this kinase may serve as a novel target for aged patients with HER-2
type breast cancer. In addition, in the oldest aged animals examined, a significant decline
in ERK5 activation was observed in conjunction with a significant increase in Akt
activation, suggesting the presence of cross-regulation between these pathways.
Future studies stemming from the current in vivo study may employ aged
conditional knockdown animals to fully determine the role of the kinase pathways. To
more closely examine the influence of the age of the animal versus the age of the tumor
with regard to kinase activity, studies in non-aged animals inoculated with aged breast
cancer cells are necessary. In addition, analyzing primary specimens from breast cancer
patients, comprising a panel of tumor subtypes, would provide the most clinically
relevant information regarding changes to the MAPK and PI3K pathways with age in
both tumor and non-diseased tissue.
To characterize the influence of ERK1/2, ERK5, and Akt upregulation in breast
cancer cells, migration and invasion were studied in both aged and non-aged cellular
models. The results of these studies indicate the critical role of ERK5 in these key
oncogenic processes and demonstrate for the first time, to the author’s knowledge, the
ability of a specific ERK5 pharmacological inhibitor to modulate these functions in
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triple-negative breast cancer cells. Furthermore, whereas ERK1/2, ERK5, and Akt proved
crucial for cell migration and invasion in an in vitro model of young breast cancer cells,
disparate results were observed in aged breast cancer cells, providing preliminary
indications that ERK5 may be more heavily involved in tumorigenic processes in
younger cohorts as opposed to elderly breast cancer patients. Future projects employing
the ERK5 inhibitor in aged animal models to study the effect on cancer cell migration
and invasion would further indicate this kinase as a potential therapeutic target for
specific subsets of patients.
The distinct patterns of pathway upregulation among the various cell lines and
observed in the tumor study provoked investigation into potential crosstalk and crossregulation within the MAPK pathway and between the MAPK and PI3K cascades.
Assessments of kinase expression and activation were performed following both single
and dual kinase inhibition of MEK1/2, MEK5, ERK5, and PI3K. These studies are of
particular clinical relevance as suboptimal results and the development of resistance
pathways in single kinase patient trials have prompted the initiation of combinatorial
trials involving MEK1/2 and inhibitors of the PI3K/Akt/mTOR cascade. To date,
however, the impact of these dual kinase inhibitor studies on the MEK5-ERK5 cascade
has been largely ignored.
Results presented herein again demonstrate variations in patterns of kinase
expression and activation among the cell lines following both single and dual kinase
inhibition. Of particular importance was the observation that an ERK5/PI3K/Akt
combination of inhibitors achieved greater Akt inhibition than a combination of ERK1/2
and PI3K inhibitors, particularly in HER2-type breast cancers, where an inverse
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correlation between HER2 and Akt has been established. Future projects resulting from
these studies may investigate the effect of these inhibitor combinations on downstream
effectors, including c-Fos and Fra-1, which have been implicated in modulating cell
invasion. In vivo assessments would also provide more clinically relevant indications
regarding the implications of current MEK/PI3K/Akt/mTOR patient trials.
The studies presented within this dissertation suggest that the novel MAPK,
ERK5, is a critical mediator of cell migration and invasion in breast cancer. An
underwhelming disproportionate number of inhibitors specific to targeting this kinase
exist, however, in comparison to the more widely studied MEK1/2-ERK1/2 pathway.
Furthermore, in addition to other related studies, the present study demonstrates the cellline specificity that exists with the MEK5-ERK5 inhibitors currently available. To that
end, a collaborative research effort has been initiated in conjunction with a medicinal
chemistry laboratory focused on the development of novel, specific MEK5 inhibitors. Of
the several classes of compounds tested to date, the diphenyl aniline series has proven
most effective at solely targeting the MEK5-ERK5 cascade while sparing the MEK1/2ERK1/2 pathway. Moreover, early studies in vivo have demonstrated the ability of one
diphenyl aniline compound to reduce tumor growth. The same compound demonstrated
the ability to revert the epithelial-to-mesenchymal transition in vitro, indicating this
inhibitor may prove effective at slowing or preventing metastasis. Novel inhibitors
designed based on the results presented herein are currently being synthesized for both in
vitro and in vivo assessments.
In conclusion, the results of this dissertation project indicate, for the first time,
age-related changes in both kinase expression and activation in components of the MAPK
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and PI3K pathways. Additionally, targeted inhibition of these kinases, in particular,
ERK5, reduced the migratory and invasive capacities of breast cancer cells in certain
contexts. Single and dual inhibitor studies promote targeting ERK5 in breast cancer and
suggest the kinase exhibits distinct patterns of upregulation with regard to particular
tumor subtypes.
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